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1. Reactive oxygen and nitrogen species (ROS/RNS)  
 
 
This Thesis has been developed in the field of Redox Biology and more 
precisely in the study of cellular mechanisms that maintain or disturb “Redox 
Homeostasis” and allow for redox regulation of protein function in signaling and 
metabolism in the context of cancer. I will begin the introduction to the subject with a 
brief description of the origin and characteristics of Reactive Oxygen and Nitrogen 
Species (ROS/RNS). Many reviews have been published on this subject of whom I 
highlight the following: 1–6. 
 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are a 
family of molecules produced in all living organisms mainly as a consequence of 
aerobic life. Traditionally these reactive species have been considered responsible for 
the oxidative stress in the cells and for the damage to most biomolecules. However, 
emerging data show that ROS and RNS are necessary for life and play an important 
role in a wide variety of essential physiological processes. Aerobic organisms take 
molecular oxygen (O2) from the air and is reduced to H2O inside the cells in the 
reactions of the electron transport chain and oxidative phosphorylation. This process 
is called cellular respiration and it is where most of ROS are produced. In general, 
ROS can be classified into two groups, radical and non-radicals. The radical group is 
composed of superoxide anion (O2.-), hydroxyl radical (·OH), peroxyl (ROO·) alkoxyl 
radicals (RO·), nitric oxide radical (NO·), and nitrogen dioxide (NO·2) which contain at 
least one unpaired electron in their external orbit capable of independent existence. 
On the other hand, the nonradical group is composed of a large variety of molecules, 
among which are hydrogen peroxide (H2O2), hypochlorous acid (HOCl), hypobromous 
acid (HOBr), lipid peroxides (ROOH), aldehydes, ozone (O3), singlet oxygen (1O2), 
peroxynitrite (ONOO-) and peroxynitrous acid (ONOOH) (Figure 1). 
 
Superoxide ion radical  (O2.-) is the most important widespread ROS resulting 
from the transfer of one electron to O2. O2.- is relatively stable and reacts poorly with 
biological components. Due to its pKa of 4.8, it can exist as either O2.-or hydroperoxyl 
radical (HO·2) at low pH which can more easily penetrate biological membranes. Both 
O2.- and HO·2 can reduce ferric (Fe3+) to ferrous (Fe2+) ions. The superoxide anion 
radical also can act as a nucleophile and as oxidizing agent against ascorbate and 
tocopherol but the most important reaction is dismutation. In this reaction that can be 
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spontaneous or catalyzed by superoxide dismutase enzyme family (SOD), one 
superoxide radical reacts with another superoxide radical in which one radical is 
oxidized to oxygen and the other is reduced to H2O2.  
 
Hydrogen peroxide (H2O2) is a stable molecule that can be also formed by the 
spontaneous transfer of two electrons to oxygen. It is not a radical but it can cause 
damage to the cell at low concentration (10 µM). Its harmful chemical effects can be 
direct or indirect by producing OH· in the presence of transition metal ions.  
 
Hydroxyl radical (OH·) is the most aggressive radical species in biological 
systems. In contrast to the superoxide anion, OH· is a short-lived species which acts 
as a powerful oxidant for a wide range of both organic and inorganic molecules that 
are present in the cells. It is formed in a Fenton reaction, in which H2O2 reacts with 
metal ions (Fe2+ or Cu2+), or by the reaction between O2.- and H2O2 called Haber-
Weiss reaction.  
 
Figure 1. Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). SOD, 
superoxide dismutase; NOS, nitric oxide synthase. Figure adapted from Nathan & Shiloh 7 
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Nitric oxide (·NO) is a relatively stable and highly diffusible free-radical gas 
which reacts with oxygen to form nitrogen oxides. It can be included in both RNS 
family and ROS, and is synthesized by nitric oxide synthase (NOS) from L-arginine, 
oxygen and NADPH. Three isoforms of NOS have been described, neuronal (nNOS 
or NOS type I), inducible (iNOS or NOS type II) and endothelial (eNOS or NOS type 
III) which play different roles 8. Nitric oxide is both water- and lipid-soluble so it 
diffuses freely through the cytoplasm and plasma membrane and has a short half-life. 
It can react with a variety of radicals to form nitrite (NO-2), and nitrate (NO-3).  
 
Peroxynitrite anion (ONOO-).-Under physiological conditions, NO· is able to 
react with a superoxide anion producing peroxynitrite anion (ONOO-). This reaction is 
important to maintain the balance of superoxide radicals and other ROS molecules. 
Peroxynitrite is a strong short-life oxidant that can diffuse across cell membranes and 
might provoke depletion of sulfhydry groups and oxidative damage on most 
biomolecules similar to OH·. It can directly react with CO2 to form nitroso peroxo 
carboxylate (ONOOCO2-) or it can protonate to peroxynitrous acid (ONOOH). 
Peroxynitrite anion can also react fast with carbon dioxide to form carbonate (CO3·-) 
and nitrogen dioxide (·NO2) radicals that are responsible for component nitration. 
Alternatively, peroxynitrous acid can undergo homolytic fission to generate hydroxyl 
radicals and nitrogen dioxide. 
 
Most ROS/RNS are short-lived species whose life span depend on the 
environmental conditions like pH or the presence of other species. For these reasons, 
the ROS/RNS selectivity for redox signaling is achieved by regulating the subcellular 
location and exposure time to promote kinetically competent redox reactions. Due to 
the instability of many types of ROS/RNS and the redox buffer capacity of the cell, it 
is very important that a colocalization exits between the source of ROS/RNS and 
targets as well as a modulation of the local redox buffer capacity 9. 
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2. Oxidative and nitrosative stress 
 
 The term "oxidative stress" was originally defined as a lack of balance between 
ROS/RNS and the antioxidant organism's capacity10, but the definition has been 
reviewed and the new version is an imbalance between oxidants and antioxidants in 
favour of the oxidants, leading to a disruption of redox signalling and control and/or 
molecular damage11. Therefore, oxidative stress can be classified according to the 
amount of ROS/RNS, with levels ranging from physiological oxidative stress (eutress) 
to pathological oxidative stress (distress). At low or moderate cell levels, ROS act as 
signaling molecules that regulate critical physiological processes such as proliferation, 
apoptosis and inflammatory responses as well as activation of transcriptional factors 12–
14. ROS play an important role as regulatory mediators in signaling processes since 
organisms have developed specific mechanisms that allow them their use as signaling 
molecules15. However, at higher concentration, both ROS and RNS generate oxidative 
stress and nitrosative stress, respectively, that easily cause irreversible modifications in 
different biomolecules like proteins, lipids, or nucleic acids. Oxidative stress has been 
associated with different pathologies as neurodegenerative diseases (Parkinson, 
Alzheimer, Huntington's disease and amyotrophic lateral sclerosis), diabetes, 
rheumatoid diseases, cardiovascular disease, cataracts and cancer 16–18. Besides, the 
progressive decline of antioxidant defence provokes the disability of physiological 
functions, promoting disease emergence and ageing14,19–21. 
 
2.1. Sources of ROS/RNS 
 Free radicals, both reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), can have exogenous and endogenous origin. The totality of exogenous 
sources has been denominated as the "exposome" 22 which includes tobacco smoke, 
pollution, ionizing or solar radiation and diet among others23,24. 
 Although the risk of the organisms exposure to exogenous sources of 
ROS/RNS is high, the endogenous sources are more important since exposure to 
endogenously produced ROS/RNS in the cell is a continuous process throughout the 
life of each organism. The subcellular localization where ROS/RNS are generated as 
well as their temporal and spatial distribution is very important.  The main organelles for 
ROS production under physiological conditions are mitochondria and cell membranes 
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but there are also other organelles, such as the endoplasmic reticulum (ER) and 
peroxisomes or even ROS/RNS producing enzymes (Figure 2).  
 
 
Figure 2. Cellular sources of ROS/RNS production. Figure adapted from Di Meo et al. 17 
 
 O2.- is produced by one-electron reduction of molecular oxygen in the 
mitochondria when the flow of electrons through the electron transport chain (ETC) 
during the synthesis of ATP eventually fails 25. The major sites of superoxide anion 
production are Complex I and Complex III of the ETC 26 and then superoxide is 
converted to hydrogen peroxide by the action of mitochondrial superoxide dismutase 
(MnSOD). In addition, monoamino oxidase, α-ketoglutarae dehydrogenase, glycerol 
phosphate dehydrogenase and p66shc protein are other mitochondrial components 
that contribute to the generation of ROS 27. Mitochondrial membrane potential has 
been proposed to influence ROS generation since an increase in the proton-motive 
force is associated with an increase in ROS production, as well as the opposite effect. 
However, the relationship between the proton-motive force and ROS production is not 
yet known 28.  
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 Another important intracellular source of ROS, mainly O2·- or H2O2, is the 
NADPH oxidases (Nox) family of enzymes, and their dual oxidase relatives (Duox), 
which are localized to various cellular membranes. Nox family was first described in 
neutrophils as an important source of ROS for the phagocytic killing of pathogens 
during the immune response. This NADPH oxidase is composed of two membrane 
proteins, Nox2 and p22phox, three cytosolic proteins p67phox, p47phox, and p40phox, 
and a small GTP binding protein Rac. NADPH oxidase has also been involved in the 
production of ROS in non-phagocytic cells 29. In human, there are seven Nox 
homologues (Nox1-5, Duox1 and 2 Duox2) that produce ROS for host defence and cell 
signaling 30–32. It has also been reported that lipoxygenase 33 and cyclooxygenase 34 
intermediaries stimulate the generation of ROS by Noxs. 
 The primary source of ROS from the ER is oxidative protein folding. The 
majority of protein disulfide formation reactions are initiated by the glycoprotein Ero1 
which catalyses the two-electrons transfer from dithiols to O2 resulting in the formation 
of H2O2  35. In addition, other enzymes of the ER such as cytochrome P450 reductase 
contribute to the formation of ROS 36. 
 Peroxisomes are subcellular respiratory organelles that produce hydroxyl and 
superoxide radicals as well as hydrogen peroxide by xanthine oxidase and other 
enzymes 37,38. In addition, peroxisomes contain the inducible form of nitric oxide 
synthase so that produces ·NO 39. Under some physiological or pathological conditions, 
peroxisomes may act as a H2O2 and ·NO source 40.  
 
2.2. Targets of ROS/RNS 
 ROS and RNS could provoke reversible or irreversible redox modifications of 
biomolecules such as proteins, lipids, DNA and RNA, altering their structure and 
functionality. 
Nucleic acids 
 Although DNA is a stable and well-protected molecule, both ROS and RNS can 
damage it by oxidation. Hydroxyl radicals are the main ROS that can directly react with 
purine and pyrimidine bases as well as deoxyribose sugar backbone and cause several 
types of damage, such as single and double DNA break and loss of purines 18,41. The 
OH· can attack guanine at its C-8 position to produce 8-hydroxy deoxyguanosine (8-
OHdG) which is considered the standard biomarker of oxidative damage in DNA 42. On 
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the other hand, peroxynitrite reacts with guanine causing nitrative and oxidative DNA 
lesions such as 8-nitroguanine and 8-oxodeoxyguanosine, respectively. 8-nitroguanine 
is unstable and can be spontaneously removed resulting in loss of purines (apurinic 
sites) and mutagenic DNA lesion 43. In the case of RNA, it is more vulnerable to 
oxidative damage than DNA and 7,8-dihydro-8-oxoguanosine (8-oxoG) is the most 
study RNA damaged product 44. 
Lipids 
  Membrane lipids, especially polyunsaturated fatty acids, are the most 
susceptible to peroxidation by peroxynitrite-derived radicals which results in the 
compromise of the integrity and functionality of cell membranes. Malondialdehyde 
(MDA) and nitrito-, nitro-., nitrosoperoxo- and/or nitrated lipids are products of lipid 
peroxidation 45,46. Peroxidation of polyunsaturated fatty acids yields lipid aldehydes 
represented by 4-hydroxynonenal (4HNE) 47,48. Peroxynitrite also provokes the 
oxidation of arachidonic acid and the formation of F2-isoprostanes which are 
considered as the marker of the oxidative lipid damage 49. 
Proteins 
 Proteins sustain most of the damage caused by ROS because they are the 
most abundant biomolecules in the cell. ROS/RNS provoke side-chain oxidation of 
amino acid residues, backbone fragmentation, unfolding and misfolding resulting in 
loss of protein function/enzymatic activity or their degradation by specific proteases 50. 
All amino acids are sensitive towards oxidation but the sulfur atom of methionines and 
cysteines is more prone to oxidation than others. Oxidations of amino acids can be 
irreversible, like carbonylation or reversible by the activity of disulfide reductases on 
oxidized Cys or methionine sulfoxide reductase on Met-sulfoxide. 
 Irreversible  
 Lysine, arginine proline and histidine residues can be oxidated by ·OH giving 
rise to carbonyl derivates that serve as markers of ROS mediated protein oxidative 
damage. Aromatic amino acids like tyrosine, are also susceptible to be oxidized by ·OH 
or ONOO- resulting in dityrosine (a marker for hydroxyl radical) and 3-nitrotyrosine (a 
marker for RNS), respectively 48. 
 Reversible 
Methionine (Met) and cysteine (Cys) residues are the amino acids most 
susceptible to oxidation by ROS. In organisms from bacteria to human, ROS are able 
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to reversibly regulate many important intracellular pathways through the redox 
modulation of specific Cys residues of target proteins which can function as redox-
dependent switches. Similar to the phosphorylation/dephosphorylation of Ser and Thr 
residues, the post-translational modification of specific Cys and their reversion provide 
a mechanism for the regulation of the protein function 51. The first evidence that 
supported the role of ROS as signal transduction was the increases of ROS generation 
after growth factor stimulation such as PDGF and EGF 52,53. The Cys residues that are 
targets for reversible oxidation at physiological pH by ROS include those with a low-pKa 
(4-5) thiol group that are in the thiolate form (S-) 54. These reactive Cys are easily 
oxidized by H2O2 to a sulfenic form (-SOH) which is unstable and can be oxidized 
successively to sulfinic acid (-SO2H) and sulphonic acid (-SO3H). The reversible 
oxidation of thiolate anion to sulphenic acid leads many effects on protein stability, 
activity, subcellular localization or protein-protein interaction 51. Other post-translational 
modifications of Cys include nitrosation (-SNO), glutathionylation (-SSG), or the 
formation of an inter- or intramolecular disulfide bond (-SS-) (Figure 3) 13,14,48,55.  
 
Figure 3. Schematic overview of reversible modifications of reactive cysteines. 
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Due to the importance of reversible modifications in cysteine residues, several 
proteomic approaches by mass spectrometry have been developed that allow us to 
identify the specific post-translational modification (PTM), the modified amino acid and 
the percentage of modified protein by that PTM. Most of the redox proteomics 
approaches initially block all free thiols with an alkylating reagent, such as 
iodoacetamide or N-ethylmaleimide, followed by the specific reduction of the PTM, 
such as dithiothreitol, and subsequent labeling with either the heavy isotope of the 
initial blocking reagent or another different 56–58. Thus, the Thiol Redox Proteome refers 
to the set of mapped protein cysteines showing reversible redox changes under given 
conditions or in response to stimuli 59. Its detailed description may provide an insightful 
snapshot of the set of thiol redox switches in a cell under given conditions 59,60. The 
identification and modulation by reversible redox PTMs of key proteins that can control 
metabolic flow, would offer promising therapeutic candidates for a number of disease 
states such as cancer 61.  
On the other hand, methionine is easily and reversibly oxidized to methionine 
sulfoxide derivatives by a wide range of ROS and might provide an analogous redox-
dependent system. Recent studies indicate that both actin polymerization and the 
activity of the Ca2+/Calmodulin-dependent kinase II (CaMKII) can be regulated by 
reversible oxidation of specific Met residue 62–64. 
This doctoral thesis has focused on the study of reversible PTMs in cysteine 
residues since its reversible nature allows them to play a critical role in 
function/enzymatic activity as redox switches involved in cell signaling. The relevance 
of these reversible modifications and their reversal by disulfide reductases will be 
described in detail later. 
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3. Redox homeostasis and antioxidant systems 
 
 The regulation of intracellular ROS levels is crucial to maintain cellular 
homeostasis since different ROS levels can induce different biological responses. 
Redox homeostasis is achieved thanks to antioxidant systems responsible for 
maintaining the balance between generation and elimination of ROS/RNS. The concept 
of biological antioxidant can be defined as any compound that is able, at low 
concentrations, to compete with another oxidizable substrate so that delays or prevents 
its oxidation. Under physiological conditions, the cell temporarily disrupts that balance, 
either by slightly increasing the concentration of ROS or decreasing the activity of one 
or more antioxidant systems, to allow redox signaling 65. Therefore, moderate levels of 
ROS promote cell proliferation and differentiation and activate stress-sensitive survival 
pathways 66. 
 As a consequence of the exposure of living beings to radical species all 
organisms have developed antioxidant systems to protect them against these reactive 
species. The antioxidant defense systems are either enzymatic or non-enzymatic. The 
enzymatic antioxidant can be divided into those that directly detoxify the radicals such 
as SOD, catalase, glutathione peroxidase (GPx), and peroxiredoxin (Prx), and those 
that react with reversibly oxidized thiol groups of proteins such as 
thioredoxin/thioredoxin reductase system (Trx/TrxR), 
glutathione/glutaredoxin/glutathion reductase system (GSH/Grx/GR), sulfiredoxin and 
methionine sulfoxide reductase. The non-enzymatic systems include numerous small 
compounds that are able to prevent oxidative damage by direct or indirect interaction 
with ROS such as lipoic acid 67, ascorbic acid 68 and glutathione 69. 
 Antioxidant enzyme systems are briefly described below and more in detail 
those that have been studied in this Thesis: Trx/TrxR  (articles 1 and 3), GSH/Grx/GR 
(article 1) and peroxiredoxins (article 2).  
 
3.1. Superoxide dismutase (SOD) 
SOD was the first well-characterized antioxidant enzyme able to catalyze the 
dismutation of O2.- to H2O2 70 . Three different types of SOD exist in mammals: copper-
zinc SOD (SOD1), manganese SOD (SOD2) and SOD3, present in the cytoplasm, 
mitochondrial matrix and extracellular medium, respectively. SODs play a critical role in 
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endothelial and mitochondrial function by preventing ONOO- and OH· formation and 
participate in compartmentalized redox signaling to regulate many vascular functions71. 
 
3.2. Catalase 
Catalase is a heme enzyme responsible for the detoxification of various 
phenols, alcohols, and hydrogen peroxide through the depletion of H2O2 to H2O and O2 
without consumption of endogenous reducing equivalents. Catalases are classified into 
three groups based on their structure and function: the first and the second group are 
formed by heme-containing enzymes whereas the third group contains manganese 
catalases. The human catalase belongs to the first group and is characterized by a 
small subunit (62 kDa), with heme b as its prosthetic group and NADPH as cofactor. 
Catalase is mainly located in peroxisomes but also in cytosol. Changes in its activity or 
expression are related to pathological processes as Zellweger syndrome, acatalasemia 
or WAGR syndrome 72. 
 
3.3 Glutathione peroxidase (GPx) 
Glutathione peroxidase is a selenium-containing enzyme that catalyses both the 
reduction of H2O2 and organic hydroperoxides to water or corresponding alcohols using 
GSH as electron donor. Eight isoforms of GPx exist in humans, five of them (GPx1, 
GPx2, GPx3, GPx4, and GPx6) contain a selenocysteine residue in their active sites 
and three employ an active-site cysteine. GPx enzymes play an important role in H2O2 
and cell signaling 73. 
The tripeptide L-γ-glutamyl-L-cysteinyl-glycine, or GSH, is the major low-
molecular-weight antioxidant in mammalian cells involved in the control of the 
thiol/disulfide redox potential of the cell. Due to the sulfhydryl group (-SH) of cysteine, 
GSH is not only used as scavenger of a wide range of ROS/RNS, but is also utilized as 
antioxidant defense by three members of glutathione peroxidase (GPx) and by 1-Cys 
peroxirredoxins. H2O2 is reduced by GSH to H2O and glutathione disulfide (GSSG) and 
then, GSSG is reduced to GSH by glutathione reductase (GR) which uses NADPH as 
electron donor. Therefore, intracellular GSH can exist as a reduced monomer or as 
oxidized disulfide dimer (GSH/GSSG) and although is mainly freely distributed in the 
cytosol (about 85-95% of concentration) can also be located in the mitochondria, 
peroxisomes, the nuclear matrix and ER.  The concentration of GSH in the cytosol is in 
the range 1-2 mM whereas in hepatocytes the concentration can reach up 10 mM. 
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However, in plasma, the concentration of GSH decreases to µM because of its rapid 
catabolism. GSH is a ubiquitous molecule that not only acts as an antioxidant defense 
molecule and an important reservoir of the amino acid cysteine but also participates in 
many different physiological processes as detoxification of xenobiotics and cell cycle 
regulation, proliferation and apoptosis 69,74,75. 
 
3.4. Peroxiredoxins (Prdx) 
 
As a member of this family, human peroxiredoxin 6, has been studied in the 
second article of this Thesis so this antioxidant family will be described in more detail. 
Peroxiredoxins (Prdx), together with CAT, SOD and GPx, are one of the most 
important enzymes involved in defense against oxidative stress, constituting a 
ubiquitous family of thiol-dependent peroxidases. Prdx family enzymes have a 
molecular weight of 20-30 kDa and are present in all the studied organisms. Their 
function consists in the reduction of H2O2, peroxynitrite and alkyl hydroperoxides to 
water, nitrite and the corresponding alcohol, respectively 76,77. For a long time, the role 
of Prdx has been studied as defense against oxidative stress and has been considered 
as the major cellular defense system against peroxides. However, in recent years, it 
has been suggested that Prxs are involved in other processes such as cell signaling or 
membrane remodelling, in addition to antioxidant defense. 
 All Prdx isoforms contain a crucially conserved active-site cysteine, known as 
the peroxidatic cysteine (Cp), which is located in a universally conserved Pxxx(T/S)xxC 
motif in the amino-terminal portion of the protein78. Six isoforms of Prdx exist in 
humans, classified into three subgroups depending on the number and localization of 
the cysteine residues involved in their catalytic activities 76,79,80: 
Typical 2-Cys Prdx subgroup (Prdx1-4)  
 They contain another additional conserved Cys, referred to as resolving 
cysteine (Cr) in the carboxyl-terminal region. Both conserved Cys residues are 
necessary for their catalytic activity. The Cp-SH is selectively oxidized by H2O2 to the 
Cp-SOH intermediate, and then an intermolecular disulfide is formed with CR-SH. 
Finally, a dithiol, usually Trx, attacks the intersubunit disulfide bridge using electrons 
from NADPH and the catalytic cycle can be repeated. Prdx can react with a second 
H2O2 molecule before it is able to react with CR-SH and originate the hyperoxidized 
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form (Cp-SO2H). The Cp-SO2H residue can be reduced by an ATP-dependent reaction 
catalyzed by sulfiredoxin (Srx) (Figure 4).  
 Typical 2-Cys Prdx in the reduced or hyperoxidized state forms homodimers 
containing two identical active sites, except Prdx2 which has been demonstrated that 
exists also in decameric forms 81. Prdx1 and Prdx2 are mainly localized in the cytosol, 
Prdx3 in mitochondria, and Prdx4 predominantly in the ER 82.  
 
Figure 4. Reaction mechanism of human Prdx1-4. Figure adapted from Seo et al. 80 Srx, Sulfiredoxin; 
Trx, Thioredoxin; TrxR, Trx reductase. 
 
 
Atypical 2-Cys Prdx subgroup (Prx5) 
 The carboxyl-terminal region of this Prdx is smaller than the 2-Cys Prdx 
described above so that the Cr (Cys-152) is closer to Cp (Cys-47). The Cp residue of the 
active site is oxidized and forms an intramolecular disulfide intermediate with the Cp 
within the same subunit. The intramolecular disulfide formed is reduced by Trx system 
(Figure 5). Prdx5 is localized in the cytosol, mitochondria and peroxisomes, and it does 
not form dimers 83. 
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Figure 5. Reaction mechanism of human Prdx5.  Figure adapted from Seo et al 80. Trx, Thioredoxin; 
TrxR, Trx reductase. 
 
1-Cys Prdx subgroup (Prdx6)  
 This Prdx has only the Cp and it does not have CR. In human, Prx6, in addition 
to the CP, contains other Cys residue at position 91. However, the function of this 
cysteine has not been solved yet. The catalytic mechanism of these peroxiredoxin 
upon exposure to H2O2 is that CP residue is oxidized and does not form a disulfide 
because of unavailability of another reduced Cys-SH nearby (Figure 6). Prdx6 uses 
GSH as a primary physiological reductant in the presence of GST-π instead of 
thioredoxin for peroxidase activity84. However, Prx1 from Saccharomyces cerevisiae 
can use glutaredoxin (Grx2) 85.  Yeast mitochondrial Prx1 can also use GSH as 
resolving thiol in a very peculiar manner without being consumed during the catalytic 
cycle and the reducing equivalents of a NAPDH provided by the mitochondrial Trx 
system 86. Prdx6 is not able to form decamers 87 and it is localized predominantly in the 
cytosol but also in other organelles such as lysosomes 88,89. 
 
Figure 6. Reaction mechanism of human Prdx6. Figure adapted from Seo et al. 80 
  
 In recent years, Prdx have been considered not only as antioxidant defense but 
also as sensors and transducers of signaling by H2O2. Because the thiol groups of the 
effectors proteins have less affinity for H2O2 compared with the Cp of Prdxs, there are 
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several mechanisms that could be involved in peroxide signaling. In addition, there are 
other enzymes that react with H2O2 faster than the target protein, such as catalase and 
glutathione peroxidase. The reversible inactivation of 2-Cys Prdx by hyperoxidation and 
the local production of H2O2 around lipid rafts are achieved by the closeness of the 
target protein to the local activation of Noxs 90. This reversible inactivation seems to be 
important for peroxide-mediated signaling and it has been labelled the 'floodgate mode' 
91. Indeed, both the local concentration of H2O2  and the inactivation of local H2O2-
eliminating enzymes are important to oxidize a target protein. Some of those target 
proteins that are directly oxidized by H2O2 are protein tyrosine phosphatases (PTPs) 
such as PTEN, protein tyrosine kinases (PTKs) such as Src family members, AGC 
protein kinases such as Akt, or transcription factors such as Activator Protein 1 (AP1) 
and Nuclear Factor-κB (NF-κB) 90,92.  
 Hyperoxidation triggers the formation of high molecular weight forms of 2-Cys 
Prdx which acquire a new function as chaperone 93. On the other hand, hyperoxidation 
allows for the accumulation of H2O2 for signaling purposes such as MAPK signaling 
pathway which has been involved in cellular outcomes as diverse as proliferation, 
survival, differentiation and death 92. An example of the inactivation of the signaling by 
inactivation of Prdx is the hyperoxidized form of Prdx3 resulting from leaky cytochrome 
p450 during the conversion of cholesterol to corticosterone that has a role in the 
regulation of steroidogenesis. The inactivation of Prdx3 activates p38 mitogen-
activated protein kinase (MAPK) which leads to the inhibition of steroidogenesis 94. 
Moreover, the Prdx3-SO2H and Srx in the mitochondria of adrenal gland have a 
circadian oscillation as a conserved mechanism which is important to control the 
circadian oscillation of corticosterone 95. 
 Another H2O2 signaling mechanism consists in Prdx-mediated oxidation instead 
of directly by H2O2. Oxidized Prdx forms a intermolecular disulfide with a bound effector 
protein that then through reshuffling of Prdx would transmit the oxidized state to the 
effector protein. In mammals, Prdx1 physically interact with apoptosis signaling kinase 
1 (ASK1) resulting in ASK1-ASK1 oligomers and then ASK1 activation. Prdx1 also 
catalyzed the oxidation of the multifunctional protein APE1/Ref-1. The same happens 
with Prdx2 and the transcriptional factor STAT3 or the redox sensitive chaperone DJ-1  
90,92,96. Oxidized Prdx4 forms an intramolecular disulfide with protein disulfide 
isomerase (PDI) which then allows PDI to transfer the disulfide bond to a target protein 
in the ER for the correct folding of the protein 92. 
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 Last but not least, Prdx are involved in H2O2 signaling by modulating the redox 
state of thioredoxin which is responsible for the reduction of the Prdx disulfide. It has 
been proposed that it is the oxidation of Trx that allows the target protein to be 
oxidized. Recent studies carried out in Saccharomyces cerevisiase suggest that in 
some cases the main role of Prdx may be regulating the redox state of Trx, rather than 
eliminating H2O2  90.  
 Prdx could regulate the redox state of signalling pathways proteins involved in 
redox homeostasis and in the control of cellular physiological functions such as growth, 
apoptosis, differentiation, embryonic development, lipid metabolism, and immune 
response. Recently, Prdx have been linked to different pathologies as the development 
of cancer and neurodegenerative and inflammatory diseases 77,97. 
3.4.1. Peroxiredoxin 6 
 Prdx6, the 'non-selenium glutathione peroxidase', is the unique member of the 
Prdx family that belongs to the 1-Cys that not only has general peroxidase activity. This 
enzyme also presents three lipid-related enzymatic activities associated with 
phospholipids such as a) hydrolysis of the sn-2 fatty acyl bond of glycerophospholipids 
to produce free fatty acids and a lysophospholipids, i.e., phospholipase A2 activity 
(PLA2) 88,98; b) reduction of phospholipids hydroperoxides to the corresponding alcohol, 
i.e., phospholipid hydroperoxide glutathione peroxidase activity (PHGPx) 99; and the 
more recently discovered c) transfer of a fatty acyl CoA to the sn-2 position of 
lysophosphatidylcholine (LPC), i.e., LPC acyl transferase (LPCAT) activity 100. Hence, 
Prdx6 is a true "moonlighting" protein. Its expression is mediated by Nrf2 via an 
antioxidant response element-driven mechanism 101. 
 It is worth to note that Prdx6 is the only member of the peroxiredoxins family to 
be able to reduce peroxidized phospholipids in the cell membrane 99,102. Ser32 and 
His26 residues of Prdx6 are essential for oxidized phospholipid binding 102. Both the 
peroxidase and PLA2 activities of Prdx6 can play an important role in the repair of 
peroxidized phospholipids in cell membranes giving to Prdx6 the ability to protect cells 
against oxidant stress 103. 
 The catalytic center for PLA2 activity of Prdx6 is formed by Ser32-His26-
Asp140, a triad of amino acids commonly expressed in proteases and proteins with 
PLA2 activity 104. The triad Ser32-His26-Asp140 is at the protein surface while Cys47 of 
peroxidase activity is located at the base of a shallow pocket (Figure 7). The distance 
between Ser32 and Cys47 is ~ 28 Å and there are few positively charged amino acids 
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forming a groove between the two active sites 105. PLA2 activity is greater with 
phosphatidylcholine (PC) as substrate than phosphatidylethanolamine and 
phosphatidylglycerol and Prdx6 shows no preference for the sn-2 acyl group 89. 
 
Figure 7. Ribbon of the model of Prdx6 3D structure with highlighted cysteine residues. 
PDB:1prx  
 
 The subcellular localization of Prdx6 is important because PLA2 activity is 
optimal at pH 4 and peroxidase activity at pH 7-8 98 and also at pH 4 the peroxidase 
activity of Prdx6 is likely 2 orders of magnitude greater than the PLA2 activity 106. This 
pH specificity for both enzymatic activities can be explained by the differential binding 
kinetics of the Prdx6 102,104. Prdx6 can be phosphorylated at Thr177 by mitogen-
activated protein kinase (MAPK; ERK or p38) activity increasing the PLA2 activity both 
at pH 4 and 7 without affecting its peroxidase activity. Thus, this suggests a 
physiologically regulated system which allows Prdx6 to act either as peroxidase or 
PLA2 at neutral pH under oxidative stress conditions 107. Furthermore, Prdx6 is targeted 
to acidic organelles after binding to the 14-4-3ε protein at a peptide (31-40 aa) 
previously phosphorylated by MAPK; Ser32 is essential for this binding 108,109. 
 Phosphorylation of Prdx6 also has a critical role in the activation of Nox2, a 
protein of the Noxs family. Nox2 is the canonical Nox responsible for O2.- generation in 
neutrophils to kill bacteria as well as playing an important role in normal cell signaling 
during cell proliferation and cell migration among other processes 51. Phosphorylated 
Prdx6 through PLA2 activity is essential for translocation of Nox2 cytoplasmic 
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components and activation of the enzyme complex in response to angiotensin II (Ang 
II) or phorbol 12-myristate 13 -acetate in pulmonary microvascular endothelial cells 
(PMVEC). However, it is unknown which product of PLA2 activity is responsible for 
Nox2 activation 110. The PLA2 activity is also regulated by p67phox, a component of the 
Nox2 activation cascade that binds to phosphorylated Prdx6 and inhibits its PLA2 
activity 111. In addition to Nox2, Prdx6 has been shown to bind to the SH3 domains of 
Nox activator 1 (Noxa1), a Nox1-supportive components, and co-stabilize it, activating 
Nox1 oxidase activity. Both peroxidase and PLA2 activities support the Nox1-mediated 
migration of colon epithelial cells. However, it seems that the mechanism that regulates 
Nox1 and Nox2 are different 112. The role of Prdx6 in the activation of Noxs denotes 
that Prdx6 acts at the same time as pro-oxidant, activating Nox1 and Nox2 that play an 
essential role in cell signaling, or anti-oxidant by peroxidase activity preventing the 
damage caused by oxidative stress.  
 
 Phospholipids are the major constituents of cell membranes and hydroperoxids 
phospholipids generated in response to oxidative stress alter the physicochemical 
properties of membranes, resulting in cellular dysfunction 113. A study carried out in 
Prdx6 -/- mice indicated that PLA2 activity plays an important role in the synthesis via 
deacylation/recyclation pathway and in the degradation of internalized dipalmitoyl 
phosphatidylcholine (DPPC), the major phospholipid component of lung surfactant,  
involving Prdx6 in both the degradation and the remodelling of lung surfactant 
phospholipids 114–116.  
 The peroxidase activity is not the main mechanism for Prdx6 antioxidant 
function, the PLA2 activity also plays an important role in protecting cells against 
oxidative stress as well as cell membrane repair. Peroxidation of cell membrane 
phospholipids is one of the major indicators of oxidative stress that can result in cell 
death. This damage can be reversed through peroxidase activity or hydrolysis of the 
phospholipid fatty acyl bond (PLA2 activity) followed by reacylation with a reduced fatty 
acyl CoA (LPCAT activity) but both activities are necessary for the maximal rate of 
recovery. Therefore, both peroxidase activity and PLA2 and LPCAT activities of Prdx6 
are responsible for repairing peroxidized membrane phospholipids, a process essential 
for cell survival 103,117,118.  
 Prdx6 not only has physiological functions in normal cells but also its 
overexpression has been demonstrated to be involved in some pathologies such as 
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CNS neurodegenerative diseases (Parkinson's disease119,120 and Alzheimer's 
disease121), diabetes 122, male infertility 123,124, and cancer 125.  
 
3.5. Thiol disfulfide reductases 
 This enzymatic antioxidant family covers those systems that react with 
reversibly oxidized thiol groups of proteins. They are thioredoxin/thioredoxin reductase 
system (Trx/TrxR system), glutathione/glutaredoxin/glutathion reductase system 
(GSH/Grx/GR system), sulfiredoxin, methionine sulfoxide reductase and S-
nitrosoglutathione reductase. 
 
3.5.1 Trx/TrxR system 
The thioredoxin system consists of redox-active thioredoxin (Trx), thioredoxin 
reductase (TrxR) and NADPH and was discovered as the electron/hydrogen donor for 
ribonucleotide reductase (RNR) 126. Trx (~12 kDa) is a small thiol-disulfide 
oxidoreductase expressed ubiquitously in all organisms and it is essential for 
embryonic development 127–129. Two distinct Trx systems exist in mammals: Trx1/TrxR1 
which constitutes the cytosolic system but also can be translocated into the nucleus or 
can be exported and acts as cytokine or chemokine, and Trx2/TrxR2 system located in 
the mitochondria. In addition, a third testis-specific TrxR3 exists that is expressed in 
germ cells and is known as thioredoxin glutathione reductase (TGR) 130,131. The 
expression of Trx1 is regulated both by nuclear factor E2-related factor 2 (Nrf2) 132. 
All members of Trx of all organisms share the same overall 3D structure called 
“Trx-fold” which consists of three α-helices surrounding a central core of a four-
stranded β-sheet. The conserved motif Cys-X-X-Cys of the active site, located on the 
exterior, promotes the electron and disulfide exchange between Trx and their 
substrates.  In mammals, the active site of Trx contains the motif Cys-Gly-Pro-Cys 
which is highly conserved 133. The first step of the catalytic mechanism consists of a 
nucleophilic attack on a target disulfide by the N-terminal active site thiol, which has a 
low pKa, resulting in the formation of a transient covalently bound mixed disulfide. In the 
second step, the mixed disulfide is reduced by the C-terminal active site thiol yielding 
the reduced target and oxidized Trx. Lastly, the disulfide in the active site of Trx is 
reduced by TrxR using the electrons provided by NADPH (Figure 8). Because of the 
low redox potential of its active site dithiol, catalysis of the reaction by Trx is 
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thermodynamically more favourable than that catalyzed by GSH. For this reason, Trx 
becomes the major disulfide reductant in the cytosol 130,131,134–136.  
 
Figure 8. Reaction mechanism of human thioredoxin. Figured adapted from Arnér & 
Holmgren 131. Trx, Thioredoxin; TrxR, Thioredoxin reductase. 
 
Unlike the rest of organisms, the three mammalian TrxR are selenoproteins with 
flavin adenine dinucleotide (FAD) and NADPH binding domains. Mammalian TrxR has 
the conserved Gly-Cys-SelenoCys-Gly motif at C-terminal as a catalytic active site that 
is essential to reduce Trx and other substrates. TrxR is a homodimeric protein and both 
subunits are essential to build the electron transfer pathway from NADPH to Trx during 
a single catalytic cycle. Due to TrxR enzymes ability to reduce a wide range of 
substrates, these could be divided into two groups: i) substrates that may be reduced 
by the easily accessible active site of the enzyme such as Grx2 and protein disulfide 
isomerase (PDI), and ii) some low molecular weight antioxidants (LMWA) that can be 
reduced directly by the FAD motif at the N-terminal domain of the enzyme such as 
dehydroascorbate. TrxR are not only important as antioxidant defense systems but 
also as regulators of redox-sensitive cell signaling pathways. TrxR are related with 
some pathologies as male infertility, cataract, Alzheimer's disease and cancer 137,138. 
TrxR1 is overexpressed in multiple types of cancer so specifically inhibiting TrxR1 
could be a good anticancer therapy 139,140. 
The reductase activity of Trx1 is inhibited by the Trx interacting protein (TXNIP), 
also called Trx-binding protein-2 (TBP-2), which interacts with the active center of Trx1 
through the formation of a disulfide bond between the Cys32 in Trx1 and Cys247 in 
TXNIP 141–143. TXNIP, together with importin α1, mediates the nuclear import of Trx1 
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144,145. In addition to inhibiting Trx1, TXNIP is a multifunctional protein that regulates 
lipids and glucose metabolism, inflammation and tumorigenesis 146.  
Nitric oxide participates in cellular signal transduction through reversible S-
nitrosation of the thiol group of Cys, forming S-nitroso-proteins (SNO-proteins).  S-
nitrosation results from three different reactions: nitric oxide-derived species, such as 
N2O3, by oxidation of SNO radical anion (RSNO.-) or by the transfer of the NO group 
from an S- nitrosothiol (SNO) to an acceptor Cys thiol known as S-transnitrosation. The 
selectivity of S-nitrosation is achieved in part by a high degree of spacetime accuracy 
and by the existence of a hydrophobic motif characterized by aromatic residues. 
Transnitrosases are SNO-proteins that transfer its NO group to an acceptor protein 147.  
The two enzymatic systems that denitrosate in physiological contexts are the 
Trx/Trx system and GSH/GSNO reductase. S-nitrosoglutathione (GSNO) represents 
the principal low-molecular-weight SNO in cells. Its levels are regulated by GSNO 
reductase (GSNOR) and it reacts with reduced Cys thiol to form SNO-proteins and 
GSH. GSNO reductase does not directly denitrosate SNO proteins, but as the GSNO 
pool is in equilibrium with protein thiols, reduction of GSNO by GSNOR indirectly 
results in protein denitrosation 148,149. 
The Trx/TrxR system catalyzes both transnitrosation and denitrosation of Cys 
thiol 147. In addition to the catalytic cysteines, Trx1 contains three extra Cys residues 
(Cys62, Cys69, and Cys73) (Figure 9). Cys73 is physiologically S-nitrosated and it is 
able to transnitrosate the caspase-3 protein forming SNO-caspase-3, which leads to 
inhibition of its activity 150. A number of studies report on targets of Trx1-mediated 
transnitrosation or denitrosation, including Prx1 151,152. Nitrosation of Cys73 of Trx is 
favoured after the formation of a disulfide between Cys32-Cys35 that is responsible to 
attenuate the Trx1 disulfide reductase and denitrosase activities 151. On the other hand, 
Trx/TrxR system is the major SNO-protein denitrosase of a wide spectrum of nitrosated 
proteins that is present in all living organisms 153,154. Trx1 catalyzes the direct 
desnitrosation of SNO-protein through the formation of a mixed disulfide intermediate 
between Cys32 and Cys35 of Trx and the target protein 148,155. Trx1 catalyzes 
desnitrosation of Caspase-3 148. NOS3 (or eNOS) itself is also a target of Trx1 leading 
to activation of the enzyme as part of a regulatory mechanism of NOS3 by reversible 
auto-S-nitrosation 155,156. Thus, as the principal regulator of redox signaling, under 
physiological conditions, Trx1 protects against oxidative damage via reductase activity, 
but under oxidative stress, the oxidized Cys32-Cys35 accumulates and Cys73 
becomes S-nitrosated. In this way, Trx1 offers an alternative modality of protein 
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regulation via transnitrosation 151. So depending on the redox state of the cell, Trx1 
catalyzes either trans-S-nitrositation or S-denitrositation. 
Due to the variety of substrates, Trx1 is involved in signaling pathways such as 
cell growth, proliferation and apoptosis, transcriptional regulation and the most widely 
studied, disulfide reduction of oxidized proteins to maintain the redox balance and 
facilitating the reduction of H2O2 by supporting peroxidase actions of peroxiredoxins. 
Trx1 supports the peroxiredoxin family in the reduction of hydrogen and lipid peroxides 
through the reduction of oxidized Prdxs 136,152. 
 
Figure 9. Ribbon of the model of Trx1 3D structure with highlighted cysteine residues. 
PDB:4rqr 
 
The phosphatase PTEN is the terminator of the Akt signaling pathway that is 
important for cell proliferation, growth, and survival. Cy32 of Trx1 directly interacts with 
Cys212 of the C2 domain of PTEN and inhibits its phosphatase activity leading to 
activation of the Akt pathway and eventually resulting in cell proliferation 157. Another 
process regulated by Trx1 is apoptosis.  Under physiological conditions, reduced Trx is 
binding to ASK1, inhibiting apoptosis. However, when ROS levels increase, Trx1 is 
oxidized leading the dissociation of the complex and activation of apoptosis signal 
cascade 158,159. Apoptosis is also redox-regulated through modulation of caspases 
whose activity depends on modifications in the thiol state of their active site such as S-
nitrosation. As described above, Trx1 catalyzes the denitrosation by means of its 
canonical active site dithiol 148 or trans-nitrosation from Cys73-SNO 150. 
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 The DNA-binding activity of several transcription factors has been shown to be 
modulated post-translationally by redox changes in cysteine residues 160–162. Trx1 
regulates the activity of the tumor suppressor protein p53, NF-кB, and AP-1. NF-кB 
controls many biological processes including cell survival, proliferation, immunity, and 
inflammation 163. In the cytosol, NF-кB activation is inhibited by reduced Trx1 but under 
oxidative conditions, Trx1 is translocated to the nucleus and enhances the DNA-
binding activity of NF-кB through the reduction of the essential Cys62 164,165. As with the 
activation of NF-кB, AP-1 is redox-regulated by Trx1 and the Redox Effector Factor 1 
(Ref-1). AP-1 is a complex formed by c-FOS, c-Jun and ATF sub-families which is 
involved in a wide range of cellular processes as cellular proliferation, death, survival 
and differentiation 166. After exposure to IR, reduced Trx1 interacts with Ref-1 in the 
nucleus and enhancing the AP-1 DNA binding activity 167–169. The same happens with 
p53, Trx1 and Ref-1 enhanced p53 expression 170. 
 
3.5.2. GSH/Grx/GR system 
The glutaredoxin system consists of glutathione (GSH), glutaredoxin (Grx) and 
NADPH-dependent glutathione reductase (GR). The Grx was discovered by Arne 
Holmgren in 1976 as an alternative electron donor for RNR in E.coli. Grx was then 
characterized as GSH-dependent oxidoreductase 171–173.  
Structurally, Grxs belong to the Trx-fold family of proteins. Trx and Grx share a 
common structural motif which consists of a four-stranded β-sheet surrounded by three 
α-helices and a similar active site motif located on the loop connecting β-sheet 1 and α-
helix 1 and a cis-Pro residue 174. Human Grx contains two additional α-helices 175. 
However, Grx displays two unique structural features:  an active site environment that 
gives the advantage to be attacked by GSH  and a hydrophobic surface area that 
allows it to interact with protein substrates (Figure 10) 176,177. Grx are, depending on the 
number of active site Cys residues, classified into dithiol (Cys-Pro-Tyr-Cys) and 
monothiol (Cys-Gly-Phe-Ser) enzymes which are able to bind and use GSH as 
substrate despite its lack of the second active site cysteine. Grx are versatile 
oxidoreductase able to reduce a variety of substrates as protein disulfides, mixed 
disulfides as in protein deglutathionylation and at least one compound devoid of thiol 
groups such as ascorbate.  
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Figure 10. Ribbon of the model of Grx1 3D structure with highlighted cysteine residues. 
PDB:1ert   
 
Similar to Trx, Grx catalyze the reversible reduction of protein disulfides through 
the dithiol mechanism which utilizes both cysteine residues in their active site and then 
the oxidized Grx is reduced by GSH and glutathione reductase (GR) using NADPH as 
electron donor. In the first step, the target disulfide is nucleophilically attacked by the 
more N-terminal Cys residue and then the disulfide intermediate formed between the 
two proteins is attacked by the second active site thiolate. The resulting disulfide in the 
active site is reduced by one molecule of GSH and the mixed disulfide form is 
subsequently reduced by a second GSH. Grx catalyze deglutathionylation of proteins 
(Proteins-SSG) usually through a monothiol mechanism in which the second Cys of the 
active site, if present, does not participate. Regardless the mechanism, the resulting 
glutathione disulfide (GSSG) is regenerated by glutathione reductase (GR) using 
NADPH (Figure 11) 130,131,174,178. Both NADPH-dependent thioredoxin reductase and 
glutathione reductase, besides providing reducing power for production of DNA 
precursors by RNR, are responsible for recycling the Trx and Grx systems in a way that 
maintains redox homeostasis, preventing and repairing oxidative stress as well as 
regulating cell signaling 179. 
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Figure 11. Reaction mechanism of human Grx1. Figured adapted from Arnér & Holmgren 131. 
GSH, reduced glutathione; GSSG, oxidized glutathione. 
 
A plethora of Grx are coded for in plant genomes 180, but in mammals, four Grxs 
have been described: Grx1 and Grx2 as dithiol, and Grx3 (also known as protein 
interacting cousin of Trx, PICOT) and Grx5 as monothiol 131. Grx1 is mainly localized in 
the cytosol, but it can be translocated to the nucleus, exported from the cell and in the 
intermembrane space of mitochondria 174,181. Grx2 is located in the mitochondria and in 
the cytoplasm and nucleus of testes and in a number of tumor cells 182. Grx3 is present 
in the nucleus and cytoplasm while Grx5 is found in mitochondria 131.  
Grx1 is involved in multicellular processes as protein disulfide reduction such as 
ribonucleotide reductase 183 and post-translational modification of proteins by S-
glutathionylation with a role mainly as a deglutathionylase 184,185. Protein S-
glutationylation is a post-translational modification of specific Cys residues regulating 
the normal function of proteins with an important role in redox signaling. S-
glutationylation may be enzymatic catalyzed by glutathione transferases such as 
glutathione s-transferase π 186, but it is mainly a spontaneous consisting of the 
reversible formation of a protein mixed disulfide with GSH (Protein-SSG). It exists 
several mechanisms of protein-SSG formation: i) the thiol-disulfide exchange with 
GSSG but it is an unlikely mechanism of protein S-glutationylation since the required 
very low GSH/GSSG ratio is unlikely under physiological conditions; ii) the sulfenic acid 
(-SOH) formed at sensitive protein Cys after oxidation by ROS/RNS reacts quickly with 
GSH to form protein-SGG; and iii) by consumption of glutathione thiyl radicals (GS·); 
and iv) by reaction with GSNO. S-glutationylation modifies key proteins that belong to 
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several functional categories such as redox homeostasis, protein folding and 
degradation, Glycolysis, energy sensing, insulin signaling, calcium homeostasis, the 
cytoskeleton, apoptosis and transcriptional regulation 184,187–189. 
The GSH/Grx/GR system catalyzes reversible deglutathionylation of protein-
SSG both through dithiol and monothiol mechanisms; however, the monothiol 
mechanism is prevalent. The N-terminal active site cysteinyl residue of Grx forms a 
GSH-mixed disulfide intermediate. Thus, the target protein is reduced and the Grx-SSG 
formed is reduced by GSH to produce GSSG as a product 190.  
Grx1 regulates apoptosis via MAPK, ASK1 and caspase-3 just like Trx1. 
Reduced Grx1 binds to ASK1 inhibiting its kinase activity but oxidation of Grx1 results 
in dissociation of the complex and therefore in the activation of ASK1 protein kinase 
activating JNK1- and p38-dependent signal pathways 191.There is a crosstalk between 
protein S-glutathionylation and S-nitrosation. Caspase-3 is also susceptible to inhibition 
by glutathionylation, and this is regulated by Grx1 192. The same happens with NOS3, 
Grx1 regulates its activity by deglutathionylation 193. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 194 and protein tyrosine phosphatase 1B (PTP1B) 195 also 
targets proteins of Grx1 deglutathionylase activity. Recently, other targets of the Grx1 
deglutathionylase activity have been found, such as IL-1β 196, DJ-1 and HSP60 197. 
 
3.5.3. Methionine sulfoxide reductase (Msr) 
 The amino acid methionine, like cysteine, is also a target ROS can be oxidized 
to methionine sulfoxide (MetO) forming two enantiomers: S-MetO and R-MetO. This 
oxidation is reversed by the methionine sulfoxide reductases (Msr) and Trx/TrxR 
system that can catalyze the reduction of free and protein-bound MetO 198. The Msr 
system consists of two major proteins, MsrA and MsrB, that can reduce both 
enantiomers. In human, MsrA enzyme can be found in two isoforms: one form that can 
be transported to the mitochondria and another form that is located in the cytosol. MsrB 
proteins (selenoprotein (MsrB1) and the other two non-selenoproteins (MsrB2 and 
MsrB3), could be targeted to different subcellular compartments. Due to their action, 
Msr enzymes are involved in regulation of protein function, in signal-transduction 
pathways, and preventing cellular accumulation of faulty proteins. Msr system failures 
can promote oxidative damage and neurodegenerative diseases as well as shorter life 
span 199. 
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3.5.4. Sulfiredoxin (Srx) 
 Sulfiredoxin (Srx) is a recently discovered member of the oxidoreductases 
family that catalyzes the reduction of the cysteine sulfinic acid (hyperoxidation) of the 2-
Cys peroxiredoxins enzymes back to their stable thiol state using ATP and magnesium 
200. Therefore, the inactivation of Prdx caused by the increased in hydrogen peroxide 
as an intracellular cell signaling agent is reversed by Srx 201. Another important 
possible function of Srx is the deglutathiolylation of proteins such as peroxiredoxin, 
actin and protein tyrosine phosphatase 1B 202. Srx is mainly located in the cytosol but it 
gets translocated to the mitochondria during an oxidative stress 203.  
 
3.5.5 S-nitrosoglutathione reductase (GSNOR) 
 Human S-nitrosoglutathione reductase (GSNOR) or ADH5, belongs to alcohol 
dehydrogenase (ADH) family. It is the unique member of the family that not only use 
short-chain alcohols as the main substrate but also GSNO and S-
hydroxymethylglutathione. GSNOR regulates the levels of intracellular NO• available by 
catalyzing the breakdown of GSNO so indirectly regulates protein-S-nitration. It is 
located to the nucleus and cytoplasm and functions as a homodimer 204. It has been 
demonstrated that GSNOR deficiency together with defective DNA repair promote 
hepatocarcinoma carcinogenesis 205.  
 
 
 
 
 
 
 
 
 
 
Introduction 
28 
 
4. Redox homeostasis, redox signaling and cancer 
 
 Redox homeostasis, that is, the correct balance between the levels of 
ROS/RNS and antioxidant systems is essential for the proper functioning of cells. A 
wide variety of stimuli by different signal molecules (growth factors, cytokines and G-
protein-coupled receptors) have been described which generate H2O2, which can have 
a dual role, either in signaling or in oxidative stress 206. In addition, a large number of 
kinases, phosphatases or transcription factors involved in signaling are regulated by 
their redox state. This will affect key cellular processes such as proliferation, 
differentiation or death.  
 In humans, oxidative stress has been linked to a wide variety of serious 
diseases, such as neurodegenerative disorders, atherosclerosis, hypertension, 
inflammatory disease, immune system dysfunctions, type 2 diabetes, aging and cancer 
16,65,207,208. The central nervous system (CNS) is particularly susceptible to oxidation 
due to the high lipid content and consumption of oxygen, and low levels of antioxidant 
enzymes. The hippocampus, subtantia nigra and striatum are region of the brain that 
may attack by free radicals. So the oxidative stress is involved in neurodegenerative 
diseases as Alzheimer's and Parkinson's 6. Type 2 diabetes is characterized by an 
altered production of ROS. The main source of ROS seems to be the mitochondria, 
whose morphology is altered resulting in mitochondrial dysfunction. The relationship 
between insulin resistance and constitutive ROS production is attributed to alterations 
in signaling pathways such as JNK pathway 14. 
 This doctoral thesis has focused on cancer, oxidative/nitrosative stress and the 
role of redoxins. Specifically, a model of human hepatocarcinoma, HepG2 cell line has 
been studied. Hepatocarcinoma (HCC) is the most common liver malignancy and is 
one of the leading causes of cancer death in the world. It represents 80% of the 
primary hepatic neoplasm that appears mainly in a context of chronic liver cirrosis. It is 
the sixth most frequent neoplasm, the third cause of cancer death, and 7% of 
registered malignancies 209. Gene mutations that encode signaling proteins that 
regulate cell division and cell death are those that transform a normal cell into tumor 
cells. Although in patients with hepatocarcinoma, the main prevalent genetic mutations 
are related to telomerase signaling, Wnt-B-catenin, PI3/Akt/mTOR, p53 and MAPK, 
alterations in redox regulatory mechanisms are also observed 210. 
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 Cancer cells are characterized by the production of high levels of ROS due to 
hypoxia-inducible factor 1 (HIF-1), enhanced metabolic activity, mitochondrial 
dysfunction, oncogene and tumor suppressor activities, activation of Nox, etc. 
Moreover, the tendency of cancer cells to undergo major changes in their own 
metabolism (Warburg metabolic reprogramming), such as increased activity in aerobic 
glycolisis and deregulation of lipid metabolism is also partly modulated by oxidative 
stress. It has been shown that there is a relationship between oncogenes signaling and 
oxidative stress (eg., activation of Ras increases ROS levels produced by oxidative 
phosphorylation that is essential for proliferation) 211–214. However, cancer cells 
proliferate despite the elevated ROS production thanks to the induction of antioxidant 
defenses 215.  
 Hanahan and Weinberg originally described six mutation-driven acquired 
competencies that a tumor cell needs 216. Ten years later, they have updated the list of 
hallmarks, and each of them is related to alterations in signaling transduction 213. Many 
signaling pathways that are involved in tumor development, progression and 
malignancy such as cellular proliferation, evasion of apoptosis or anoikis, tissue 
invasion and metastasis and angiogenesis are redox-sensitive 217. A number of 
signaling proteins that undergo redox changes are targets of redoxins, including Trx1 
and Grx1. In addition, it has been shown that Trx1 and TrxR1 are often overexpressed 
in tumor cells and that high Trx1 could be linked to drug resistance during cancer 
treatment 218.  
 
4.1. Redox signaling pathways involved in carcinogenesis 
In cancer cells, high rate of proliferation and evasion of apoptosis depends on 
the constitutive activation of redox-sensitive signal-transduction at the level of kinases 
such as MAPK family and PI3K/Akt, phosphatases as PTPB1, PPA2 and PTEN or 
some redox-sensitive transcription factor as NF-κB, Nrf2 and STAT. ROS activates the 
members of MAPK family including ERK1/2, JNK, and p38 promoting proliferation, 
migration, and invasion in HCC 219. Hepatocyte growth factor (HGF) induced H2O2 
generation and JNK phosphorylation in HCC 220. This MAPK activation requires the 
oxidation and inactivation of several PTPs that dephosphorylate MAPKs including 
oxidation in the active site Cys215 of PTPB1 221 which is reduced by Trx1 222. 
Moreover, Grx1 also regulates Cys215 of PTPB1 via glutathionylation 195. On the other 
hand, activities of JNK and p38 are regulated by the upstream ASK1. ASK1 plays 
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important role in tumorigenesis by regulating apoptosis and inflammation 223,224 and the 
association with Trx1 159,225 and Grx1 191 regulates its activity.  
 ROS induce also PI3K/Akt signaling which contributes to tumorigenesis and 
facilitates the invasion and metastasis by promoting matrix metalloproteinase-9 (MMP-
9) secretion 226. Akt, also called protein kinase B (PKB) can be inactivated by protein 
phosphatase 2 (PP2A) dephosphorylation when Akt is in its oxidized form which 
suggests that Akt is a redox-regulated protein. It has been shown that Grx1 prevented 
Akt from forming a specific disulfide bond between Cys297 and Cys311 and 
suppressed its association with PP2A under oxidative stress 227. ROS-Akt signaling is 
activated by inactivation of PTEN through sulfenylation at Cys124 followed by Cys71-
Cys124 disulfide bonding that is reverted by Trx1 228. Therefore, ROS mediate 
hyperactivation of PI3K/Akt signaling that results in promotion of tumor cell survival, 
apoptosis inhibition and resistance to chemotherapy 229. Regarding apoptosis, there is 
a relationship with the level of redoxins. As described before, Trx/TrxR system 
catalyzes the denitrosation of caspase-3 thus showing an anti-apoptotic action. Some 
experimental data suggested that Trx/TrxR system also participates in the denitrosation 
of SNO-caspase-9 and the reductive reactivation of caspase-8 230. NO· production has 
an important role in the regulation of the carcinogenic process. For instance, S-
nitrosation of some proteins, such as CD95, stimulates apoptosis whereas S-
nitrosation of other proteins, such as caspases and Bcl-2, inhibits apoptosis 231. In 
addition, NO· stimulates the proliferation of tumor cells through PI3K/Akt signaling 
activation by nitrosation of Ras Cys118 232. In HepG2 cells, overexpression of NOS3 
has antiproliferative effect 233. NF-κB is a redox-sensitive transcription factor that plays 
an important role in regulating gene expression involved in cell survival, proliferation, 
immunity, and inflammation 163. ROS can regulate NF-κB activity. As described above, 
DNA-binding activity of NF-кB is regulated by Trx1 164,165. In cancer cells, NF-кB 
activates the expression of many genes involved in cell transformation, proliferation, 
and angiogenesis 234. It has been described that ROS production and NF-κB activation 
promote hepatocellular carcinoma progression 235. 
 Despite the high production of ROS, cancer cells proliferate thanks to the 
induction of antioxidant defense expression such as Trx and proteins that regulate 
GSH levels through the activation of the transcription factor Nrf2 215, the major driver of 
redox-sensitive gene expression. In the cytoplasm, Kelch-like ECH-as-associating 
protein 1 (Keap1) interacts with Nrf2 inhibiting its activity. Under oxidative conditions, 
Keap1 is oxidized and dissociates from Nrf2 allowing its activation 66. The redox state 
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of Cys273 and Cys 288 of Keap1 seem to be critical for the ubiquitination-promoting 
activity 236.  
 STAT3 is a transcription factor that promotes cell survival and proliferation and 
is constitutively activated in human cancer cell lines. STAT3 is activated by tyrosine 
phosphorylation and then dimerized and translocated into the nucleus, where together 
with other transcription factors activates the expression of latent genes. Constitutive 
phosphorylation of STAT3 causes important changes in apoptosis, angiogenesis, 
invasion, migration and proliferation resulting in malignant transformation in cancer 
cells 237. Tyrosine phosphorylation of STAT3 is regulated by ROS and itself also 
influences ROS production. It has been described that STAT3 transcriptional activity 
depends on its thiol state, which is influenced by H2O2 and Prx2 levels and by the 
thioredoxin system activity 238. These authors have found that inhibition of TrxR 
increased STAT3 oxidation and as a consequence decreased its activity. In this 
oxidation state of STAT3 they have observed the formation of Trx1-STAT3 disulfide 
exchange intermediates, suggesting that Trx1 may be a direct mediator of STAT3 
disulfide reduction. Prdx6 also promoted growth of lung tumors in mice through 
activation of JAK2/STAT3 signaling 239. The role of Prdx6 is cancer is controversial and 
it has not been much related to cell signaling. Both, peroxidase and PLA2 activities of 
Prdx6 were required for tumor development in xenografted mice lung in a process 
dependent on arachidonic acid (AA) release 240. AA production and Nox2 activation 
was also involved in stimulation of metastasis by Prdx6 PLA2 activity in several cancer 
models 240,241, although in another study Nox2 activation was shown to proceed by 
Prdx6 mediated lysophosphatidic acid (LPA) receptor activation 242. 
 
 
4.2. Impact of redox modulation of protein function on cell metabolism in HCC 
 
 The activation of oncogenes and the inactivation of tumor suppressors cause a 
reprogramming in the metabolism of a tumor cell 243. Cancer cells are characterized by 
having a high rate of aerobic glycolysis that they use to generate ATP in the presence 
of oxygen, which is known as the Warburg effect. Tumor cells redirect glucose to the 
pentose phosphate pathway (PPP) to generate NADPH, and macromolecules such as 
non-essential amino acids, nucleotides and fatty acids that are necessary to cope with 
the high proliferation rate 244,245. Glucose can also be used to produce ATP and lactate 
thus maintaining the NAD/NADH ratio, which contributes to tumor progression 246. The 
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tricarboxylic acid cycle (TCA) is still active in tumor cells but depends primarily on 
glutamine metabolism, which replenishes the TCA intermediates. Cancer cells, instead 
of using TCA for the synthesis of ATP, prefer the intermediates for the production of 
NADPH and to support fatty acid synthesis in hypoxia or under downregulation of 
oxidative phosphorylation 247. 
The increase in the metabolism of a tumor cell is usually related to an increase 
in ROS. However, tumor cells adapt to acquire resistance to oxidative stress so that 
they can increase their metabolism and proliferation rate without suffering oxidative 
damage 207. The tumor cell uses, in addition to the PPP 248, the folate 249 and malic 
enzyme pathways 207 to generate NADPH, a cofactor that is necessary in the 
biosynthetic pathways and to maintain reduced levels of GSH 250. The diversion of 
glucose to PPPs, glycerol and serine pathways is determined in part by the activity of 
pyruvate kinase 2 (PKM2) and glyceraldehyde-3-phosphate dehydrogesase (GAPDH) 
which are redox-regulated enzymes. PKM2 is an isoform of pyruvate kinase expressed 
in tumor cells, whose Cys358 can be reversibly oxidized when ROS levels are 
elevated, inactivating the enzyme and lowering the production of the end product 
pyruvate. This closing of the exit of glycolytic flux induces the accumulation of 
intermediates upstream stimulating its diversion at 3-phophoglycerate (3PGA) towards 
Serine, glycine, the folate cycle, which is another source of NADPH, and eventually 
towards glutathione biosynthesis 251. As with PKM2, reversible oxidation of Cys152 of 
GADPH results in enzyme inactivation allowing for diversion of dihydroxyacetone-
phosphate (DHAP) towards glycerol for phospholipid biosynthesis, and diversion of 
triose phosphate and hexose phosphate via PPP towards NADPH and ribose for 
nucleotide biosynthesis. Moreover, GADPH can be S-glutathionylated and reduced by 
Grx1 194. NO· also regulates the activity of several metabolic enzymes by S-nitrosation 
such as aconitase (ACO) 252, isocitrate dehydrogenase (IDH) and α-ketoglutarate 
dehydrogenase (α-KGDH) 253 that are reversibly denitrosated by Trx1. In addition, S-
nitrosation of Cys247 of GAPDH and its reversion by Trx1 stimulates apoptosis 231. 
Redox modulation of these two enzymes, GAPDH and PKM2, and the 
consequences in the glycolytic and lateral fluxes are well documented, but the 
responsibility of flux control does not rely exclusively on them. Other glycolytic 
enzymes are also sensitive to redox changes at specific cysteines with effects on their 
activity and also contribute to connect redox status with flux control like 
phosphoglycerate mutase (PGAM) 254 and Triose phosphate isomerase 255,256. 
Changes in the activity of one single enzyme cannot be extrapolated to equivalent 
changes in metabolic flux through the whole pathway. 
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4.3. Redox involvement in HCC progression to invasiveness and metastasis 
 
 Epithelial-mesenchymal transition (EMT) is an important process that happens 
in normal development in which epithelial cells lose many of their properties to become 
mesenchymal cells, which means important changes in architecture and behavior 257. 
This de-differentiation process also takes place in tumor cells and constitutes the first 
step towards metastasis as the disease progresses. 
 There are several ROS-associated signaling pathways involved in EMT. Among 
these pathways, there are ROS-dependent activation proteins such as Smad, Snail, E-
Cadherin, β-catenin and matrix metalloproteinases (MMPs). Transforming Growth 
Factor-β (TGFB) provokes an increase in the production of ROS that results in the 
phosphorylation of Smad2, p38MAPK and ERK 1/2 258. In addition,  ROS may regulate 
EMT through a mechanism that involves NF-кB in closed collaboration with HIF-1 and 
cyclooxygenase-2 (COX-2). A critical molecular event of EMT is down-regulation of the 
cell adhesion molecule E-cadherin and its replacement by N-cadherin. E-cadherin is 
present in the plasma membrane of normal epithelial cells but not in mesenchymal 
cells 259, it acts as a suppressor factor of invasion and metastasis in tumor cells and it is 
usually degraded during transformation or malignancy 260. It has been described by 
several authors that the activation of Akt leads to a significant reduction in E-cadherin 
expression and nuclear localization of Snail, suggesting a role for the PI3K/Akt 
signaling pathway in the transient shift from E-cadherin to N-cadherin, and EMT 
progression in cancer 260,261. The hyperactivation of PI3K/Akt signaling by mediated by 
ROS has been described previously and its relationship with tumor cell survival, 
apoptosis inhibition and resistance to chemotherapy 229. In fact, the activation of Akt is 
thought to be responsible for mediating the acquired resistance to sorafenib via mTOR 
but independent of protein phosphatase 2A in hepatocarcinoma cells 262. Sorafenib 
simultaneously targets tyrosine kinase receptors such as vascular endothelial growth 
factor receptor (VEGFR) 2 and 3, platelet- derived growth factor receptor-β (PDGFR-
β), Flt3 and c-Kit, as well as molecular components of the MAPK signaling pathway 263. 
Several studies have reported Sorafenib downregulates cell survival pathways and 
increase apoptosis in hepatoma cells and these effects have been associated with the 
induction of oxidative stress in hepatocarcinma cells 264. Sorafenib is the recommended 
therapy for the patients with locally advanced/metastatic disease but the effectiveness 
is not high and tumor cells become resistant as its invasive capacity and mallignity 
progresses. It is important to consider the adaptations that occur in this process similar 
to EMT. JAK/STAT3 has also been related to EMT and cancer progression 237. It has 
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been observed that STAT3 activation is involved in EMT, invasion and generation of 
metastasis in hepatocellular carcinoma (HCC) 265. Trx1 expression in cancer cells is 
associated with aggressive tumor growth, which makes Trx1 an attractive target for 
cancer therapy. Although Trx1 has been suggested as potential prognostic marker of 
HCC, the mechanism of Trx in the pathogenesis and treatment of HCC is still not well 
known 266. 
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Hypothesis 
 
Redox signaling and oxidative damage are balanced in the cell. 
Oxidative/nitrosative stress is critical for the accumulation of intracellular altered 
proteins, induction of autophagy, and further cellular apoptosis in unsolved 
physiopathological intracellular outcome while redox signaling through the transient 
oxidation/reduction of key Cys residues in regulatory proteins plays a role in all 
hallmarks of cancer. 
 Nitric oxide (NO) is a signaling molecule that is produced in cells by the action 
of nitric oxide synthases in response to various stimuli and that generates nitrosative 
and oxidative stress with consequences on cell proliferation and death. Most of the 
effects of NO are produced by reversible S-nitrosation and other types of oxidations of 
sensitive cysteines in key proteins of metabolic and cell signaling pathways, with 
consequences on the function of these target proteins. The reversal of these oxidations 
is carried out by the "Redoxin" family of proteins, that play a role in antioxidant defense 
and redox signaling. There are several studies that link ROS/RNS with the redoxins, 
thioredoxin, glutarredoxin and peroxiredoxin, and the process of regulated cell death 
and cell proliferation. 
 This project aims to demonstrate that redoxins exert their role acting on 
metabolic fluxes by controlling the redox state of metabolic enzymes and on proteins 
involved in signaling pathways. 
 The hypothesis will be tested in various models of cellular cytotoxicity and 
experimental hepatocarcinogenesis and in a model of apoptosis induction in 
hepatocarcinoma cells (HepG2) with elevated levels of NO due to overexpression of 
NOS3, as well as with reduced levels of the different redoxins by gene silencing. 
Determination of proliferation and cell death parameters; measurement of the activation 
status of various signaling pathways (AKT, mTOR, etc.); analysis of the Redox 
Proteome, the metabolome and the main metabolic fluxes of these cells will be also 
carried out. 
 The data obtained are intended to demonstrate the potential beneficial effect 
of NO as a pro-apoptotic or anti-tumor agent, and the role of redoxins in the resistance 
of tumor cells against this effect. The obtained results will contribute to the knowledge 
of redox posttranslational modification (PTM) mechanisms that participate in an 
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integrated manner with other PTMs in the regulation of cell metabolism, proliferation 
and death. The effect of Trx on the resistance of cells to treatment with Sorafenib (a 
drug that is administered to patients with hepatocarcinoma) as a function of the 
invasiveness and malignancy potential will be tested using a set of cell lines with 
different degrees of differentiation (HepG2, SNU423 and SNU475) treated with the 
drug and with interfering RNA of Trx1. 
 The results are reported in three articles and are expected to provide new 
insights for the design of antitumor therapies. 
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Objectives 
 
 The aim of this PhD Thesis project is to study the functions of redoxins (Trx1, 
Grx1 and Prdx6) in the regulation of signaling pathway and metabolism in 
hepatocarcioma cell lines subjected or not to oxidative/nitrosative stress. To achieve 
the main objective, the following partial objectives have been carried out: 
 
1. Determination of the differential "thiolic redox proteome" of HepG2 cells that 
express different levels of nitric oxide by ESI-LC-MS/MS when the levels of Trx1, Grx1 
and Prdx6 are down-regulated by specific interfering RNAs. This objective was 
addressed in Articles 1 and 2. It included optimization of the methodology in the case 
of Prdx6 redox proteome. (Article 2). 
2. Description of the in vivo physiological significance of Trx1, Grx1 and Prdx6 
induced redox changes in the proteome. This objective was dealt with in Article 1 
measuring the metabolic flux of glycolysis and pentose phosphate with radioactively 
labelled glucose and the activity of glycolytic enzymes. In addition, the functions of the 
three redoxins in the context of proliferation and cell death by apoptosis were studied. 
(Article 1 and 2). 
3. Extension of the study of the metabolic functions of the three redoxins to the 
greatest possible number of metabolic pathways. This objective was addressed by a 
comprehensive analysis of the metabolome of HepG2 cells with silenced levels of each 
of the 3 redoxins (Trx1, Grx1 and Prdx6). (Articles 1 and 2). 
4. Quantification of the activity and expression levels of Trx1, Grx1  and Prdx6 in 
HepG2 cells subject or not to high levels of NO as well as low levels of Prdx6. 
(Unpublished data).  
5. Correlation and integration of the results obtained in the previous sections 
with the degree of cell death due to apoptosis and their metabolic state in these tumor 
cells. (Articles 1 and 2). 
6. Comparing the effects of Trx1 in HepG2 cells with its effect in other 
hepatoblastoma cell lines with different degree of differentiation, malignancy and 
invasiveness potential. This objective was addressed in Article 3 by quantifying the 
Global Proteome in samples of HepG2, SNU423 and SNU475 cells treated with 
Sorafenib, a drug that is administered to patients with hepatocarcinoma, and/or 
interfering RNA of Trx1. 
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7. Obtaining the HepG2 Knockout line for Prdx6 through CRISPR/Cas9 
technology. (Unpublished data). 
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Conclusions 
 
1. The data presented here in show that Trx and/or Grx are involved in redox 
modifications of targeted cysteines of several glycolytic enzymes affecting their activity, 
but importantly, changes in the activity of one single enzyme cannot be extrapolated to 
equivalent changes in metabolic flux through the whole pathway. These changes are 
part of a widespread adaptive mechanism aimed at redistributing metabolic fluxes 
between Glycolysis and its off-shooting pathways to respond to subtle changes in the 
cellular redox environment. Trx and Grx share a number of protein Cys redox targets 
but down regulation of either redoxin has markedly different metabolic outcomes: 
silencing of Trx1 stimulates glycolytic flux while silencing of Grx1 decelerates it. 
(Article 1) 
 
2. Besides its canonical antioxidant action, Trx1 also contributes to oxidative 
modification of some protein thiols, likely by activation of NOS3 and unbalancing 
ROS/RNS levels, reflecting the delicate sensitivity of redox equilibrium to changes in 
any of the elements involved and the difficulty of forecasting metabolic responses to 
redox environmental changes. (Article 1) 
 
3. A correlation can be put forward between the reversible oxidation of Cys91 of 
Prdx6 upon Grx1 silencing that is accompanied by a significative increase in sn-2-
arachidonyl containing phospholipids and Cys91 sensitivity to glutathionylation, 
considering the well-known deglutathionylase activity of Grx1. (Article 1) 
 
4. The complex wide effects of moderate Prdx6 down-regulation should be a 
reflection of its moonlighting properties acting as peroxidase, phospholipase and LPC-
acyltransferase. The response of HepG2 cells to Prdx6 silencing spans from metabolic 
and signaling pathways remodeling to alterations in the redox proteome and 
membrane turnover with effects in cell cycle progression and proliferation. The role of 
Prdx6 in cancer cells has been studied previously with conflicting outcomes. Most 
reports point to a pro-proliferating and antiapoptotic action of Prdx6, but some studies 
have found the opposite effect, depending on the stage of tumor development. 
Moreover, these effects have not always been assigned to a particular activity of 
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Prdx6, either peroxidase, PLA2 or LPCAT, neither a common mechanism has been 
provided. In the study reported in Article 2 Prdx6 silencing down to ≈40% would 
represent a situation mimicking a cellular response to endogenous or exogenous 
stimuli under normal or oxidative stress conditions. It appears that the cell responds to 
Prdx6 down-regulation by initiating a biosynthetic program leading to membrane and 
vesicle trafficking rearrangement with signs of entering cell cycle G1 phase but inability 
to proceed on to S phase. The mechanisms behind these phenomena involve 
reversible thiol oxidative changes in key proteins. HK2-Cys368 and Prdx6 “extra” Cys91 
stand out as relevant thiol switches. The former could affect association with the 
mitochondrial membrane with consequences on the rate of glucose catabolism and 
mitochondrial permeability; the latter is not conserved among the 1-Cys type 
Peroxiredoxin and has been given little attention so far but could turn out to bear 
relevant functions in human cells. (Article 2) 
 
5. Based on the results obtained in Article 2 and the contrasting reports on the 
roles and mechanisms of multifunctional Prdx6 in several pathologies, obtaining a 
knockout cell line of the human peroxiredoxin 6 can be a first step to determine the 
implications of this protein into a cellular level. With this objective and using the 
CRISPR-Cas9 technique, a human hepatocarcinoma cell line HepG2prdx6-/prdx6-has 
been constructed and characterized demonstrating that both alleles of the Prdx6 gene 
were mutated by deletion. (Unpublished data) 
 
6. The study presented in Article 3 shows that Sorafenib treatment had a limited 
effect on Trx1/TrxR1- reach and poorly-differentiated HCC cells expected to be present 
at high proportion in the advanced stage of the disease. However, when the application 
of Sorafenib is combined with Trx1 knock-down, which implies a thiol oxidative redox 
change of STAT3, it affects very significantly the signaling pathways involved in 
metastatic and invasive potential of mesenchymal cells. It is suggested that 
combination of Sorafenib with thioredoxin inhibitors should be taken into account in the 
design of anticancer therapies. (Article 3) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
41 
 
References 
 
1. Gutteridge, J. M. C. Biological origin of free radicals, and mechanisms of 
antioxidant protection. Chem. Biol. Interact. 91, 133–140 (1994). 
2. Nordberg, J. & Arnér, E. S. J. Reactive oxygen species, antioxidants, and the 
mammalian thioredoxin system. Free Radic. Biol. Med. 31, 1287–1312 (2001). 
3. Kohen, R. & Nyska, A. Invited Review: Oxidation of Biological Systems: 
Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for 
Their Quantification. Toxicol. Pathol. 30, 620–650 (2002). 
4. Szabó, C., Ischiropoulos, H. & Radi, R. Peroxynitrite: biochemistry, 
pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6, 
662–680 (2007). 
5. Ozcan, A. & Ogun, M. Biochemistry of Reactive Oxygen and Nitrogen Species. 
in Basic Principles and Clinical Significance of Oxidative Stress (InTech, 2015). 
doi:10.5772/61193 
6. Phaniendra, A., Jestadi, D. B. & Periyasamy, L. Free Radicals: Properties, 
Sources, Targets, and Their Implication in Various Diseases. Indian J. Clin. 
Biochem. 30, 11–26 (2015). 
7. Nathan, C. & Shiloh, M. U. Reactive oxygen and nitrogen intermediates in the 
relationship between mammalian hosts and microbial pathogens. Proc. Natl. 
Acad. Sci. 97, 8841–8848 (2000). 
8. Alderton, W. K., Cooper, C. E. & Knowles, R. G. Nitric oxide synthases: 
structure, function and inhibition. Biochem. J. 357, 593 (2001). 
9. Dickinson, B. C. & Chang, C. J. Chemistry and biology of reactive oxygen 
species in signaling or stress responses. Nat. Chem. Biol. 7, 504–511 (2011). 
10. Sies, H. Oxidative Stress: Introductory Remarks. in Oxidative Stress 1–8 
(Elsevier, 1985). doi:10.1016/B978-0-12-642760-8.50005-3 
11. Sies, H. On the history of oxidative stress: Concept and some aspects of current 
development. Curr. Opin. Toxicol. 7, 122–126 (2018). 
12. Sies, H., Berndt, C. & Jones, D. P. Oxidative Stress. Annu. Rev. Biochem. 86, 
715–748 (2017). 
13. Janssen-Heininger, Y. M. W. et al. Redox-based regulation of signal 
transduction: Principles, pitfalls, and promises. Free Radic. Biol. Med. 45, 1–17 
(2008). 
14. Finkel, T. Signal transduction by reactive oxygen species. J. Cell Biol. 194, 7–15 
(2011). 
15. D’Autréaux, B. & Toledano, M. B. ROS as signalling molecules: Mechanisms 
that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8, 813–
824 (2007). 
16. Valko, M. et al. Free radicals and antioxidants in normal physiological functions 
and human disease. Int. J. Biochem. Cell Biol. 39, 44–84 (2007). 
References 
42 
 
17. Di Meo, S., Reed, T. T., Venditti, P. & Victor, V. M. Role of ROS and RNS 
Sources in Physiological and Pathological Conditions. Oxid. Med. Cell. Longev. 
2016, 1–44 (2016). 
18. Halliwell, B. & Gutteridge, J. M. C. Free Radicals in Biology and Medicine. 
(Oxford University Press, 2015). 
doi:10.1093/acprof:oso/9780198717478.001.0001 
19. Krause, K.-H. Aging: A revisited theory based on free radicals generated by 
NOX family NADPH oxidases. Exp. Gerontol. 42, 256–262 (2007). 
20. Schieber, M. & Chandel, N. S. ROS Function in Redox Signaling and Oxidative 
Stress. Curr. Biol. 24, R453–R462 (2014). 
21. Liguori, I. et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging 13, 
757–772 (2018). 
22. Wild, C. P. The exposome: from concept to utility. Int. J. Epidemiol. 41, 24–32 
(2012). 
23. Go, Y. M. & Jones, D. P. Redox biology: Interface of the exposome with the 
proteome, epigenome and genome. Redox Biol. 2, 358–360 (2014). 
24. Jones, D. P., Park, Y. & Ziegler, T. R. Nutritional Metabolomics: Progress in 
Addressing Complexity in Diet and Health. Annu. Rev. Nutr. 32, 183–202 (2012). 
25. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J. 
417, 1–13 (2009). 
26. Quinlan, C. L., Perevoshchikova, I. V., Hey-Mogensen, M., Orr, A. L. & Brand, 
M. D. Sites of reactive oxygen species generation by mitochondria oxidizing 
different substrates. Redox Biol. 1, 304–312 (2013). 
27. Starkov, A. A. The Role of Mitochondria in Reactive Oxygen Species 
Metabolism and Signaling. Ann. N. Y. Acad. Sci. 1147, 37–52 (2008). 
28. Mailloux, R. J. & Harper, M.-E. Mitochondrial proticity and ROS signaling: 
lessons from the uncoupling proteins. Trends Endocrinol. Metab. 23, 451–458 
(2012). 
29. Takeya, R., Ueno, N. & Sumimoto, H. Regulation of Superoxide‐ Producing 
NADPH Oxidases in Nonphagocytic Cells. in Methods in Enzymology 406, 456–
468 (2006). 
30. Lambeth, J. D. Nox/Duox family of nicotinamide adenine dinucleotide 
(phosphate) oxidases. Curr. Opin. Hematol. 9, 11–17 (2002). 
31. Bedard, K. & Krause, K.-H. The NOX Family of ROS-Generating NADPH 
Oxidases: Physiology and Pathophysiology. Physiol. Rev. 87, 245–313 (2007). 
32. Schröder, K., Weissmann, N. & Brandes, R. P. Organizers and activators: 
Cytosolic Nox proteins impacting on vascular function. Free Radic. Biol. Med. 
109, 22–32 (2017). 
33. Cho, K.-J., Seo, J.-M. & Kim, J.-H. Bioactive lipoxygenase metabolites 
stimulation of NADPH oxidases and reactive oxygen species. Mol. Cells 32, 1–5 
(2011). 
References 
43 
 
34. Hong, H.-Y., Jeon, W.-K. & Kim, B.-C. Up-regulation of heme oxygenase-1 
expression through the Rac1/NADPH oxidase/ROS/p38 signaling cascade 
mediates the anti-inflammatory effect of 15-deoxy-Δ 12,14 -prostaglandin J 2 in 
murine macrophages. FEBS Lett. 582, 861–868 (2008). 
35. Gross, E. et al. Generating disulfides enzymatically: Reaction products and 
electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p. Proc. Natl. 
Acad. Sci. 103, 299–304 (2006). 
36. Hrycay, E. G. & Bandiera, S. M. Involvement of Cytochrome P450 in Reactive 
Oxygen Species Formation and Cancer. in Advances in Pharmacology 74, 35–
84 (Elsevier Inc., 2015). 
37. del Río, L. A., Sandalio, L. M., Palma, J., Bueno, P. & Corpas, F. J. Metabolism 
of oxygen radicals in peroxisomes and cellular implications. Free Radic. Biol. 
Med. 13, 557–580 (1992). 
38. Schrader, M. & Fahimi, H. D. Peroxisomes and oxidative stress. Biochim. 
Biophys. Acta - Mol. Cell Res. 1763, 1755–1766 (2006). 
39. Stolz, D. Peroxisomal localization of inducible nitric oxide synthase in 
hepatocytes. Hepatology 36, 81–93 (2002). 
40. Fritz, R. et al. Compartment-dependent management of H2O2 by peroxisomes. 
Free Radic. Biol. Med. 42, 1119–1129 (2007). 
41. Dizdaroglu, M., Jaruga, P., Birincioglu, M. & Rodriguez, H. Free radical-induced 
damage to DNA: mechanisms and measurement. Free Radic. Biol. Med. 32, 
1102–1115 (2002). 
42. Helbock, H. J., Beckman, K. B. & Ames, B. N. 8-Hydroxydeoxyguanosine and 8-
hydroxyguanine as biomarkers of oxidative DNA damage. in Methods in 
Enzymology 300, 156–166 (1999). 
43. Hiraku, Y., Kawanishi, S., Ichinose, T. & Murata, M. The role of iNOS-mediated 
DNA damage in infection- and asbestos-induced carcinogenesis. Ann. N. Y. 
Acad. Sci. 1203, 15–22 (2010). 
44. Hofer, T. et al. Hydrogen peroxide causes greater oxidation in cellular RNA than 
in DNA. Biol. Chem. 386, 333–337 (2005). 
45. Rubbo, H. et al. Nitric oxide regulation of superoxide and peroxynitrite-
dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized 
lipid derivatives. J. Biol. Chem. 269, 26066–26075 (1994). 
46. Marnett, L. J. Lipid peroxidation - DNA damage by malondialdehyde. Mutat. Res. 
- Fundam. Mol. Mech. Mutagen. 424, 83–95 (1999). 
47. Doorn, J. A. & Petersen, D. R. Covalent adduction of nucleophilic amino acids 
by 4-hydroxynonenal and 4-oxononenal. Chem. Biol. Interact. 143–144, 93–100 
(2003). 
48. Kelly, F. J. & Mudway, I. S. Protein oxidation at the air-lung interface. Amino 
Acids 25, 375–396 (2003). 
49. Milne, G. L., Musiek, E. S. & Morrow, J. D. F 2 -Isoprostanes as markers of 
oxidative stress in vivo : An overview. Biomarkers 10, 10–23 (2005). 
References 
44 
 
50. Davies, K. J. & Delsignore, M. E. Protein damage and degradation by oxygen 
radicals. J. Biol. Chem. 262, 9895–9901 (1987). 
51. Holmström, K. M. & Finkel, T. Cellular mechanisms and physiological 
consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 15, 411–
421 (2014). 
52. Sundaresan, M., Yu, Z.-X., Ferrans, V. J., Irani, K. & Finkel, T. Requirement for 
Generation of H(2)O(2) for Platelet-Derived Growth Factor Signal Tran sduction. 
Science (80-. ). 270, 296–299 (1995). 
53. Bae, Y. S. et al. Epidermal Growth Factor (EGF)-induced Generation of 
Hydrogen Peroxide. J. Biol. Chem. 272, 217–221 (1997). 
54. Meng, T., Fukada, T. & Tonks, N. K. Reversible Oxidation and Inactivation of 
Protein Tyrosine Phosphatases In Vivo. Mol. Cell 9, 387–399 (2002). 
55. Ghezzi, P. Oxidoreduction of protein thiols in redox regulation. Biochem. Soc. 
Trans. 33, 1378–1381 (2005). 
56. McDonagh, B., Ogueta, S., Lasarte, G., Padilla, C. A. & Bárcena, J. A. Shotgun 
redox proteomics identifies specifically modified cysteines in key metabolic 
enzymes under oxidative stress in Saccharomyces cerevisiae. J. Proteomics 72, 
677–89 (2009). 
57. McDonagh, B. Detection of ROS Induced Proteomic Signatures by Mass 
Spectrometry. Front. Physiol. 8, 1–7 (2017). 
58. McDonagh, B., Sakellariou, G. K., Smith, N. T., Brownridge, P. & Jackson, M. J. 
Differential cysteine labeling and global label-free proteomics reveals an altered 
metabolic state in skeletal muscle aging. J. Proteome Res. 13, 5008–5021 
(2014). 
59. Go, Y.-M. & Jones, D. P. Thiol/disulfide redox states in signaling and sensing. 
Crit. Rev. Biochem. Mol. Biol. 48, 173–181 (2013). 
60. Klomsiri, C., Karplus, P. A. & Poole, L. B. Cysteine-based redox switches in 
enzymes. Antioxidants Redox Signal. 14, 1065–1077 (2011). 
61. Tennant, D. A., Durán, R. V. & Gottlieb, E. Targeting metabolic transformation 
for cancer therapy. Nat. Rev. Cancer 10, 267–277 (2010). 
62. Erickson, J. R. et al. A Dynamic Pathway for Calcium-Independent Activation of 
CaMKII by Methionine Oxidation. Cell 133, 462–474 (2008). 
63. Hung, R.-J., Spaeth, C. S., Yesilyurt, H. G. & Terman, J. R. SelR reverses Mical-
mediated oxidation of actin to regulate F-actin dynamics. Nat. Cell Biol. 15, 
1445–1454 (2013). 
64. Lee, B. C. et al. MsrB1 and MICALs Regulate Actin Assembly and Macrophage 
Function via Reversible Stereoselective Methionine Oxidation. Mol. Cell 51, 
397–404 (2013). 
65. Dröge, W. Free Radicals in the Physiological Control of Cell Function. Physiol. 
Rev. 82, 47–95 (2002). 
66. Trachootham, D., Lu, W., Ogasawara, M. A., Valle, N. R. & Huang, P. Redox 
Regulation of Cell Survival. Antioxid. Redox Signal. 10, (2008). 
References 
45 
 
67. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R. & Hagen, T. M. Alpha-lipoic 
acid as a dietary supplement: Molecular mechanisms and therapeutic potential. 
Biochim. Biophys. Acta - Gen. Subj. 1790, 1149–1160 (2009). 
68. Beyer, R. E. The role of ascorbate in antioxidant protection of biomembranes: 
Interaction with vitamin E and coenzyme Q. J. Bioenerg. Biomembr. 26, 349–
358 (1994). 
69. Helmut, S. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 
27, 916–921 (1999). 
70. McCord, JM and Fridovich, I. Superoxide dismutase. An enzymic function for 
erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049–6055 (1969). 
71. Fukai, T. & Ushio-Fukai, M. Superoxide Dismutases: Role in Redox Signaling, 
Vascular Function, and Diseases. Antioxid. Redox Signal. 15, 1583–1606 
(2011). 
72. Glorieux, C. & Calderon, P. B. Catalase, a remarkable enzyme: targeting the 
oldest antioxidant enzyme to find a new cancer treatment approach. Biol. Chem. 
398, 1095–1108 (2017). 
73. Labunskyy, V. M., Hatfield, D. L. & Gladyshev, V. N. Selenoproteins: Molecular 
Pathways and Physiological Roles. Physiol. Rev. 94, 739–777 (2014). 
74. Forman, H. J., Zhang, H. & Rinna, A. Glutathione: Overview of its protective 
roles, measurement, and biosynthesis. Mol. Aspects Med. 30, 1–12 (2009). 
75. Franco, R. & Cidlowski, J. A. Apoptosis and glutathione : beyond an antioxidant. 
Cell Death Differ. 16, 1303–1314 (2009). 
76. Rhee, S. G., Kang, S. W., Chang, T. S., Jeong, W. & Kim, K. Peroxiredoxin, a 
novel family of peroxidases. IUBMB Life 52, 35–41 (2001). 
77. Nicolussi, A., D’inzeo, S., Capalbo, C., Giannini, G. & Coppa, A. The role of 
peroxiredoxins in cancer (Review). Mol. Clin. Oncol. 139–153 (2017). 
doi:10.3892/mco.2017.1129 
78. Nelson, K. J. et al. Analysis of the peroxiredoxin family: Using active-site 
structure and sequence information for global classification and residue analysis. 
Proteins Struct. Funct. Bioinforma. 79, 947–964 (2011). 
79. Hofmann, B., Hecht, H. & Flohé, L. Peroxiredoxins. Biol. Chem. 383, 347–364 
(2002). 
80. Rhee, S. G., Woo, H. A., Kil, I. S. & Bae, S. H. Peroxiredoxin functions as a 
peroxidase and a regulator and sensor of local peroxides. J. Biol. Chem. 287, 
4403–4410 (2012). 
81. Wood, Z. A., Poole, L. B., Hantgan, R. R. & Karplus, P. A. Dimers to doughnuts: 
Redox-sensitive oligomerization of 2-cysteine peroxiredoxins. Biochemistry 41, 
5493–5504 (2002). 
82. Sue, G. R., Ho, Z. C. & Kim, K. Peroxiredoxins: A historical overview and 
speculative preview of novel mechanisms and emerging concepts in cell 
signaling. Free Radic. Biol. Med. 38, 1543–1552 (2005). 
83. Seo, M. S. et al. Identification of a new type of mammalian peroxiredoxin that 
References 
46 
 
forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275, 
20346–20354 (2000). 
84. Manevich, Y., Feinstein, S. I. & Fisher, A. B. Activation of the antioxidant 
enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by 
heterodimerization with  GST. Proc. Natl. Acad. Sci. 101, 3780–3785 (2004). 
85. Pedrajas, J. R., Padilla, C. A., McDonagh, B. & Bárcena, J. A. Glutaredoxin 
participates in the reduction of peroxides by the mitochondrial 1-CYS 
peroxiredoxin in saccharomyces cerevisiae. Antioxidants Redox Signal. 13, 
249–258 (2010). 
86. Pedrajas, J. R. et al. Glutathione Is the Resolving Thiol for Thioredoxin 
Peroxidase Activity of 1-Cys Peroxiredoxin Without Being Consumed During the 
Catalytic Cycle. Antioxid. Redox Signal. 24, 115–128 (2016). 
87. Barranco-Medina, S., Lázaro, J. J. & Dietz, K. J. The oligomeric conformation of 
peroxiredoxins links redox state to function. FEBS Lett. 583, 1809–1816 (2009). 
88. Kim, T. S. et al. Identification of a human cDNA clone for lysosomal type Ca2+- 
independent phospholipase A2 and properties of the expressed protein. 
J.Biol.Chem. 272, 2542–2550 (1997). 
89. Akiba S, Docia C, Chen X, F. A. Characterization of acidic Ca(2+)-independent 
phospholipase A2 of bovine lung. Comp Biochem Physiol B Biochem Mol Biol 
120, 393–404 (1998). 
90. Netto, L. E. S. & Antunes, F. The Roles of Peroxiredoxin and Thioredoxin in 
Hydrogen Peroxide Sensing and in Signal Transduction. Mol. Cells 39, 65–71 
(2016). 
91. Wood, Z. A., Poole, L. B. & Karplus, P. A. Peroxiredoxin Evolution and the 
Regulation of Hydrogen Peroxide Signaling. Science (80-. ). 300, 650–653 
(2003). 
92. Rhee, S. G., Woo, H. A. & Kang, D. The Role of Peroxiredoxins in the 
Transduction of H2O2 signals. 28, 537–557 (2018). 
93. Toledano, M. B. & Huang, B. Microbial 2-Cys Peroxiredoxins : Insights into Their 
Complex Physiological Roles. 39, 31–39 (2016). 
94. Kil, I. S. et al. Feedback Control of Adrenal Steroidogenesis via H 2 O 2 -
Dependent , Reversible Inactivation. Mol. Cell 46, 584–594 (2012). 
95. Rhee, S. G. Overview on Peroxiredoxin. Mol. Cells 39, 1–5 (2016). 
96. Latimer, H. R. & Veal, E. A. Peroxiredoxins in Regulation of MAPK Signalling 
Pathways ; Sensors and Barriers to Signal Transduction. Mol. Cells 39, 40–45 
(2016). 
97. Park, M. H., Jo, M., Kim, Y. R., Lee, C. K. & Hong, J. T. Roles of peroxiredoxins 
in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol. 
Ther. 163, 1–23 (2016). 
98. Chen, J. W., Dodia, C., Feinstein, S. I., Jain, M. K. & Fisher, A. B. 1-Cys 
peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and 
phospholipase A2 activities. J. Biol. Chem. 275, 28421–28427 (2000). 
References 
47 
 
99. Fisher, A. B., Dodia, C., Manevich, Y., Chen, J. W. & Feinstein, S. I. 
Phospholipid hydroperoxides are substrates for non-selenium glutathione 
peroxidase. J. Biol. Chem. 274, 21326–21334 (1999). 
100. Fisher, A. B. et al. A novel lysophosphatidylcholine acyl transferase activity is 
expressed by peroxiredoxin 6. J. Lipid Res. 57, 587–596 (2016). 
101. Chowdhury, I. et al. Oxidant stress stimulates expression of the human 
peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant 
response element. Free Radic. Biol. Med. 46, 146–153 (2009). 
102. Manevich, Y. et al. Binding of peroxiredoxin 6 to substrate determines differential 
phospholipid hydroperoxide peroxidase and phospholipase A2 activities. Arch. 
Biochem. Biophys. 485, 139–149 (2009). 
103. Li, Haitao; Benipal, Bavneet, Zhou, Suiping; Dodia, Chandra; Chatterjee, 
Shampa, Tao, Jian-Qin; Sorokina, Elena M; Raabe, Tobias; Feinstein, Sheldon I 
and Fisher, A. B. Critical Role of Peroxiredoxin 6 in the Repair of Peroxidized 
Cell Membranes. Free Radic. Biol. Med. 87, 356–365 (2015). 
104. Manevich, Y., Reddy, K. S., Shuvaeva, T., Feinstein, S. I. & Fisher, A. B. 
Structure and phospholipase function of peroxiredoxin 6: identification of the 
catalytic triad and its role in phospholipid substrate binding. J. Lipid Res. 48, 
2306–2318 (2007). 
105. Kim, K. H., Lee, W. & Kim, E. E. K. Crystal structures of human peroxiredoxin 6 
in different oxidation states. Biochem. Biophys. Res. Commun. 477, 717–722 
(2016). 
106. Kang, S. W., Baines, I. C. & Rhee, S. G. Characterization of a mammalian 
peroxiredoxin that contains one conserved cysteine. J. Biol. Chem. 273, 6303–
6311 (1998). 
107. Wu, Y. et al. Mitogen-activated protein kinase-mediated phosphorylation of 
peroxiredoxin 6 regulates its phospholipase A 2 activity. Biochem. J 679, 669–
679 (2009). 
108. Sorokina, E. M. et al. Mutation of serine 32 to threonine in peroxiredoxin 6 
preserves its structure and enzymatic function but abolishes its trafficking to 
lamellar bodies. J. Biol. Chem. 291, 9268–9280 (2016). 
109. Sorokina, E. M., Feinstein, S. I., Zhou, S. & Fisher, A. B. Intracellular targeting of 
peroxiredoxin 6 to lysosomal organelles requires MAPK activity and binding to 
14-3-3ε. Am. J. Physiol. Cell Physiol. 300, C1430–C1441 (2011). 
110. Chatterjee, S. et al. Peroxiredoxin 6 phosphorylation and subsequent 
phospholipase A2 activity are required for agonist-mediated activation of 
NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar 
macrophages. J. Biol. Chem. 286, 11696–11706 (2011). 
111. Krishnaiah, S. Y., Dodia, C., Feinstein, S. I. & Fisher, A. B. p67phox terminates 
the phospholipase A2-derived signal for activation of NADPH oxidase (NOX2). 
FASEB J. 27, 2066–2073 (2013). 
112. Kwon, J. et al. Peroxiredoxin 6 (Prdx6) supports NADPH oxidase1 (Nox1)-based 
superoxide generation and cell migration. Free Radic. Biol. Med. 96, 99–115 
(2016). 
References 
48 
 
113. Catalá, A. Lipid peroxidation of membrane phospholipids generates hydroxy-
alkenals and oxidized phospholipids active in physiological and/or pathological 
conditions. Chem. Phys. Lipids 157, 1–11 (2009). 
114. Fisher, A. B., Dodia, C., Yu, K., Manevich, Y. & Feinstein, S. I. Lung 
phospholipid metabolism in transgenic mice overexpressing peroxiredoxin 6. 
Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1761, 785–792 (2006). 
115. Fisher, A. B., Dodia, C., Feinstein, S. I. & Ho, Y.-S.  Altered lung phospholipid 
metabolism in mice with targeted deletion of lysosomal-type phospholipase A 2 . 
J. Lipid Res. 46, 1248–1256 (2005). 
116. Fisher, A. B. & Dodia, C. Lysosomal-type PLA2 and turnover of alveolar DPPC. 
Am. J. Physiol. Lung Cell. Mol. Physiol. 280, L748-54 (2001). 
117. Lien, Y.-C., Feinstein, S. I., Dodia, C. & Fisher, A. B. The Roles of Peroxidase 
and Phospholipase A2 Activities of Peroxiredoxin 6 in Protecting Pulmonary 
Microvascular Endothelial Cells Against Peroxidative Stress. Antioxid. Redox 
Signal. 16, 440–451 (2011). 
118. Fisher, A. B. et al. Peroxiredoxin 6 phospholipid hydroperoxidase activity in the 
repair of peroxidized cell membranes. Redox Biol. 14, 41–46 (2018). 
119. Power, J. H. T., Shannon, J. M., Blumbergs, P. C. & Gai, W. P. Nonselenium 
glutathione peroxidase in human brain: Elevated levels in Parkinson’s disease 
and dementia with Lewy bodies. Am. J. Pathol. 161, 885–894 (2002). 
120. Yun, H., Choi, D. Y., Oh, K. W. & Hong, J. T. PRDX6 Exacerbates Dopaminergic 
Neurodegeneration in a MPTP Mouse Model of Parkinson’s Disease. Mol. 
Neurobiol. 52, 422–431 (2015). 
121. Power, J. H. T. et al. Peroxiredoxin 6 in human brain: Molecular forms, cellular 
distribution and association with Alzheimer’s disease pathology. Acta 
Neuropathol. 115, 611–622 (2008). 
122. Pacifici, F. et al. Peroxiredoxin 6, a novel player in the pathogenesis of diabetes. 
Diabetes 63, 3210–3220 (2014). 
123. Ozkosem, B., Feinstein, S. I., Fisher, A. B. & O’Flaherty, C. Advancing age 
increases sperm chromatin damage and impairs fertility in peroxiredoxin 6 null 
mice. Redox Biol. 5, 15–23 (2015). 
124. Ozkosem, B., Feinstein, S. I., Fisher, A. B. & O’Flaherty, C. Absence of 
Peroxiredoxin 6 Amplifies the Effect of Oxidant Stress on Mobility and 
SCSA/CMA3 Defined Chromatin Quality and Impairs Fertilizing Ability of Mouse 
Spermatozoa1. Biol. Reprod. 94, 1–10 (2016). 
125. Fisher, A. B. The phospholipase A2 activity of peroxiredoxin 6. J. Lipid Res. 59, 
1132–1147 (2018). 
126. Laurent, T. C., Mooren, E. C. & Reichard, P. Enzymatic synthesis of 
deoxyribonucleotides. iv. isolation and characterization of thioredoxin, the 
hydrogen donor from Escherichia coli B. J. Biol. Chem. 239, 3436–3444 (1964). 
127. Matsui, M. et al. Early Embryonic Lethality Caused by Targeted Disruption of the 
Mouse Thioredoxin Gene. Dev. Biol. 178, 179–185 (1996). 
128. Conrad, M. et al. Essential Role for Mitochondrial Thioredoxin Reductase in 
References 
49 
 
Hematopoiesis, Heart Development, and Heart Function. Mol. Cell. Biol. 24, 
9414–9423 (2004). 
129. Jakupoglu, C. et al. Cytoplasmic Thioredoxin Reductase Is Essential for 
Embryogenesis but Dispensable for Cardiac Development. Mol. Cell. Biol. 25, 
1980–1988 (2005). 
130. Holmgren, A. et al. Thiol redox control via thioredoxin and glutaredoxin systems. 
Biochem. Soc. Trans. 33, 1375 (2005). 
131. Hanschmann, A. U. E., Godoy, R., Berndt, C., Hudemann, C. & Lillig, C. H. 
Thioredoxins, Glutaredoxins, and Peroxiredoxins-Molecular Mechanisms and 
Health Significance: From Cofactor to Antioxidants to Redox Signaling. 19, 
1539–1605 (2013). 
132. Kim, Y.-C. et al. Hemin-induced Activation of the Thioredoxin Gene by Nrf2. J. 
Biol. Chem. 276, 18399–18406 (2001). 
133. Eklund, H., Gleason, F. K. & Holmgren, A. Structural and functional relations 
among thioredoxins of different species. Proteins Struct. Funct. Genet. 11, 13–
28 (1991). 
134. Arnér, E. S. J. & Holmgren, A. Physiological functions of thioredoxin and 
thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109 (2000). 
135. Holmgren, A. & Bjornstedt, M. Thioredoxin and thioredoxin reductase. in 
Methods in Enzymology 252, 199–208 (1995). 
136. Matsuzawa, A. Thioredoxin and redox signaling: Roles of the thioredoxin system 
in control of cell fate. Arch. Biochem. Biophys. 617, 101–105 (2017). 
137. Mustacich, D. & Powis, G. Thioredoxin reductase. Biochem. J 346, 1–8 (2000). 
138. Arnér, E. S. J. Focus on mammalian thioredoxin reductases — Important 
selenoproteins with versatile functions. Biochim. Biophys. Acta - Gen. Subj. 
1790, 495–526 (2009). 
139. Arnér, E. S. J. Targeting the Selenoprotein Thioredoxin Reductase 1 for 
Anticancer Therapy. in Advances in Cancer Research 136, 139–151 (2017). 
140. Stafford, W. C. et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as 
a mechanistic basis for anticancer therapy. Sci. Transl. Med. 10, eaaf7444 
(2018). 
141. Chen, K.-S. & DeLuca, H. F. Isolation and characterization of a novel cDNA from 
HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim. Biophys. Acta - 
Gene Struct. Expr. 1219, 26–32 (1994). 
142. Junn, E. et al. Vitamin D 3 Up-Regulated Protein 1 Mediates Oxidative Stress 
Via Suppressing the Thioredoxin Function. J. Immunol. 164, 6287–6295 (2000). 
143. Patwari, P., Higgins, L. J., Chutkow, W. A., Yoshioka, J. & Lee, R. T. The 
Interaction of Thioredoxin with Txnip. J. Biol. Chem. 281, 21884–21891 (2006). 
144. Ago, T. et al. A Redox-Dependent Pathway for Regulating Class II HDACs and 
Cardiac Hypertrophy. Cell 133, 978–993 (2008). 
145. Nishinaka, Y. et al. Importin α 1 (Rch1) Mediates Nuclear Translocation of 
References 
50 
 
Thioredoxin-binding Protein-2/Vitamin D 3 -up-regulated Protein 1. J. Biol. 
Chem. 279, 37559–37565 (2004). 
146. Spindel, O. N., World, C. & Berk, B. C. Thioredoxin Interacting Protein: Redox 
Dependent and Independent Regulatory Mechanisms. Antioxid. Redox Signal. 
16, 587–596 (2012). 
147. Anand, P. & Stamler, J. S. Enzymatic mechanisms regulating protein S-
nitrosylation: implications in health and disease. J. Mol. Med. 90, 233–244 
(2012). 
148. Benhar, M., Forrester, M. T., Hess, D. T. & Stamler, J. S. Regulated Protein 
Denitrosylation by Cytosolic and Mitochondrial Thioredoxins. Science (80-. ). 
320, 1050–1054 (2008). 
149. Benhar, M., Forrester, M. T. & Stamler, J. S. Protein denitrosylation: enzymatic 
mechanisms and cellular functions. Nat. Rev. Mol. Cell Biol. 10, 721–732 (2009). 
150. Mitchell, D. A. & Marletta, M. A. Thioredoxin catalyzes the S-nitrosation of the 
caspase-3 active site cysteine. Nat. Chem. Biol. 1, 154–158 (2005). 
151. Wu, C. et al. Redox Regulatory Mechanism of Transnitrosylation by Thioredoxin. 
Mol. Cell. Proteomics 9, 2262–2275 (2010). 
152. Wu, C. et al. Thioredoxin 1-Mediated Post-Translational Modifications: 
Reduction, Transnitrosylation, Denitrosylation, and Related Proteomics 
Methodologies. Antioxid. Redox Signal. 15, 2565–2604 (2011). 
153. Benhar, M., Thompson, J. W., Moseley, M. A. & Stamler, J. S. Identification of S-
Nitrosylated Targets of Thioredoxin Using a Quantitative Proteomic Approach. 
Biochemistry 49, 6963–6969 (2010). 
154. Forrester, M. T. et al. Proteomic analysis of S-nitrosylation and denitrosylation 
by resin-assisted capture. Nat. Biotechnol. 27, 557–559 (2009). 
155. Benhar, M. Nitric oxide and the thioredoxin system: a complex interplay in redox 
regulation. Biochim. Biophys. Acta - Gen. Subj. 1850, 2476–2484 (2015). 
156. Ravi, K., Brennan, L. A., Levic, S., Ross, P. A. & Black, S. M. S-nitrosylation of 
endothelial nitric oxide synthase is associated with monomerization and 
decreased enzyme activity. Proc. Natl. Acad. Sci. 101, 2619–2624 (2004). 
157. Meuillet, E. J., Mahadevan, D., Berggren, M., Coon, A. & Powis, G. Thioredoxin-
1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity 
and membrane binding: a mechanism for the functional loss of PTEN’s tumor 
suppressor activity. Arch. Biochem. Biophys. 429, 123–133 (2004). 
158. Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., 
Kawabata, M., Miyazono, K., and Ichijo, H. Mammalian thioredoxin is a direct 
inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17, 2596–2606 
(1998). 
159. Matsuzawa, A. & Ichijo, H. Redox control of cell fate by MAP kinase: 
physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim. 
Biophys. Acta - Gen. Subj. 1780, 1325–1336 (2008). 
160. Morel, Y. & Barouki, R. Repression of gene expression by oxidative stress. 
Biochem. J. 342, 481 (1999). 
References 
51 
 
161. Dalton, T. P., Shertzer, H. G. & Puga, A. Regulation of gene expression by 
reactive oxygen. Annu. Rev. Pharmacol. Toxicol. 39, 67–101 (1999). 
162. Arrigo, A.-P. Gene expression and the thiol redox state. Free Radic. Biol. Med. 
27, 936–944 (1999). 
163. Chen, Z. J. Ubiquitin signalling in the NF-κB pathway. Nat. Cell Biol. 7, 758–765 
(2005). 
164. Matthews, J. R., Wakasugi, N., Virelizier, J.-L., Yodoi, J. & Hay, R. T. Thiordoxin 
regulates the DNA binding activity of NF-χB by reduction of a disulphid bond 
involving cysteine 62. Nucleic Acids Res. 20, 3821–3830 (1992). 
165. Hirota, K. et al. Distinct Roles of Thioredoxin in the Cytoplasm and in the 
Nucleus. J. Biol. Chem. 274, 27891–27897 (1999). 
166. Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 
4, E131–E136 (2002). 
167. Galter, D., MIihm, S. & Dröge, W. Distinct effects of glutathione disulphide on the 
nuclear transcription factors kappaB and the activator protein-1. Eur. J. 
Biochem. 221, 639–648 (1994). 
168. Hirota, K. et al. AP-1 transcriptional activity is regulated by a direct association 
between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. 94, 3633–3638 (1997). 
169. Wei, S. J. et al. Thioredoxin nuclear translocation and interaction with redox 
factor-1 activates the activator protein-1 transcription factor in response to 
ionizing radiation. Cancer Res. 60, 6688–6695 (2000). 
170. Ueno, M. et al. Thioredoxin-dependent redox regulation of p53-mediated p21 
activation. J. Biol. Chem. 274, 35809–35815 (1999). 
171. Holmgren, A. Hydrogen donor system for Escherichia coli ribonucleoside-
diphosphate reductase dependent upon glutathione. Proc. Natl. Acad. Sci. 73, 
2275–2279 (1976). 
172. Holmgren, A. Glutathione-dependent synthesis of deoxyribonucleotides. J. Biol. 
Chem 254, 3664–3671 (1979). 
173. Holmgren, A. Glutathione-dependent synthesis of deoxyribonucleotides. 
Characterization of the enzymatic mechanism of Escherichia coli glutaredoxin. J. 
Biol. Chem. 254, 3672–3678 (1979). 
174. Lillig, C. H., Berndt, C. & Holmgren, A. Glutaredoxin systems. Biochim. Biophys. 
Acta - Gen. Subj. 1780, 1304–1317 (2008). 
175. Sun, C., Berardi, M. J. & Bushweller, J. H. The NMR solution structure of human 
glutaredoxin in the fully reduced form. J. Mol. Biol. 280, 687–701 (1998). 
176. Xia, T.-H. et al. NMR structure of oxidized Escherichia coli glutaredoxin: 
Comparison with reduced E. coli glutaredoxin and functionally related proteins. 
Protein Sci. 1, 310–321 (2008). 
177. Bushweller, J. H., Aaslund, F., Wuethrich, K. & Holmgren, A. Structural and 
functional characterization of the mutant Escherichia coli glutaredoxin 
(C14.fwdarw.S) and its mixed disulfide with glutathione. Biochemistry 31, 9288–
9293 (1992). 
References 
52 
 
178. Berndt, C. & Lillig, C. H. Glutathione, Glutaredoxins, and Iron. Antioxid. Redox 
Signal. 27, 1235–1251 (2017). 
179. Miller, C. G., Holmgren, A., Arnér, E. S. J. & Schmidt, E. E. NADPH-dependent 
and -independent disulfide reductase systems. Free Radic. Biol. Med. 127, 248–
261 (2018). 
180. Meyer, Y., Belin, C., Delorme-Hinoux, V., Reichheld, J. P. & Riondet, C. 
Thioredoxin and glutaredoxin systems in plants: Molecular mechanisms, 
crosstalks, and functional significance. Antioxidants Redox Signal. 17, 1124–
1160 (2012). 
181. Padilla, C. A., Martinez-Galisteo, E., Barcena, J. A., Spyrou, G. & Holmgren, A. 
Purification from Placenta, Amino Acid Sequence, Structure Comparisons and 
cDNA Cloning of Human Glutaredoxin. Eur. J. Biochem. 227, 27–34 (1995). 
182. Lönn, M. E. et al. Expression Pattern of Human Glutaredoxin 2 Isoforms: 
Identification and Characterization of Two Testis/Cancer Cell-Specific Isoforms. 
Antioxid. Redox Signal. 10, 547–558 (2008). 
183. Holmgren, A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264, 13963–
13966 (1989). 
184. Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A. & Shelton, M. D. 
Molecular Mechanisms and Clinical Implications of Reversible Protein S -
Glutathionylation. Antioxid. Redox Signal. 10, 1941–1988 (2008). 
185. Shelton, M. D., Chock, P. B. & Mieyal, J. J. Glutaredoxin: Role in Reversible 
Protein S -Glutathionylation and Regulation of Redox Signal Transduction and 
Protein Translocation. Antioxid. Redox Signal. 7, 348–366 (2005). 
186. Townsend, D. M. et al. Novel Role for Glutathione S -Transferase π. J. Biol. 
Chem. 284, 436–445 (2009). 
187. Grek, C. L., Zhang, J., Manevich, Y., Townsend, D. M. & Tew, K. D. Causes and 
Consequences of Cysteine S -Glutathionylation. J. Biol. Chem. 288, 26497–
26504 (2013). 
188. Popov, D. Protein S -glutathionylation: from current basics to targeted 
modifications. Arch. Physiol. Biochem. 120, 123–130 (2014). 
189. Dominko, K. & Đikić, D. Glutathionylation: a regulatory role of glutathione in 
physiological processes. Arch. Ind. Hyg. Toxicol. 69, 1–24 (2018). 
190. Gravina, S. A. & Mieyal, J. J. Thioltransferase is a specific glutathionyl mixed-
disulfide oxidoreductase. Biochemistry 32, 3368–3376 (1993). 
191. SONG, J. J. & LEE, Y. J. Differential role of glutaredoxin and thioredoxin in 
metabolic oxidative stress-induced activation of apoptosis signal-regulating 
kinase 1. Biochem. J. 373, 845–853 (2003). 
192. Pan, S. & Berk, B. C. Glutathiolation Regulates Tumor Necrosis Factor-α–
Induced Caspase-3 Cleavage and Apoptosis. Circ. Res. 100, 213–219 (2007). 
193. Chen, C.-A., De Pascali, F., Basye, A., Hemann, C. & Zweier, J. L. Redox 
Modulation of Endothelial Nitric Oxide Synthase by Glutaredoxin-1 through 
Reversible Oxidative Post-Translational Modification. Biochemistry 52, 6712–
6723 (2013). 
References 
53 
 
194. Lind, C., Gerdes, R., Schuppe-Koistinen, I. & Cotgreave, I. A. Studies on the 
mechanism of oxidative modification of human glyceraldehyde-3-phosphate 
dehydrogenase by glutathione: Catalysis by glutaredoxin. Biochem. Biophys. 
Res. Commun. 247, 481–486 (1998). 
195. Barrett, W. C. et al. Regulation of PTP1B via glutathionylation of the active site 
cysteine 215. Biochemistry 38, 6699–6705 (1999). 
196. Zhang, X. et al. Positive Regulation of Interleukin-1β Bioactivity by Physiological 
ROS-Mediated Cysteine S-Glutathionylation. Cell Rep. 20, 224–235 (2017). 
197. Yang, F. et al. Glutaredoxin-1 Silencing Induces Cell Senescence via 
p53/p21/p16 Signaling Axis. J. Proteome Res. 17, 1091–1100 (2018). 
198. Moskovitz, J. et al. Identification and characterization of a putative active site for 
peptide methionine sulfoxide reductase (MsrA) and its substrate 
stereospecificity. J. Biol. Chem. 275, 14167–14172 (2000). 
199. Moskovitz, J. Methionine sulfoxide reductases: ubiquitous enzymes involved in 
antioxidant defense, protein regulation, and prevention of aging-associated 
diseases. Biochim. Biophys. Acta - Proteins Proteomics 1703, 213–219 (2005). 
200. Rhee, S. G., Jeong, W., Chang, T.-S. & Woo, H. A. Sulfiredoxin, the cysteine 
sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism 
of action, and biological significance. Kidney Int. 72, S3–S8 (2007). 
201. Ramesh, A., Varghese, S. S., Doraiswamy, J. & Malaiappan, S. Role of 
sulfiredoxin in systemic diseases influenced by oxidative stress. Redox Biol. 2, 
1023–1028 (2014). 
202. Findlay, V. J. et al. A Novel Role for Human Sulfiredoxin in the Reversal of 
Glutathionylation. Cancer Res. 66, 6800–6806 (2006). 
203. Noh, Y. H., Baek, J. Y., Jeong, W., Rhee, S. G. & Chang, T.-S. Sulfiredoxin 
Translocation into Mitochondria Plays a Crucial Role in Reducing Hyperoxidized 
Peroxiredoxin III. J. Biol. Chem. 284, 8470–8477 (2009). 
204. Barnett, S. D. & Buxton, I. L. O. The role of S-nitrosoglutathione reductase 
(GSNOR) in human disease and therapy. Crit. Rev. Biochem. Mol. Biol. 52, 
340–354 (2017). 
205. Tang, C.-H., Wei, W., Hanes, M. A. & Liu, L. Hepatocarcinogenesis Driven by 
GSNOR Deficiency Is Prevented by iNOS Inhibition. Cancer Res. 73, 2897–
2904 (2013). 
206. Rhee, S. G., Bae, Y. S., Lee, S.-R. & Kwon, J. Hydrogen Peroxide: A Key 
Messenger That Modulates Protein Phosphorylation Through Cysteine 
Oxidation. Sci. Signal. 2000, pe1–pe1 (2000). 
207. Sosa, V. et al. Oxidative stress and cancer: An overview. Ageing Res. Rev. 12, 
376–390 (2013). 
208. Duracková, Z. Some current insights into oxidative stress. Physiol. Rev. 59, 
459–469 (2010). 
209. Galle, P. R. et al. EASL Clinical Practice Guidelines: Management of 
hepatocellular carcinoma. J. Hepatol. 69, 182–236 (2018). 
References 
54 
 
210. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new 
mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505–511 
(2015). 
211. Weinberg, F. & Chandel, N. S. Reactive oxygen species-dependent signaling 
regulates cancer. Cell. Mol. Life Sci. 66, 3663–3673 (2009). 
212. Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential 
for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. 107, 8788–8793 (2010). 
213. Hanahan, Douglas and Weinberg, R. A. Hallmarks of Cancer: The Next 
Generation. Cell 144, 646–674 (2011). 
214. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. 
Nat. Rev. Cancer 11, 85–95 (2011). 
215. DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS 
detoxification and tumorigenesis. Nature 475, 106–109 (2011). 
216. Hanahan, D. & Weinberg, R. A. The Hallmarks of Cancer. Cell 100, 57–70 
(2000). 
217. Hornsveld, M. & Dansen, T. B. The Hallmarks of Cancer from a Redox 
Perspective. Antioxid. Redox Signal. 25, 300–325 (2016). 
218. Du, Y., Zhang, H., Lu, J. & Holmgren, A. Glutathione and Glutaredoxin Act as a 
Backup of Human Thioredoxin Reductase 1 to Reduce Thioredoxin 1 Preventing 
Cell Death by Aurothioglucose. J. Biol. Chem. 287, 38210–38219 (2012). 
219. Du, J. et al. Lysophosphatidic Acid Induces MDA-MB-231 Breast Cancer Cells 
Migration through Activation of PI3K/PAK1/ERK Signaling. PLoS One 5, e15940 
(2010). 
220. Wu, J.-R. et al. Hydrogen peroxide inducible clone-5 mediates reactive oxygen 
species signaling for hepatocellular carcinoma progression. Oncotarget 6, 
32526–32544 (2015). 
221. Lou, Y.-W. et al. Redox regulation of the protein tyrosine phosphatase PTP1B in 
cancer cells. FEBS J. 275, 69–88 (2008). 
222. Schwertassek, U. et al. Reactivation of oxidized PTP1B and PTEN by 
thioredoxin 1. FEBS J. 281, 3545–3558 (2014). 
223. Iriyama, T. et al. ASK1 and ASK2 differentially regulate the counteracting roles 
of apoptosis and inflammation in tumorigenesis. EMBO J. 28, 843–853 (2009). 
224. Kamiyama, M., Naguro, I. & Ichijo, H. In vivo gene manipulation reveals the 
impact of stress-responsive MAPK pathways on tumor progression. Cancer Sci. 
106, 785–796 (2015). 
225. Saitoh, M. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-
regulating kinase (ASK) 1. EMBO J. 17, 2596–2606 (1998). 
226. Ruhul Amin, A. R. M., Senga, T., Oo, M. L., Thant, A. A. & Hamaguchi, M. 
Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-
1beta: a role for the dual signalling pathways, Akt and Erk. Genes to Cells 8, 
515–523 (2003). 
References 
55 
 
227. Murata, H. et al. Glutaredoxin Exerts an Antiapoptotic Effect by Regulating the 
Redox State of Akt. J. Biol. Chem. 278, 50226–50233 (2003). 
228. Kwon, J. et al. Reversible oxidation and inactivation of the tumor suppressor 
PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. 101, 
16419–16424 (2004). 
229. Helfinger, V. & Schröder, K. Redox control in cancer development and 
progression. Mol. Aspects Med. 63, 88–98 (2018). 
230. Sengupta, R., Billiar, T. R., Kagan, V. E. & Stoyanovsky, D. A. Nitric oxide and 
thioredoxin type 1 modulate the activity of caspase 8 in HepG2 cells. Biochem. 
Biophys. Res. Commun. 391, 1127–1130 (2010). 
231. Li, H., Wan, A., Xu, G. & Ye, D. Small changes huge impact: the role of 
thioredoxin 1 in the regulation of apoptosis by S-nitrosylation. Acta Biochim. 
Biophys. Sin. (Shanghai). 45, 153–161 (2013). 
232. Lim, K.-H., Ancrile, B. B., Kashatus, D. F. & Counter, C. M. Tumour maintenance 
is mediated by eNOS. Nature 452, 646–649 (2008). 
233. González, R., López-Grueso, M. J., Muntané, J., Bárcena, J. A. & Padilla, C. A. 
Redox regulation of metabolic and signaling pathways by thioredoxin and 
glutaredoxin in NOS-3 overexpressing hepatoblastoma cells. Redox Biol. 6, 
122–134 (2015). 
234. Antunes, F. & Han, D. Redox Regulation of NF-κB: From Basic to Clinical 
Research. Antioxid. Redox Signal. 11, 2055–2056 (2009). 
235. Wang, F. et al. Activation of the NF-κB pathway as a mechanism of alcohol 
enhanced progression and metastasis of human hepatocellular carcinoma. Mol. 
Cancer 14, 10 (2015). 
236. Kobayashi, M. & Yamamoto, M. Molecular Mechanisms Activating the Nrf2-
Keap1 Pathway of Antioxidant Gene Regulation. Antioxid. Redox Signal. 7, 385–
394 (2005). 
237. Linher-Melville, K. & Singh, G. The complex roles of STAT3 and STAT5 in 
maintaining redox balance: Lessons from STAT-mediated xCT expression in 
cancer cells. Mol. Cell. Endocrinol. 451, 40–52 (2017). 
238. Sobotta, M. C. et al. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 
signaling. Nat. Chem. Biol. 11, 64–70 (2015). 
239. Yun, H.-M. et al. PRDX6 promotes tumor development via the JAK2/STAT3 
pathway in a urethane-induced lung tumor model. Free Radic. Biol. Med. 80, 
136–144 (2015). 
240. Ho, J. N. et al. Phospholipase A2 Activity of Peroxiredoxin 6 Promotes Invasion 
and Metastasis of Lung Cancer Cells. Mol. Cancer Ther. 9, 825–832 (2010). 
241. Schmitt, A., Schmitz, W., Hufnagel, A., Schartl, M. & Meierjohann, S. 
Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-
dependent lipid signalling. 267–279 (2015). doi:10.1042/BJ20141204 
242. Vázquez-Medina, J. P. et al. The phospholipase A 2 activity of peroxiredoxin 6 
modulates NADPH oxidase 2 activation via lysophosphatidic acid receptor 
signaling in the pulmonary endothelium and alveolar macrophages. FASEB J. 
References 
56 
 
30, 2885–2898 (2016). 
243. Levine, A. J. & Puzio-Kuter, A. M. The Control of the Metabolic Switch in 
Cancers by Oncogenes and Tumor Suppressor Genes. Science (80-. ). 330, 
1340–1344 (2010). 
244. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? 
Nat. Rev. Cancer 4, 891–899 (2004). 
245. Ward, P. S. & Thompson, C. B. Metabolic Reprogramming: A Cancer Hallmark 
Even Warburg Did Not Anticipate. Cancer Cell 21, 297–308 (2012). 
246. Dhup, S., Kumar Dadhich, R., Ettore Porporato, P. & Sonveaux, P. Multiple 
Biological Activities of Lactic Acid in Cancer: Influences on Tumor 
Growth,Angiogenesis and Metastasis. Curr. Pharm. Des. 18, 1319–1330 (2012). 
247. DeBerardinis, R. J. et al. Beyond aerobic glycolysis: Transformed cells can 
engage in glutamine metabolism that exceeds the requirement for protein and 
nucleotide synthesis. Proc. Natl. Acad. Sci. 104, 19345–19350 (2007). 
248. Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends 
Biochem. Sci. 39, 347–354 (2014). 
249. Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH 
production. Nature 510, 298–302 (2014). 
250. Gill, J. G., Piskounova, E. & Morrison, S. J. Cancer, Oxidative Stress, and 
Metastasis. Cold Spring Harb. Symp. Quant. Biol. 81, 163–175 (2016). 
251. Anastasiou, D. et al. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen 
Species Contributes to Cellular Antioxidant Responses. Science (80-. ). 334, 
1278–1283 (2011). 
252. Tórtora, V., Quijano, C., Freeman, B., Radi, R. & Castro, L. Mitochondrial 
aconitase reaction with nitric oxide, S-nitrosoglutathione, and peroxynitrite: 
Mechanisms and relative contributions to aconitase inactivation. Free Radic. 
Biol. Med. 42, 1075–1088 (2007). 
253. Shi, Q. et al. Inactivation and Reactivation of the Mitochondrial α-Ketoglutarate 
Dehydrogenase Complex. J. Biol. Chem. 286, 17640–17648 (2011). 
254. Prehu, M.-O., Prehu, C., Calvin, M. & Rosa, R. Rabbit M type 
phosphoglycermutase: comparative effects of two thiol reagents, antibody 
reaction and hybridization studies. Comp. Biochem. Physiol. Part B Comp. 
Biochem. 89, 257–262 (1988). 
255. Hameed M. S., S. & Sarma, S. P. The Structure of the Thioredoxin–
Triosephosphate Isomerase Complex Provides Insights into the Reversible 
Glutathione-Mediated Regulation of Triosephosphate Isomerase. Biochemistry 
51, 533–544 (2012). 
256. Dumont, S., Bykova, N. V., Pelletier, G., Dorion, S. & Rivoal, J. Cytosolic 
triosephosphate isomerase from Arabidopsis thaliana is reversibly modified by 
glutathione on cysteines 127 and 218. Front. Plant Sci. 7, 1–16 (2016). 
257. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial–
mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014). 
References 
57 
 
258. Rhyu, D. Y. et al. Role of reactive oxygen species in TGF-β1-induced mitogen-
activated protein kinase activation and epithelial-mesenchymal transition in renal 
tubular epithelial cells. J. Am. Soc. Nephrol. 16, 667–675 (2005). 
259. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-
mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142 (2006). 
260. Larue, L. & Bellacosa, A. Epithelial-mesenchymal transition in development and 
cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24, 
7443–7454 (2005). 
261. Barber, A. G. et al. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 
in aggressive prostate cancer. Cancer Med. 4, 1258–1271 (2015). 
262. Dong, J. et al. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling 
pathway contributes to epithelial-mesenchymal transition-induced multi-drug 
resistance to sorafenib in hepatocellular carcinoma cells. PLoS One 12, 1–16 
(2017). 
263. Cervello, M. et al. Molecular mechanisms of sorafenib action in liver cancer 
cells. Cell Cycle 11, 2843–2855 (2012). 
264. Coriat, R. et al. Sorafenib-induced hepatocellular carcinoma cell death depends 
on reactive oxygen species production in vitro and in vivo. Mol. Cancer Ther. 11, 
2284–2293 (2012). 
265. Zhang, C., Guo, F., Jia, W. & Ge, Y. STAT3 activation mediates epithelial-to-
mesenchymal transition in human hepatocellular carcinoma cells. 
Hepatogastroenterology 61, 1082–1089 (2014). 
266. Reichl, P. & Mikulits, W. Accuracy of novel diagnostic biomarkers for 
hepatocellular carcinoma: An update for clinicians (Review). Oncol. Rep. 36, 
613–625 (2016). 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
58 
 
Abstract 
 The redoxins Thioredoxin (Trx), Glutaredoxin (Grx) and Peroxiredoxins (Prdx) 
play a very important role both in the maintenance of redox homeostasis and in 
signaling through reversible oxidation/reduction reactions in cysteine residues key to 
the regulation of protein function. The main objective of this project is to demonstrate 
that redoxins exert a role in the control of metabolic flux of tumor cells by regulating the 
redox state of metabolic enzymes and proteins involved in cell signaling.  
To study the functions of human Trx1 and Grx1, we have used the hepatocarcinoma-
derived HepG2 cell line as an experimental model under both normal and 
oxidative/nitrosative conditions. We have shown that silencing of Trx1 or Grx1 causes 
major changes in the redox proteome reflected in significant changes in the 
reduced/oxidized ratio of enzyme cysteines such as glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) Cys247 and triosephosphate isomerase (TPI) Cys255 that 
affect their activity. Trx1 silencing increases glycolytic flux and induces membrane 
remodelling as indicated by the increase in sphingomyelins and ceramides. On the 
other hand, Grx1 silencing decreases the glycolytic fluxand increases the synthesis of 
fatty acids and phospholipids stimulating lipogenesis. These results indicate that, 
although both redoxins have some common target cysteines, their down-regulation 
causes different metabolic changes. Among the redox targets of Grx1 is the “extra” 
non-peroxidatic Cys91, of Prdx6, the only member of the 1-Cys peroxiredoxin family in 
humans, which in addition to having characteristic peroxidase activity is the only one 
that also has phospholipase A2 activity calcium independent (iPLA2).  
 Prdx6 silencing in HepG2 cells decreases proliferation and increases cell 
volume without changing the number of cells; decreases the rate of glucose entry and 
nucleotide biosynthesis while the levels of amino acids, polyamines, phospholipids and 
most glycolipids increase. Changes in the global proteome reflect an increase in 
vesicle traffic while the redox proteome shows changes in various enzymes among 
which are hexokinase 2 (HK2) Cys368, phosphoenolpyruvate carboxykinase 2 (PCK2) 
Cys55-63, and 3-phosphoglycerate dehydrogenase (PHGDH) Cys18-19 and Cys281. 
These results indicate that Prdx6 silencing induces both a predominant metabolic 
remodelling towards a glyconeogenic flow from amino acids with diversion at the 
synthesis of serine and other biosynthetic pathways, as well as cell cycle arrest at 
G1/S transition. It remains to be determined which Prdx6 activity is responsible for 
these effects, whether its peroxidase or PLA2 or both and what are the detailed 
mechanisms that lead to these effects. 
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 The next step has been to verify whether these actions of the studied redoxins 
also take place in advanced states of hepatocarcinoma in which resistance to the 
standard treatment with Sorafenib is frequent. In line with this, a study has been carried 
out in three hepatocarcinoma cell lines with different degrees of epithelial-
mesenchymal transition and therefore with increasing invasive potential and 
malignancy (HepG2, SNU423 and SNU475), treated with Sorafenib and/or silenced for 
Trx1. This drug is jnown as a tyrosine kinase inhibitor and we have observed that 
treatment with Sorafenib induces reductive changes in key tumor signaling proteins, 
such as STAT3, MAPK and Akt, in the three cell lines but large changes in the global 
proteome have only been seen in cells of intermediate dedifferentiation state 
(SNU423). Silencing of Trx1 does not have a great effect on the overall proteome of 
the three cell lines but it does counteract the reducing effect of Sorafenib on a thiol 
group at STAT3 and sensitizes the more mesenchymal hepatocarcinoma cell line 
(SNU475) against Sorafenib, inactivating TGFß1 pathway and stimulating HIPPO 
signaling. Therefore, these results support the idea that the combined treatment of 
Sorafenib with Trx1 inhibitors could help to design more effective therapies against 
advanced hepatocarcinoma resistant to Sorafenib. 
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Resumen 
 Las redoxinas Tiorredoxina (Trx), Glutarredoxina (Grx) y Peroxirredoxina (Prdx) 
juegan un papel muy importante tanto en el mantenimiento de la homeostais redox 
como en señalización a través de reacciones de oxido/reducción reversibles en 
residuos de cisteína claves para la regulación de la función de la proteína. El objetivo 
principal de este proyecto es estudiar las funciones de las redoxinas en señalización 
celular y metabolismo en líneas celulares derivadas de hepatocarcinoma sometidas o 
no a altos niveles de óxido nítrico.   
 Para el estudio de las funciones de la Trx1 y Grx1 hemos empleado como 
modelo experimental la línea celular derivada de hepatoblastoma (HepG2) bajo 
condiciones normales y de estrés oxidativo/nitrosativo. Hemos demostrado que el 
silenciamiento de Trx1 o Grx1 provoca grandes cambios en el proteoma redox tiólico 
reflejado en cambios significativos en la ratio reducido/oxidado de cisteínas de 
enzimas como la Cys247 de la gliceraldehido-3-fosfato deshidrogenasa (GAPDH) y 
Cys255 de la triosafosfato isomerasa (TPI) los cuales afectan a la actividad de dichas 
enzimas. El silenciamiento de Trx1 aumenta el flujo glucolítico e induce 
remodelamiento de la membrana lipídica como indica el incremento de esfingomielinas 
y ceramidas. Por otro lado, el silenciamiento de Grx1 disminuye el flujo glucolítico y 
aumenta la síntesis de ácidos grasos y fosfolípidos estimulando lipogenesis. Los 
resultados indican que, a pesar de que ambas redoxinas tengan algunas cisteínas 
diana comunes, su silenciamiento provoca cambios metabólicos diferentes. Entre las 
dianas redox de la Grx1 se encuentra la Cys91, no peroxidática, de la Prdx6, el único 
miembro de la familia de las peroxiredoxinas de 1-Cys en humanos, que además de 
poseer la actividad peroxidasa característica, es la única que presenta actividad 
actividad fosfolipasa A2 independiente de calcio (iPLA2). 
 El silenciamiento de Prdx6 en HepG2 disminuye la proliferación y el número de 
células mientras que el volumen celular aumenta. Además la entrada de glucosa y la 
biosíntesis de nucleótidos disminuyen mientras que los niveles de amino ácidos, 
poliaminas, fosfolípidos y la mayoría de glicolípidos aumentan. El efecto del 
silenciamiento de Prdx6 sobre el proteoma global muestra un aumento en el tráfico de 
vesículas mientras que el proteoma redox muestra cambios en diversas enzimas de 
rutas metabólicas entre las que se encuentran la Cys368 de la hexoquinasa 2 (HK2), 
la Cys55-63 de la fosfoenolpiruvato carboxiquinasa 2 (PCK2), y las Cys18-19 y 
Cys281 de la 3-fosfoglicerato deshidrogenasa (PHGDH). Los resultados indican que el 
silenciamiento de Prdx6 induce tanto un remodelamiento metabólico predominante 
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hacia gluconeogénesis desde amino ácidos con desviación hacia la síntesis de serina 
y otras vías biosintéticas, así como detención del ciclo celular en la transición G1/S. 
Está por determinar qué actividad de la Prdx6 es responsable de estos efectos, si su 
peroxidasa o la PLA2 o ambas y cuáles son los mecanismos detallados que conducen 
a esos efectos. 
 El siguiente paso ha sido comprobar si estas acciones de las redoxinas 
estudiadas tienen lugar igualmente en estados avanzados de hepatocarcinoma en los 
que se suele dar una resistencia al tratamiento estándar con Sorafenib. En línea con 
esto, se ha llevado a cabo un estudio en tres líneas celulares de hepatocarcinoma con 
distinto grado de transición epitelio-mesenquimal y por tanto, con mayor potencial de 
invasividad y malignicidad (HepG2, SNU423 y SNU475), tratadas con Sorafenib y/o 
silenciando la Trx1. El Sorafenib es un medicamento conocido por su actividad como 
un inhibidor de tirosinas quinasas y nosotros hemos observado que el tratamiento con 
Sorafenib induce cambios reductores en proteínas clave de señalización tumoral, tales 
como STAT3, MAPK y Akt, en las tres líneas celulares pero los grandes cambios en el 
proteoma global se han visto únicamente en células en estado intermedio de 
desdiferenciación (SNU423). El silenciamiento de Trx1 no tiene un gran efecto en el 
proteoma global de las tres líneas pero sí contrarresta el efecto reductor del Sorafenib 
sobre un grupo tiol de STAT3 y sensibiliza a las células de hepatocarcinoma más 
mesenquimales (SNU475) frente al Sorafenib, inactivando la vía de TGFß1 y 
estimulando la vía de señalización HIPPO. Por lo tanto, los resultados apoyan la idea 
de que el tratamiento combinado de Sorafenib con inhibidores de la Trx1 podría 
ayudar al diseño de terapias más efectivas contra el hepatocarcinoma en estado 
avanzado resistente a Sorafenib. 
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A B S T R A C T
The aim of the present study was to deﬁne the role of Trx and Grx on metabolic thiol redox regulation and
identify their protein and metabolite targets. The hepatocarcinoma-derived HepG2 cell line under both normal
and oxidative/nitrosative conditions by overexpression of NO synthase (NOS3) was used as experimental model.
Grx1 or Trx1 silencing caused conspicuous changes in the redox proteome reﬂected by signiﬁcant changes in the
reduced/oxidized ratios of speciﬁc Cys's including several glycolytic enzymes. Cys91 of peroxiredoxin-6 (PRDX6)
and Cys153 of phosphoglycerate mutase-1 (PGAM1), that are known to be involved in progression of tumor
growth, are reported here for the ﬁrst time as speciﬁc targets of Grx1. A group of proteins increased their CysRED/
CysOX ratio upon Trx1 and/or Grx1 silencing, including caspase-3 Cys163, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) Cys247 and triose-phosphate isomerase (TPI) Cys255 likely by enhancement of NOS3 auto-
oxidation. The activities of several glycolytic enzymes were also signiﬁcantly aﬀected. Glycolysis metabolic ﬂux
increased upon Trx1 silencing, whereas silencing of Grx1 had the opposite eﬀect. Diversion of metabolic ﬂuxes
toward synthesis of fatty acids and phospholipids was observed in siRNA-Grx1 treated cells, while siRNA-Trx1
treated cells showed elevated levels of various sphingomyelins and ceramides and signs of increased protein
degradation. Glutathione synthesis was stimulated by both treatments. These data indicate that Trx and Grx have
both, common and speciﬁc protein Cys redox targets and that down regulation of either redoxin has markedly
diﬀerent metabolic outcomes. They reﬂect the delicate sensitivity of redox equilibrium to changes in any of the
elements involved and the diﬃculty of forecasting metabolic responses to redox environmental changes.
1. Introduction
The importance of redox homeostasis for cancer cell survival in the
context of energy metabolism is well established [2,57,83]. Sensitive
cysteine residues on target proteins are at the center of regulatory
mechanisms, whose redox state are controlled by two major cellular
systems, the Thioredoxin (Trx)/Trx reductase (TrxR) and the Glutar-
edoxin (Grx)/glutathione (GSH) systems [30,8].
Nitric oxide (NO) plays important roles in signal transduction [52].
It is synthesized in cells by NO synthase (NOS) isoenzymes whose ex-
pression may be regulated as part of cellular responses to several sti-
muli [1]. NO has contradictory eﬀects on tumor cells, either pro-
apoptotic or anti-apoptotic according to cell type, intracellular
concentration range and subcellular site of its generation [23,44]. Post-
translational redox modiﬁcations (redox PTM) of target sensitive pro-
teins and more speciﬁcally, S-nitrosation of sensitive cysteine residues
in those proteins, is the basis of NO activity in signaling pathways, al-
though other reversible oxidative modiﬁcations of cysteines are also to
be expected since high levels of NO are accompanied by increased le-
vels of reactive oxygen species (ROS) [85]. Reversible regulation of
redox PTMs is necessary for this process to have regulatory and biolo-
gical meaning. Intracellular levels of GSNO and S-nitrosated proteins
are controlled by GSNO reductase, alcohol dehydrogenase class-3 (ADH
III), which is a NADH-dependent enzyme that is conserved from bac-
teria to human and metabolizes GSNO to oxidized glutathione and NH3
[47]. GSNO reductase does not directly denitrosate SNO proteins, but as
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the GSNO pool is in equilibrium with protein thiols, reduction of GSNO
by the GSNO reductase indirectly results in protein denitrosation [47].
Trx has been shown to catalyze denitrosation in vitro and to aﬀect
levels of cellular protein nitrosothiols. It has been shown to also cata-
lyze the direct denitrosation of proteins in vivo through the action of its
conserved active site dithiol, which in human Trx1 is Cys32 and Cys35
[4,5]. NOS3 (or eNOS) itself is a target of Trx leading to activation of
the enzyme as part of a regulatory mechanism of NOS3 by reversible
auto-S-nitrosation [15,4,64,67].
Mammalian Trx1 contains additional conserved Cys at positions 62,
69 and 73. Cys73 is particularly prone to S-nitrosation [26] and is
implicated in the speciﬁc and reversible transfer of a nitrosothiol be-
tween Trx1 and caspase 3 with the resulting inhibition of apoptosis
[60]. It has been shown that S-nitrosation of Cys73 is favored after
formation of a disulﬁde between Cys32-Cys35, that attenuates Trx1
disulﬁde reductase and denitrosase activities [86]. Depending on the
redox state of the cell, Trx1 catalyzes either trans-S-nitrosation or S-
denitrosation so that upon inhibition of disulﬁde reduction or S-deni-
trosation activity, Cys73-SNO-Trx1 could catalyze trans-S-nitrosation of
target proteins [26,86]. Thus, as a master regulator of redox signaling,
Trx1 would protect proteins via its reductase activity, but under highly
oxidative environments, the Cys32/Cys35 oxidized disulﬁde form ac-
cumulates, Cys73 becomes S-nitrosated and Trx1 oﬀers an alternative
modality of protein regulation via transnitrosation [86].
Glutaredoxin is involved in post-translational modiﬁcation of pro-
teins by S-glutathionylation with a role mainly as a deglutathionylase
[39,54,75]. Grx1 catalyzes reversible S-glutathionylation of protein
targets involved in Glycolysis, energy sensing, calcium homeostasis,
apoptosis and transcriptional regulation [59]. Grx1 has also been
shown to counteract the proapoptotic action of NO in tumor cell lines
[22,35] and to regulate NOS3 activity by glutathionylation [9], an
activity shared with Trx [78]. However, no direct evidence of Grx1 as
denitrosase has been reported so far.
The thiol-based mechanism of NO multiple actions and the roles of
Trx and Grx in the context of protein function regulation by reversible
redox changes at target cysteines justify the study of cells under ni-
trosative stress. Exogenous addition of NO donors is a widely used ex-
perimental approach to this end, but endogenously produced RNS
would better mimic a physiological situation. The levels of ROS and NO
increase to 140% in NOS3 overexpressing HepG2 cells relative to con-
trol cells [21], which makes them a good experimental model to study
the signiﬁcance of Trx and Grx roles in the regulation of cellular phy-
siology under nitrosative and oxidative conditions.
The Thiol Redox Proteome refers to the set of mapped protein cy-
steines showing reversible redox changes under given conditions or in
response to stimuli [20]. Its detailed description may provide an in-
sightful snapshot of the set of thiol redox switches [19,38] in a cell
under given conditions. Several qualitative and quantitative proteomic
approaches have been devised to study the redox proteome
[24,27,32,43,46,50,53,55] and to deﬁne Trx target proteins either as
reductase or transnitrosase [46,6,87] or target proteins of Grx as de-
glutathionylase [54]. The identiﬁcation and modulation by reversible
redox PTMs of key proteins that can control metabolic ﬂow, would oﬀer
promising therapeutic candidates for a number of disease states such as
cancer [80]. Moreover, redox signals work in tandem with other signals
to control diﬀerent cellular processes.
One common characteristic to all types of cancers is reprogramming
of energy metabolism to generate ATP through intense glycolytic ﬂux
from glucose to lactate even when oxygen is present, a phenomenon
known as “the Warburg eﬀect”. Mitochondria remain functional and
part of the glucose consumed is diverted into biosynthetic pathways
upstream of pyruvate. Altered cell metabolism is a characteristic feature
of many cancers resulting in changes to metabolite concentrations and
eventually aﬀecting cell signaling pathways and metabolic ﬂuxes
[79,83]. There is a complex connection between metabolism and pro-
liferation with many checkpoints still to be discovered.
We have previously assessed the role of NOS-3 overexpression on
several metabolic checkpoints in HepG2 cells showing the prominence
of the oxidative branch of the Pentose Phosphate Pathway (oxPPP) to
direct the metabolic ﬂux towards NADPH and the increase in Trx and
Grx, but at the same time a decrease in nucleotide biosynthesis and
proliferation [23]. Downregulation of Trx and Grx reduced cell pro-
liferation and increased caspase-8 and caspase-3.
Here we have applied a quantitative proteomic and metabolomic
approach to evaluate HepG2 cells under high levels of endogenous NO
and ROS by NOS3 overexpression and≈ 80% down-regulation of Grx1
or Trx1 with speciﬁc siRNA. Proteins undergoing signiﬁcant redox
changes have been identiﬁed, their sensitive cysteines have been
mapped and their “reduced Cys/oxidized Cys” ratios have been de-
termined. Known targets of redox PTMs have been conﬁrmed and new
targets have been discovered, mostly metabolic enzymes. Glycolytic
metabolic ﬂux, complex lipids and glutathione metabolism and protein
degradation, among other pathways, were aﬀected by Trx1 or Grx1
silencing, concomitant with redox changes at speciﬁc cysteines in gly-
colytic enzymes.
2. Material and methods
2.1. Materials and reagents
All reagents were of analytical grade and were purchased from
Sigma, unless otherwise stated. HepG2 cell line used in this work was
obtained from ATCC LGC Standards Company (Teddington, UK). Cell
culture dishes and ﬂasks were from TPP (Switzerland). Anti-Trx1 and
anti-Grx1 were obtained from rabbit in our laboratory. Antibodies
against PKM2, caspase-3, NOS-3 and β-actin were from Santa Cruz
Biotechnology, (Dallas, TX, USA). Antibodies against PRDX6 were from
Abcam (Cambridge, UK). ECL was from GE Healthcare (Wauwatosa,
Wisconsin, USA). siRNA for Grx1 and Trx1 were from GE Healthcare
Dharmacon (Wauwatosa, Wisconsin, USA). [14C-1]-Glucose, [14C-6]-
Glucose and [3H-3]-Glucose were from Perkin Elmer (USA).
2.2. Cell growth conditions
Cells were transfected with the pcDNA/4TO (5100 bp; Invitrogen,
Molecular Probes, Inc.) resulting in 4TO control cell line, as well as with
the same expression vector containing NOS3 cDNA sequence (3462 bp;
NCBI, ImaGenes, full length cDNA clone sequence BC063294) under the
control of the cytomegalovirus promoter resulting in 4TO-NOS cell line.
Cell lineages 4TO and 4TO-NOS were selected with zeocin (15mg/L;
Invitrogen) as was described by González et al. [21]. Cells were
maintained in EMEM Medium (Eagle Minimum Essential Medium), pH
7.4, supplemented with 10% fetal bovine serum, 2.2 g/L NaHCO3,
1mM sodium pyruvate, 100 U/L penicillin, 100 µg/mL streptomycin,
0.25 µg/mL amphotericin, and the corresponding selective zeocin an-
tibiotic in 5% CO2 atmosphere at 37 °C.
2.3. Silencing of Trx1 and Grx1
Human Grx1 and Trx1 were down-regulated in non-transfected
HepG2 cells (WT), 4TO and 4TO-NOS cells using speciﬁc siRNA in 6-
well plates (20,000 cells/cm2) according to the manufacturer's re-
commendations (Dharmacon, GE Healthcare Life Sciences). Grx and Trx
siRNA (25 nmol) were mixed with the transfection reagent
DharmaFECT 1, previously pre-incubated with culture medium (anti-
biotic/antimycotic and serum free), and incubated for 20min at room
temperature. Afterwards, the interference solutions were added to
cultured cells for 72 h in 2% culture medium in the absence of anti-
biotic/antimycotic solution [89]. Silencing of Trx 1 and Grx1 was al-
ways checked by Western blot and activity assay to conﬁrm that their
levels were reduced by ≈ 80% [22].
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2.4. Sample preparation for redox proteomics
The experiments were routinely carried out at 100,000 cells/cm2
and the cells were washed with PBS. The methodological strategy is
summarized in Fig. 1 as described before [55]. Reversibly oxidized Cys
were labeled with “heavy” NEM in which 5 hydrogen atoms had been
substituted by deuterium atoms here named “d(5)NEM” and reduced
cysteines were blocked with “light” NEM, here named “d(0)NEM”. Cell
extracts were obtained with lysis solution (50mM ammonium bi-
carbonate, 50mM d(0)NEM, 0.5% CHAPS, 1mM PMSF); samples were
centrifuged at 15,000g for 5min at 4 °C, excess d(0)NEM was removed
using Zeba spin desalting columns (Thermo Scientiﬁc). 100 µg of pro-
tein were diluted up to 160 µl with 25mM ammonium bicarbonate,
incubated with denaturing reagent by addition of 10 µl of 1% w/v
RapiGest (Waters) in 25mM ammonium bicarbonate, incubated at
80 °C for 10min and vortexed. 10 µl of a 100mM solution of TCEP was
added followed by incubation at 60 °C for 10min to reduce the re-
versibly oxidized cysteines that were subsequently alkylated by adding
10 µl of 200mM d(5)NEM and incubated at room temperature for
30min. An aliquot was taken at this point to check the procedure by
SDS-PAGE.
Proteolytic digestion was performed by addition of 10 µl 12.5 ng/µl
of trypsin (Promega) in 25mM ammonium bicarbonate and incubated
at 37 °C temperature overnight. Protein digestion was stopped by
addition of 3 µl triﬂuoroacetic acid (1.5% ﬁnal concentration). Digested
samples were dialyzed through detergent removal column (Pierce) to
eliminate any possible rest of CHAPS and dried in speedvac.
2.5. LC–MS/MS
Protein analyses were performed at the Proteomics Facility (SCAI)
at the University of Córdoba. Peptides were scanned and fragmented
with the LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientiﬁc)
equipped with a nano-UHPLC Ultimate 3000 (Dionex-Thermo
Scientiﬁcs). Chromatography conditions were: mobile phase solution A:
0.1% formic acid in ultrapure water; mobile phase solution B: 80%
acetonitrile, 0.1% formic acid. A chromatography gradient was per-
formed in C18 nano-capillary column (Acclaim PepMap C18, 75 µm
internal diameter, 3 µm particle size, Dionex-Thermo Scientiﬁcs) as
follows: 5 min, 4% solution B; 60min, 4–35% solution B; 10min,
35–80% B; 10min, 80% B; 10min 4% B. The nano-electrospray voltage
was set to 1300 V and the capillary voltage to 50 V at 190 °C. The LTQ
Orbitrap XL was operated in parallel mode, allowing for the accurate
measurement of the precursor survey scan (400–1500m/z) in the
Orbitrap selection, a 30,000 full-width at half-maximum (FWHM) re-
solution at m/z 400 concurrent with the acquisition of top ﬁve CID
Data-Dependent MS/MS scans in the LIT for peptide sequence. Singly
charged ions were excluded. The normalized collision energies used
were 35% for CID. The maximum injection times for MS and MS/MS
were set to 500ms and 50ms, respectively. The precursor isolation
width was 3 amu and the exclusion mass width was set to 5 ppm.
Monoisotopic precursor selection was allowed and singly charged spe-
cies were excluded. The minimum intensity threshold for MS/MS was
500 counts for the linear ion trap and 1000 counts for the Orbitrap.
MS2 spectra were searched with SEQUEST engine against a database of
Uniprot_Human_Nov2014 (www.uniprot.org). Peptides were generated
from a tryptic digestion with up to one missed cleavage, including NEM
and (d5)NEM modiﬁcation in Cys and methionine oxidation as dynamic
modiﬁcations. Statistical data were calculated with percolator tool
against decoy database using 1% FDR as threshold for signiﬁcance.
2.6. Label-free MS protein quantiﬁcation
The analysis of MS raw data of the two studies was performed using
the MaxQuant (v1.5.7.0) [12] and Perseus (v1.5.6.0) [82] software.
Three RAW data ﬁles per sample from 3 separate experiments were
analyzed. Proteins were identiﬁed by searching raw data against the
human UniprotKB/Swiss-Prot protein database (February 2018 ver-
sion). The modiﬁcations NEM and d(5)NEM and methionine oxidation
was set as variable modiﬁcations for the second study. Cleavage spe-
ciﬁcity was by trypsin, allowing for a maximum of two missed clea-
vages, a mass tolerance of 10 ppm for precursors and 0.01 Da for
fragment ions. The false discovery (FDR) cut-oﬀ for protein identiﬁca-
tion was 1%. Enabling the “match between runs” option allowed for
identiﬁcation transfer between samples. Similar proteins were grouped,
and only unique peptides were used for quantiﬁcation. Identiﬁed from
reverse database or contaminants hits proteins were removed prior to
further analysis. Finally, the resultant list was analyzed according to the
instructions of the software developers [82]. The criteria for con-
sidering a diﬀerentially expressed protein were that it was identiﬁed
and quantiﬁed using at least two unique peptides; has a fold change of
at least 1.5 and had a P≤ 0.05 value.
2.7. Targeted analysis of diﬀerentially labeled Cys residues
The method devised has been described before [55]. Brieﬂy, Cys-
containing peptides detected with identical amino acid sequences and
both d(0) and d(5) NEM modiﬁcations independently with a conﬁdent
individual peptide ion score were considered redox peptides. Redox
peptides detected from Proteome Discoverer analyses of RAW ﬁles were
Fig. 1. Proteomics experimental strategy. The procedure follows the already
classical three-step approach. In this case, the thiol blocking agent was NEM,
the cysteine reductant was TCEP and the newly formed thiols were labeled with
“heavy” d(5)-NEM in which 5 hydrogen atoms had been substituted by deu-
terium atoms. LC-MS/MS data were analyzed for global protein changes with
MaxQuant software for “label-free” quantitation [12]. Redox protein changes
were analyzed from the set of Cys-peptides identiﬁed by targeted quantiﬁcation
using Skyline [48] and calculating the “light”(reduced)/“heavy”(oxidized) Cys
ratio. See M&M section for a detailed description.
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selected for targeted analysis using m/z data and retention times with
the open software Skyline [48]. Targeted analysis applying m/z, re-
tention times, and fragmentation spectra for peptide selection allowed
the calculation of the reduced/oxidized ratio (or d(0)/d(5) NEM) of the
Cys residues using the individual parent ion intensities. The individual
reduced/oxidized ratio for redox Cys peptides in each sample was used
to calculate an average ratio of reduced/oxidized calculated for the
speciﬁc Cys residues.
2.8. Metabolomic analysis
Metabolomic analyses were performed at Metabolon, NC USA and
the samples were prepared following the speciﬁc guidelines. Global
biochemical proﬁles were determined in 2×106 HepG2 cells collected
from diﬀerent treatment groups (wild type, 4TO and 4TO-NOS cells
treated with speciﬁc siRNA for Trx and Grx or with non-target siRNA).
Each experiment was done four times and the dry cell pellets were
immediately frozen in liquid nitrogen and stored at −80 °C until
shipment. Samples were prepared using the automated MicroLab
STAR® system from Hamilton Company. To remove protein, dissociate
small molecules bound to protein or trapped in the precipitated protein
matrix, and to recover chemically diverse metabolites, proteins were
precipitated with methanol under vigorous shaking for 2min (Glen
Mills GenoGrinder 2000) followed by centrifugation. The resulting ex-
tract was divided into ﬁve fractions: two for analysis by two separate
reverse phase (RP)/UPLC-MS/MS methods with positive ion mode
electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with
negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with
negative ion mode ESI, and one sample was reserved for backup. Raw
data was extracted, peak-identiﬁed and QC processed using Metabolon's
hardware and software. Peaks were quantiﬁed using area-under-the-
curve and normalized.
2.9. Biotin switch technique
All operations were performed in darkness and following the pro-
tocol described by Martínez-Ruiz et al. [51] with some modiﬁcations.
Treated cells were resuspended in lysis buﬀer (50mM Tris-HCl, pH 7.4,
300mM NaCl, 5 mM EDTA, 0.1 mM neocuproine, 1% Triton X-100,
1mM PMSF, 1 µg/mL aprotinin and 2 µg/mL leupeptin) and incubated
on ice for 15min. Samples were centrifuged at 10,000g, 4 °C for 15min
and supernatants were collected. Extracts were adjusted to 1.0mg/mL
of protein and were blocked with 4 volumes of blocking buﬀer (225mM
HEPES, pH 7.2, 0.9mM EDTA, 90 µM neocuproine, 2.5% SDS and
50mM NEM) at 37 °C for 30min with stirring. After blocking, samples
were precipitated with cold acetone and pellets were resuspended in
HENS buﬀer (250mM HEPES, pH 7.2, 1 mM EDTA, 0.1 mM neocu-
proine, 1% SDS) with 100mM ascorbate and 1mM biotin-HPDP and
incubated for 1 h at room temperature. Finally, samples were passed
through Zeba spin desalting columns (Thermo Scientiﬁc Pierce) to
eliminate ascorbate and biotinylated proteins were detected by western
blot with “anti-biotin”. In addition, the biotinylated proteins were
captured with neutravidin-agarose (Pierce) and recovered using
100mM ß-mercaptoethanol for subsequent Western blot analysis of
speciﬁc target proteins.
2.10. Rate of glycolysis and Pentose Phosphate Pathway (PPP)
These were measured following the protocol described by Requejo-
Aguilar et al. [68] with some modiﬁcations. The resuspended cells
(1.5×105 cells) were incubated in “Elliot” buﬀer (122mM NaCl,
11 mM Na2HPO4, 0.4 mM KH2PO2, 1.2 mM SO4Mg, 3.1 mM KCl,
1.3 mM CaCl2, pH7.4) in the presence of 5 μCi of D-[3-3H]glucose,(0.5
μCi mL−1of D-[1–14C]glucose or 1 μCi mL−1 of [6–14C]glucose and
5mM D-glucose in sealed vials. The glycolytic ﬂux was measured by
assaying the rate of 3H2O production from [3-3H]glucose, and the PPP
ﬂux as the diﬀerence between [1–14C]glucose and [6–14C]glucose in-
corporated into 14CO2. Glucose concentrations in Elliot buﬀer were
measured by enzymatic analysis spectrophotometrically.
2.11. Measurement of enzymatic activities, lactate and protein
All glycolytic enzymatic activities were measured in fresh cell ly-
sates obtained in the absence of reducing agents. Cell lysates were
prepared with lysis buﬀer containing 50mM HEPES pH 7.2, 2 mM
EDTA, 100mM NaCl, 1% Triton X-100, 1mM PMSF. Commercial pre-
parations of pure enzymes were used to calibrate the assays and to
determine the linear dependence activity range. Pyruvate kinase (PK)
and triose phosphate isomerase (TPI) activities were measured ac-
cording to the method described by Fielek and Mohrenweiser [16]
without DTT in the assay mixture. Glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH) activity was measured as an increase in absorption
at 340 nm resulting from reduction of NAD+ at 25 °C. The reaction
mixture contained 130mM Tris-HCl, pH 8.0, 0.25mM NAD+, and
5mM DL-glyceraldehyde-3-phosphate. Three technical replicates were
routinely done for each independent experiment. Lactate concentration
in the culture medium after 72 h of treatment with the siRNA Grx1 or
siRNA Trx1 was determined by an enzymatic colorimetric assay
(505 nm) using the kit Labkit (Chemelex, S.A). Protein concentration
was determined by the Bradford method (Bio-Rad) using BSA as stan-
dard.
2.12. SDS-PAGE and Western blotting
SDS-PAGE was performed with homogeneous 10% non-reducing
gels for detection of biotinylated proteins and 12% Criterium XT
Precast Gel (Bio-Rad) for detection of speciﬁc proteins (Trx1, PRDX6,
PKM2, caspase-3, NOS3). After electrophoresis, proteins were trans-
ferred to a nitrocellulose membrane with a semi-dry electrophoretic
transfer system (Bio-Rad). The membranes were incubated overnight at
4 °C with the corresponding dilutions of primary antibodies: 1:4000
against biotin, 1:1000 against PRDX6, 1:500 against PKM2, caspase-3
and NOS3, 1:500 against Trx1 and Grx1. Then washed and incubated
with the corresponding secondary antibodies conjugated to peroxidase
(anti-rabbit, anti-goat or anti-mouse) used at 1:8000 dilution and the
chemiluminescent signal was induced by ECL reagent (Thermo-Fisher).
Ponceau staining was used as cell protein-loading control and actin was
used as reference for quantitative densitometric normalization.
2.13. Statistics
Where appropriate, results are expressed as mean ± SEM of at least
three independent experiments. Data were compared using ANOVA
with the least signiﬁcant diﬀerence test post hoc multiple comparison
analysis. The threshold for statistically signiﬁcant diﬀerences was set at
p≤ 0.05. In the case of Global and Redox Proteome, data were ana-
lyzed using Student's T-test comparing control vs siRNA treatment. The
threshold for this statistically signiﬁcant diﬀerences was set at q≤ 0.05
according to the method of Storey [77] using the R-package. In the case
of the metabolomic analysis following normalization to Bradford pro-
tein concentration and log transformation a mixed model ANOVA was
used to identify biochemicals that diﬀered signiﬁcantly between ex-
perimental groups; statistical signiﬁcance was set at p≤ 0.05.
3. Results and discussion
Overexpression of NOS3 in HepG2 cells caused a≈ 25% increase in
ROS, NO and NOS activity compared with the same cells transformed
with the empty vector [21] and constituted a physiological model for
endogenously oxidative/nitrosative stressed cells to study the role of
Trx1 and Grx1. Treatment with Trx1 or Grx1 speciﬁc siRNA down-
regulated the levels and activities of either redoxin by ≈ 80% (Ref.
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Fig. 5 in [22]). These cells were collected and lysed under conditions
that allowed blocking of reduced protein thiols with “light” d(0)NEM
followed by reduction of reversibly oxidized Cys and labelling with
“heavy” d(5)NEM (Fig. 1). Samples were prepared and analyzed by a
proteomics LC-MS/MS approach allowing for global “label-free” quan-
titation and for targeted analysis of diﬀerentially labeled Cys-peptides
[55,71].
3.1. Global proteome
Quantitative diﬀerences between the proteomes of WT, 4TO and
4TO-NOS, treated or not with siRNA-Trx1 and siRNA-Grx1, were de-
termined by “label-free” analysis. The signiﬁcant diﬀerential proteomes
were determined from roughly 600 unique proteins identiﬁed in each
study. Only 14 proteins varied signiﬁcantly between 4TO-NOS and 4TO
HepG2 cells and a smaller number changed upon either siRNA treat-
ment in 4TO or 4TO-NOS cells, as shown in Suppl. File 1.
Overexpression of NOS3 and down-regulation of Trx1 or Grx1 in
HepG2 cells has marked phenotypical consequences like slow-down of
proliferation and apoptosis exacerbation as previously reported [22].
To investigate whether these phenotypical changes might have been
triggered by redox postranslational modiﬁcation of key proteins, we
analyzed the redox proteome.
3.2. Redox proteome
Trx1 and Grx1 main action is to reverse oxidative changes in protein
thiols, not only those involved in regulatory postranslational mod-
iﬁcations of metabolic and signaling proteins, but also those associated
with thiol-dependent ROS scavenging enzymes, like peroxiredoxins.
Any change in the levels of either redoxin should have consequences on
the redox state of sensitive proteins which could reveal detailed
knowledge on their functions. Silencing with speciﬁc siRNA provides a
gentler experimental approach to mimic physiological down-regulation
events compared to a full knockout, although detection of the expected
subtle changes in molecular indicators requires precise analytical
methods to study the redox proteome.
3.2.1. NOS3 overexpression alters the Redox Proteome
The levels of ROS and NO had been measured in 4TO-NOS cells by
standard general methods (DCFH2-DA ﬂuorescence and colorimetric
nitrite determination, respectively) showing an increase of 40% in the
cells overexpressing NOS3 [21]. Now, the Cysred/Cysox ratio was de-
termined for every Cys peptide identiﬁed/quantiﬁed in WT (234/168
peptides), 4TO (411/328 peptides) and 4TO-NOS (366/289 peptides)
HepG2 cells. Overlapping of Cys-peptides between samples was
65–68% for identiﬁed peptides and 71–77% for quantiﬁed peptides
(Suppl. Fig. 2). The majority of quantiﬁed peptides were in the Cys-SH
state with Cysred/Cysox ratios ranging from nearly 40 to around 2.
Ninety-four Cys-peptides underwent signiﬁcant changes in their Cysred/
Cysox ratios when the cells overexpressed NOS3 compared to cells
transfected with empty vector (Fig. 2; Suppl. File 2). Changes were
predominantly oxidative, but 13 proteins were ≥ 1.5 fold reduced in
the oxidative/nitrosative environment of NOS3 overexpressing cells.
Their reductive change could be direct or indirect consequence of the
observed marked induction of Trx1 and Grx1 [22], but other pertur-
bations in metabolic and signaling pathways induced by NOS3 over-
expression could also be responsible.
The presence of acidic residues around the modiﬁed cysteine in
these redox target proteins is particularly apparent (Fig. 2B). 77% (10/
13) of the proteins showing an increase in their reduced/oxidized Cys
ratio had at least one Glu or Asp between positions + 2 and −2, cen-
tered on the target cysteine, whereas this percentage was lower (46%;
16/35) for the proteins undergoing an oxidative change. The accumu-
lated content of Asp and Glu in the average protein from the UniProtKB
TrEMBL is 11.65%, therefore, the frequency of at least one acidic
residue at these positions is markedly higher than expected at random
and could be related to the sensitivity of these Cys residues to ni-
trosative stress induced redox changes.
Taken together, these changes show that NOS3 overexpression ex-
erts oxidative pressure on a number of protein cysteine residues with
potential regulatory eﬀects mainly at the level of Glycolysis/gluco-
neogenesis, protein synthesis and folding, endoplasmic reticulum pro-
cesses, and cell death and survival (Fig. 2C). To check whether Trx1 or
Grx1 are involved in this redox disturbance, both redoxins were down-
regulated with speciﬁc siRNA and the redox state of individual Cys
residues was measured again.
3.2.2. Speciﬁc protein cysteines underwent oxidative and reductive changes
upon Trx1 or Grx1 silencing depending on NOS3 overexpression
Silencing of Trx1 or Grx1 to ≈ 20% their normal levels in WT and
NOS3-overexpressing HepG2 cells did result in signiﬁcant redox
changes of speciﬁc protein cysteines, compared with their respective
controls. We had previously reported that the activities of both redoxins
decreased to the same extent as Trx1 and Grx1 protein levels in their
respective siRNA treated cells, excluding the induction of other active
isoforms [22]. Moreover, analysis of the diﬀerential proteome of these
cells in the present study did not show compensatory induction of
isoforms.
A selection of target proteins with ≥ 1.5 or ≤ 0.67 fold redox
changes is presented in Fig. 3A. Three groups can be distinguished in
this table. i) Proteins in the upper part of the table showed sensitive
cysteines which underwent an oxidative shift in WT cells, but a re-
ductive shift in NOS3 overexpressing cells, upon silencing of either
redoxin. ii) A second group in the middle part of the table shows cy-
steines that were more oxidized only in 4TO-NOS cells upon either
redoxin silencing. iii) Finally, a third group was only sensitive towards
Trx1 silencing almost exclusively in NOS3-overexpressing cells. Six
proteins: Coﬁlin-1, 40 S ribosomal protein S5 and isoforms Gamma,
Theta/delta and Beta/alpha of the 14–3-3 family of proteins, showed
high sensitivity to both redoxins but their redox changes, though con-
spicuous, did not display clear trends and have been omitted.
These changes could be the consequence of direct interaction of
either redoxin with the target proteins or could be due to indirect ef-
fects. They were almost exclusively oxidative in WT cells as one would
expect from the canonical antioxidant functions of Grx1 and Trx1.
However, in NOS3 overexpressing cells, the eﬀect of silencing the re-
doxins, especially Trx1, also resulted in reductive changes in several
protein cysteines. The reason for this apparently contradictory result
could rely on the fact that NOS3 itself is sensitive to redox modiﬁcation
and can be activated by Trx1 and Grx1 through denitrosation and de-
glutathionylation [4,78]. Hence, decreasing the levels of these redoxins
by speciﬁc siRNA should result in higher levels of redox modiﬁed NOS3,
lower NOS3 activity and lower protein S-nitrosation levels followed by
higher reduced/oxidized ratio of sensitive cysteines in target proteins.
We had previously determined the level of Tyr nitration, a good in-
dication of the degree of nitrosative/oxidative stress, in siRNA-Trx1 and
siRNA-Grx1 treated WT and NOS3 overexpressing HepG2 cells [22].
Nitro-tyrosine levels were markedly higher in WT HepG2 cells but de-
creased to 50% in NOS3 overexpressing HepG2 cells which is a further
evidence of NOS3 inactivation upon Trx1 and Grx1 down-regulation.
3.2.3. Redoxins-sensitive cysteines show speciﬁc sequence motifs
Deﬁning sequence signatures around redox sensitive cysteines
would help predict and ﬁnd redox regulated target proteins. A search
for short linear motifs in the sequences around the redox modiﬁed Cys's
shown in Fig. 3A using the motif-x algorithm [10] produced three motifs
with high enrichment score among the input set of proteins compared
with the background occurrence in the whole human proteome
(Fig. 3B). There is a Lys at position +1 or +4 in motifs 1 and 2 re-
spectively and a threonine at + 4 in motif 3. It is well known that
nucleophilic reactivity of Cys's is dependent on ionization to thiolate
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favored by low pKa. Computational and experimental results indicate
that the surrounding charged side chains can contribute, but do not
primarily control, the thiolate pKa in the Trx superfamily and other
proteins with reactive Cys [69,70]. However, a search for denitrosation
sites in proteins found two potential motifs with lysine at + 6 and + 7
[87] and a structural analysis of cysteine S-nitrosation sites found lysine
at position +3 and threonine at + 5 with moderate frequency [49].
The presence of a lysine residue near the target Cys is also common to
human proteins S-nitrosation motifs [42]. A study that combined se-
quence, structure, and electrostatic approaches predicted that Thr, its
hydroxyl group, and hydrogen-bonding capabilities play an important
role in Cys deprotonation and reactivity [70]. Hence, our results with
Lys or Thr upstream of Cys ﬁt in with the current structural landscape of
redox sensitive Cys's, where some signatures have been put forward but
evidences for a strong consensus sequence motif has not yet been
achieved.
Two proteins were speciﬁcally sensitive to Grx1 silencing, PGAM-
1(Cys153) and PRDX6(Cys91). Alignment of both Cys-peptides showed a
striking conservation score around the aﬀected Cys stressing their as-
signment as Grx1 targets (Fig. 3C). These Cys's are positioned in a coil
in the protein structure with 3.78% and 4.00% solvent accessibility,
respectively, and are enriched in acidic residues around the central
cysteine. They ﬁt in the Homo sapiens HC05 group glutathionylation
motif as catalogued at dbGSH (http://csb.cse.yzu.edu.tw/dbGSH).
PRDX6 is 1-Cys peroxiredoxin with prominent features as it depends on
GSH and GST-Pi for peroxidase activity and also has phospholipase A2
(PLA2) activity, which plays a role for activation of NADPH oxidase 1
and 2 (NOX1, NOX2) [17,41]. The Grx-dependent redox modiﬁed Cys
at position 91 is not the canonical catalytic (“peroxidatic”) cysteine that
lies at position 47 of PRDX6. Cys91 has not been given attention so far
and has been routinely substituted by Ser in the recombinant protein,
supposedly to avoid unwanted thiol oxidation and “shuﬄing” and to
facilitate handling. Further experiments have been undertaken to ﬁnd
out whether the Grx-speciﬁc redox sensitivity of PRDX6 Cys91 plays a
role on any of the protein functions.
3.2.4. Part of the observed cysteine redox changes were due to direct S-
nitrosation
As determined previously [21], NOS3 overexpression not only in-
creases the levels of NO but those of other ROS as well, so reversible
oxidation of Cys residues could be due to S-nitrosation or other types of
oxidative modiﬁcations induced by ROS. To ascertain whether S-ni-
trosation was actually taking place, we have carried out the Biotin
Switch Technique (BST). We have limited this analysis to siRNA-Trx1
Fig. 2. NOS3 over expression alters the Reduced/Oxidized ratio of speciﬁc Cys on target proteins. A) The UniProt ID of the protein is shown in the vertical axis
and the relative change in the Cysred/Cysox ratio in 4TO_NOS cells is indicated in the horizontal axis as fold change relative to the ratio in control 4TO cells
transformed with the empty vector. Proteins are ordered according to their statistical q score (Storey & Tibshirani) from 0.0000516 (top) to 0.0497383 (bottom).
Proteins with negative values were more oxidized after NOS3 overexpression; those with positive values (IDs in italic) were more reduced. Two proteins showed
reductive changes higher than ﬁvefold as indicated. P10599, square boxed with thick line, is Trx1(C73); ID of enzymes of Glycolysis and its branching pathways are
highlighted with grey squares and ribosomal proteins are square boxed with thin line. B) sequence context around the cysteine residue of 13 peptides whose reduced/
oxidized ratio increased ≥ 1.5 on NOS3 overexpression, showing the presence of acidic residues (white letters highlighted in black) close to the aﬀected cysteine
(grey shadowed). Protein names and Cys mapping are detailed in sheet “NOS3 Vo” of the Excel ﬁle shown in Suppl Fig. 2. C) Systems Biology analysis of the whole set
of redox modiﬁed proteins using Ingenuity Pathway Analysis (Qiagen) and DAVID [Huang et al. Nature Protoc. 2009;4(1):44–57]. The ﬁve most signiﬁcant terms from
each analysis are shown with p values ranging from 9.18E−19 to 9.75E−04.
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treated cells, since Trx1 is well-known to display denitrosase activity.
Analysis of total biotinylated proteins by Western blotting showed
clear diﬀerences between control and NOS3 overexpressing HepG2 cells
as expected. When we compared Trx1 silenced cells with their control,
no signiﬁcant diﬀerences were detected at the level of total protein, but
interestingly clear diﬀerences were found in band patterns indicating
changes in S-nitrosated Cys's at the level of individual proteins: some
proteins increased while others decreased upon Trx1 silencing
(Fig. 4A). These results are in agreement with the ﬁnding that several
proteins underwent a signiﬁcant reductive shift on their key Cys's
(Fig. 3).
To test individual proteins, PRDX6, PKM2, caspase-3, NOS3 and
Trx1 were chosen to analyze their nitrosation state on Trx1 silencing by
the BST as shown in Fig. 4B and C. All ﬁve proteins were captured with
the BST, indicating that they are targets of S-nitrosation. Despite the
high variability of the technique, a clear trend was observed in 4TO-
NOS cells showing higher amounts of S-nitrosated PRDX6 and PKM in
Trx1-silenced cells than in control cells. This trend was also observed in
4TO and in normal HepG2 cells (not shown). PRDX6 and PKM are likely
substrates of Trx1 denitrosase activity, although the involved cysteines
cannot be mapped with this technique and we cannot tell whether the
S-nitrosated Cys are Cys91 or Cys47 in PRDX6 and Cys358 or another Cys
in PKM. The peptide containing peroxidatic Cys47 of PRDX6 was not
detected in any of our samples. We have previous experience on the
diﬃculty of detecting this tryptic peptide [65], but it was detected
using diﬀerent technical tools in another study where Cys47 was actu-
ally more oxidized in sciatic nerve of old compared to young mice [56].
Since we have found that the “extra” Cys91 of PRDX6 is not sensitive to
Trx1 but to Grx1 silencing (Fig. 3), which has no denitrosase activity, it
is tempting to conclude that Cys47 might be target of S-nitrosation in a
Trx1-dependent manner while Cys91 might be a Grx1-dependent target
of glutathionylation. A preliminary mass spectrometric analysis of re-
combinant PRDX6 showed that both Cys47 and Cys91 are liable to
spontaneous reversible glutahionylation (Suppl. Fig. 1). These data
open the door to interesting insights into PRDX6 molecular properties
and functions.
Redox sensitivity of PKM2 Cys358 has been reported before [2,53],
however the identity of its redox reversible modiﬁcation was not de-
termined. Our data show higher S-nitrosation levels of PKM2 in Trx1
silenced cells in parallel with reversible oxidative modiﬁcation of
Cys358 suggesting PKM2 as target of Trx1 denitrosase activity. On the
other hand, caspase-3, Trx1 and NOS3 itself, were S-nitrosated in NOS3
overexpressing cells, apparently to a lesser extent when Trx1 was si-
lenced (Fig. 3C).
Fig. 3. Changes in the reduced/oxidized ratio of speciﬁc Cys on target proteins upon Trx1 and Grx1 silencing. A) The UniProt ID and name of the protein, the
sequence of the Cys-peptide and the position of the Cys residue aﬀected are shown together with the redox change observed expressed as fold change of the Cysred/
Cysox ratio relative to the non-silenced cells. Oxidative changes are colored red and reductive changes are green. Only proteins showing fold changes≥ 1.5 or≤ 0.66
are included. All the values are statistically signiﬁcant according to their q value (Storey & Tibshirani). Cells colored yellow with a value of 1.00 represent non-
signiﬁcant changes; ND, peptide not detected. B) Putative consensus sequences of Trx1 and Grx1 related sensitive Cys-peptides; the sequences of the peptides
showing signiﬁcant redox changes upon Trx1 or Grx1 silencing in WT and NOS3-overexpressing HepG2 cells were subjected to Motif-X ([10]; http://motif-x.med.
harvard.edu) with the following parameters: central character “C”, width “13”, occurrences “20”, signiﬁcance “0.0001”, background “ipi. HUMAN.fasta”; motif
scores for logos 1, 2 and 3 were 8.57, 6.30 and 4.86, respectively. C) Two Cys peptides speciﬁcally sensitive towards Grx1 but not Trx1 belonging to Phos-
phoglyceromutase-1(Cys153) and Peroxiredoxin-6(Cys91) were highly conserved as shown by pairwise alignment with a 17 residue window around the sensitive
Cys, matrix EBLOSUM62, gap penalty 2; a very high conservation score was found with 2 identities (11.8%) and 6 similarities (35.3%).
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These results conﬁrm that S-nitrosation contributes to redox
changes taking place on target Cys's in HepG2 cells depending on the
overexpression of NOS3 and aﬀected by the prevailing levels of Trx1.
3.2.5. Proteins with redoxin-sensitive cysteines are abundant in Glycolysis
Clustering of redox sensitive proteins with DAVID [33,34] revealed
a signiﬁcant enrichment in Glycolysis in either normal or NOS3 over-
expressing HepG2 cells for both redoxins, but with higher score for
Grx1 silencing. Enzymes belonging to Glycolysis or its branching
pathways aﬀected by thiol redox changes upon Tx1 or Grx1 silencing or
upon overexpression of NOS3 are listed in Fig. 5A and are shown in
context schematically in Fig. 5B.
3.2.5.1. Glyceraldehyde-3-phosphate dehydrogenase. The peptide
containing Cys152/Cys156 of GAPDH was markedly more oxidized in
NOS3 overexpressing cells. Cys152 is part of the active site and its
oxidation renders the enzyme inactive [25,61]. We conﬁrmed that
GAPDH activity decreased in NOS3 overexpressing HepG2 cells
(Fig. 5C). Silencing of Trx1 or Grx1 in normal HepG2 cells did result
in diminished levels of GAPDH activity as expected, but this loss
correlated with oxidation of another Cys residue, Cys247, and not with
the redox state of Cys152/156, that did not change (Fig. 5A). GAPDH
Cys247 was indeed more oxidized in Trx1 and Grx1 down-regulated WT
cells, but more reduced in NOS3 overexpressing cells when Trx1 was
silenced. Reversible S-thiolation of GAPDH was earlier reported [73]
and since then Cys247 or its equivalent has been mapped and found to
be S-glutathionylated, S-nitrosated and S-acetylated [24] even in plants
[3], as well as a predicted target of Trx trans-nitrosation [86].
It would seem that GAPDH-C247 is prone to oxidative modiﬁcation
by nitrosation or glutathionylation under the prevailing redox cellular
Fig. 4. Protein S-nitrosation in HepG2 cells over expressing NOS3 and treated with speciﬁc siRNA-Trx1. A) NOS3 over expressing HepG2 cells, 4TO-NOS, and
control 4TO cells transformed with empty vector were silenced or not, for Trx1 and subject to BST; biotinylated proteins constituting the “S-nitrosome” were
separated on SDS-PAGE, transferred to Nitrocellulose membrane and revealed with avidin-peroxidase conjugate. Membranes stained with Ponceau reagent before
transfer are presented in the left panels to show the protein load. Arrows point to bands with increased or diminished intensity upon Trx1 silencing. B) and C)
biotinylated proteins from 4TO-NOS HepG2 cells were captured on avidin-agarose, eluted with ß-ME, subjected to Western blot and revealed with speciﬁc antibodies
to 5 selected proteins as indicated. The intensity of the bands was quantiﬁed by image analysis as described in M&M; relative abundances of each protein in the
fraction of biotinylated proteins compared to non-silenced control cells are shown, together with the number of replicas and the bars showing standard deviation;
trimmed images from membranes showing representative band patterns are included below each graph.
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environment in normal HepG2 cells and to its reversal by either Trx or
Grx, respectively. When this fragile equilibrium is displaced by down
regulation of either redoxin, the oxidative state of Cys247 increases.
However, as discussed in Section 2b, decreasing the levels of Trx1 by
speciﬁc siRNA in NOS3 overexpressing cells should result in higher
levels of redox modiﬁed NOS3, lower NOS3 activity and lower GAPDH-
C247 nitrosation levels. The levels of nitro-Tyr, an indication of ROS and
RNS, did actually decrease down to 50% on either redoxin silencing
[22]. This would explain the reductive shift in GAPDH-C247.
Besides its conventional metabolic role, a number of studies have
identiﬁed the participation of GAPDH in diverse cellular functions and
these oxidative changes not only aﬀect its glycolytic function but also
stimulate the participation of GAPDH in cell death [11,25]. Our ﬁnd-
ings point to Cys247 as a sensitive target of the antioxidant activity of
Trx1 and Grx1 in WT cells with consequences on its enzymatic activity.
The rational to explain the decrease in activity of GAPDH would be
that it is rewarding for the cells to slow down the glycolytic ﬂux at this
point to facilitate upstream diversion of glucose catabolism toward the
Pentose Phosphate Pathway (PPP) and to increase NADPH production
in this prevalent oxidative environment. However, it has yet to be de-
monstrated whether inactivation of GAPDH is reﬂected directly in
slowing down of glycolytic ﬂux. Actually, we have observed that in-
activation of GAPDH in siRNA-Trx1 treated cells is paralleled by an
increase in glycolytic ﬂux (Fig. 5C). Alterations in glycolytic enzymes
can regulate autophagy e.g. the moonlighting behaviour of GAPDH
enables its direct interaction with mTOR [58] or translocate to the
nucleus and upregulate Atg12 [11], both mechanisms being related to
the activation of autophagic process. siTrx1 and siGrx1 increased
caspase-3 and TUNEL in 4TO and 4TO-NOS3 cells [22] and increased
the oxidative status of the heat shock 70 kDa protein 4 (HspA4) Cys270
(Fig. 3A), an interactor with HspA8 (heat shock cognate 71 protein),
which drives chaperone-mediated autophagy [13]. Redox changes at
target cysteines in GAPDH and HspA4 suggest that Trx1 and Grx1 sig-
naling promoted a shift from autophagic survival to apoptotic pathway.
3.2.5.2. Phosphoglyceromutase-1. (PGAM1) Cys153 was more oxidized
in WT cells when Grx1 was down-regulated. PGAM1 is commonly
upregulated in human cancers and regulates anabolic biosynthesis by
controlling intracellular levels of 3-phosphoglycerate (3-PG) and 2-
phosphoglycerate (2-PG) to promote tumor growth [28]. Both 3-PG and
2-PG are allosteric regulators of glycolytic branching pathways: 3-PG
inhibits 6-phosphogluconate dehydrogenase (6PGD) of PPP, whereas 2-
PG activates phosphoglycerate dehydrogenase (PHGDH) of glycine and
serine synthesis pathway. It is worth noting that activation of PGAM1
by phosphorylation at Tyr26, common in human cancer cells, promotes
cell proliferation and tumor growth [29]. Cys153 is not close to the
active site but it has been noted that proteomes of Cys PTMs have
localized these modiﬁcations primarily in non-catalytic regions [24].
Moreover, Cys153 is in the same region of the protein as Tyr26 and
Lys100. It has been demonstrated that increased levels of ROS stimulate
PGAM Lys100 deacetylation and activity by promoting its interaction
with SIRT2 [88]; its modiﬁcation by oxidation could equally aﬀect its
activity or even the phosphorylation and acetylation state of Tyr26 and
Lys100 located nearby.
Cellular response to oxidative stress are mediated by the HIF-1α,
which is required for the upregulation of mRNAs encoding glucose
Fig. 5. Silencing Trx1 or Grx1 aﬀects glycolytic enzymes redox state and activities and glycolytic ﬂux. A) Enzymes of Glycolysis and related pathways
undergoing signiﬁcant (q≤0.1) cysteine redox changes on NOS3 overexpression and upon Trx1 or Grx1 down-regulation have been selected. The precise cysteine
residues aﬀected and the changes in the values of their reduced/oxidized cysteine ratios relative to the control (4TO-NOS vs 4TO; siRNA treated vs untreated) are
shown. The values for siRNA treated 4TO-NOS cells have been weighted by subtracting the changes observed in siRNA treated 4TO control cells; B) Glycolysis
centered metabolic network showing the main glycolytic stream and oﬀ-shooting pathways; the ﬁnal destinations of metabolic ﬂuxes are indicated with thick arrows;
the enzymes with redox altered cysteines and their residue position are highlighted. C) Enzymatic activities of triosephosphate isomerase, glyceraldehyde-3-phos-
phate dehydrogenase and pyruvate kinase, Glycolysis and Pentose Phosphate Pathway ﬂuxes and lactate concentration in siRNA Trx1 and siRNAGrx1 treated
4TO_NOS and 4TO cells are shown relative to untreated 4TO control cells. Between 4 and 9 independent experiments were done for each parameter and a Student t-
test was calculated for statistical signiﬁcance with values p≤ 0.001, 0.001 > p≤ 0.01 and 0.01 > p≤ 0.05 marked with *** , * * and * , respectively.
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transporters and glycolytic enzymes, with the notable exception of
PGAM [37], indicating a possible postranscriptional regulatory me-
chanism. Sensitivity of PGAM1 activity to thiol speciﬁc reagents was
initially reported for the rabbit enzyme [66], but to our knowledge, this
is the ﬁrst time that a Grx1-dependent redox change is observed and
mapped to Cys153 suggesting a novel form of regulation that could
contribute to modulation of glycolytic ﬂux for biosynthetic and anti-
oxidant purposes in response to the redox environment.
3.2.5.3. Pyruvate Kinase. PKM2 (P14618-1) behaves similarly: its
Cys358 is close to the allosteric activator fructose-1,6-bisphosphate
(FBP) binding site and is sensitive to oxidative stress [2,53]. It has
been shown that ROS-dependent inhibition of PKM2 is needed to
maintain the availability of glucose-6-phosphate (G-6-P) for ﬂux into
the PPP and to sustain cell survival when endogenous ROS accumulate.
Regulation of PKM2 via oxidation of Cys358 is critical under these
conditions for optimal tumor growth [2]. Coherent with this, we show
here that NOS3 overexpression oxidizes Cys358 accompanied by a
signiﬁcant decrease in activity (Fig. 5C). Cys358 is further oxidized
when Trx1 is down-regulated, but surprisingly, PKM activity is
signiﬁcantly recovered to the same level as in siRNA-Trx1 treated
control cells (Fig. 5C). An increase in the PKM1/PKM2 isoenzyme ratio
induced by redox regulation of splicing events as reported in hepatoma
cells [84] would explain this result. These data demonstrate the
complexity of Trx1 involvement in maintaining the redox state of this
Cys358 and the activity of this critical enzyme.
3.2.5.4. Enolase. Cys119 of Alpha-enolase is sensitive to oxidative
conditions in NOS3 cells and is a target of Grx1 antioxidant activity
in WT cells (Fig. 5A). This cysteine was found to be reactive toward
mercury resin speciﬁc for Cys-SNO [24] and its glutathionylation in SH-
SY5Y neuroblastoma cells resulted in loss of enzymatic activity [36].
Further studies will conﬁrm the regulatory role of this Grx1 dependent
redox change of α-Enolase Cys119.
3.2.5.5. Triose phosphate isomerase. TPI Cys255 was more reduced when
either Trx1 or Grx1 were silenced in NOS3 cells (Fig. 5A). TPI from
several organisms has been shown to be regulated by redox changes
involving glutathione at a cysteine equivalent to human Cys255. The
equivalent Cys in P. falciparum TPI, Cys217, is located at the interphase
of a complex formed between TPI and Trx [74], whereas A. thaliana TPI
is inactivated by glutathionylation at Cys218 in a manner reverted by
Grx [14]. Our results agree with these showing a signiﬁcant decrease in
TPI activity when Grx1 is silenced in control cells. However, silencing
of either Trx1 or Grx1 in NOS3 overexpressing cells increased the
activity of TPI in parallel with reduction of Cys255, a likely consequence
of NOS3 inactivation, as already discussed above. It is tempting to
speculate that TPI Cys255 could act as a thiol redox switch to help divert
the glycolytic ﬂow from DHAP towards lipid synthesis as part of a
metabolic response to changes in the redox environment [45].
Several enzymes from Glycolysis oﬀ-shooting pathways showed
signiﬁcant redox changes: Lactate dehydrogenase A (LDHA) Cys293 and
6-phosphogluconate dehydrogenase (PGD) Cys170/171 were slightly
more oxidized in NOS3 cells; Glutamine-Fructose-6-phosphate amino-
transferase [isomerizing] 1 (GFAT) Cys434 was sensitive to both Trx1
and Grx1 down-regulation; and Transaldolase (TALDO) Cys250 was
markedly more reduced in NOS3 cells
Altogether, these data show widespread redox sensitivity of key
cysteines in glycolytic enzymes eventually aﬀecting their activities. The
prominent role played by Trx1 and Grx1 on these thiol redox switches
could be meaningful as part of a pleiotropic redoxin reductive action as
a kind of “redox regulon” [20] to coordinate an integrated response to
ROS that would balance pyruvate and NADPH production and biosyn-
thetic ﬂux diversion (Fig. 5B). However, the precise consequences of
these redoxin-dependent redox changes on metabolic ﬂuxes cannot be
predicted from the changes of individual enzymatic activities [81].
Knowledge of Flux Control Coeﬃcients of each enzyme would be ne-
cessary and the ﬂuxes through glycolysis branched pathways should
also be taken into account. As a ﬁrst approach we have measured gly-
colytic metabolic ﬂux and metabolites levels, as described below.
3.3. Glycolytic ﬂux and metabolite proﬁles were diﬀerentially aﬀected by
Trx1 and Grx1 silencing
Glycolytic and Pentose Phosphate Pathway ﬂuxes were determined
using radiolabelled glucose and measuring the formation of [3H]H2O
from [3-3H]glucose during the reaction catalysed by enolase and that of
[14C]CO2 from [1–14C]glucose by 6-phophogluconate dehydrogenase,
respectively. A metabolomic analysis was also undertaken. As shown in
Fig. 5C, Trx1 silencing had a stimulating eﬀect on both pathways in
either NOS3 overexpressing cells and control cells, whereas Grx1 si-
lencing had the opposite eﬀect in all cases. These eﬀects could be a
reﬂection of the diﬀerential action of both redoxins on the redox state
of glycolytic enzymes (see Fig. 5A).
3.3.1. Grx1 silencing slows down Glycolysis and stimulates lipogenesis
The relationships between cysteine redox state, enzymatic activities
and metabolic ﬂuxes are not straightforward, the metabolic proﬁles in
siRNA-Grx1 treated cells were coherent with lower glycolytic ﬂux
showing increased levels of extracellular and intracellular glucose
(Fig. 6A). Sedoheptulose-7-phosphate (Su7P) accumulated in WT and
NOS3 overexpressing HepG2 cells treated with siRNA-Grx1 (Fig. 6B).
This was accompanied by increased levels of several polyols including
arabitol, xylitol, ribitol, mannitol and sorbitol, indicative of transaldo-
lase (TALDO) malfunctioning [76], and decreased levels of ribose.
These metabolic changes indicate slowing down of glucose processing
through the non-oxidative part of PPP as a consequence of Grx1 silen-
cing. Redox changes detected in TALDO-Cys250, 6-phosphogluconate
dehydrogenase (PGD) Cys170/171 and TPI-Cys255 could be involved in
the underlying regulatory mechanisms.
Another eﬀect of Grx1 silencing was an increase in 3-phosphogly-
cerate (3PG) and lower levels of pyruvate (Fig. 6C) coincident with
PGAM-Cys153 oxidation and likely deviation of 3PG toward serine
pathway. Moreover, unchanged or increased levels of citrate and lower
levels of α-ketoglutarate and fumarate (Fig. 6D), might indicate slowing
down of Krebs cycle but deviation of citrate to fatty acid biosynthesis.
Accordingly, elevated levels of acyl-carnitine (Fig. 6H) and de novo
synthesis of phospholipids, was evidenced in siRNA-Grx1 treated cells,
represented by high levels of phosphatidylcholine and the family of 2-
arachidonoyl phospholipids with the exception of phosphatidylserine
(Figs. 6L and 6N). The increase in 2-arachidonoyl phospholipids runs
parallel with oxidation of PRDX6 Cys91 and it is worth noting the
speciﬁcity of cytosolic Ca2+-independent PLA2 activity for sn-2-ara-
chidonic acid glycerophospholipids [63], a precursor of eicosanoids,
which represent a class of lipid mediators. Moreover, arachidonic acid
has been shown to mediate the known proliferative action of PRDX6
[72]. These changes speak of active membrane remodeling and/or lipid
signaling events in Grx1 down-regulated cells.
Levels of several intermediary metabolites of purine pathway were
markedly elevated in Grx1 silenced cells with the exception of IMP but
including S-adenosylmethionine (SAM) (Fig. 6G). Elevated levels of
SAM should indicate intensiﬁcation of the methionine/folate pathway
connected to glutathione synthesis and supplier of NADPH as an al-
ternative to PPP (Fig. 5B). The synthesis of glutathione was actually
exacerbated as indicated by increased levels of gamma-glutamylcys-
teine and cysteinylglycine (Fig. 6F).
3.3.2. Trx1 silencing induces membrane remodeling
There were similarities and diﬀerences between the eﬀects of Grx1
and Trx1 silencing in metabolites’ levels. Increased glutathione meta-
bolism (Fig. 6F) and a marked decrease in 3-hydroxy-3-methylglutarate
(Fig. 6M) of mevalonate pathway are among the coincidences, but the
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levels of gamma-glutamylaminoacids is higher in siRNA-Grx1 (see
Suppl. File 3) and siRNA-Trx1 did not aﬀect Su7P and glucose levels
(Fig. 6B). Trx silencing elicited trending and signiﬁcant increases in
dipeptides (see Suppl. File 3) that may reﬂect increased proteasome-
mediated elimination of oxidized proteins in the setting of oxidative
stress. Increases in protein degradation could suggest Keap1-Nrf2 sig-
naling and increased autophagy. Notably, many of these changes were
not observed in NOS3 overexpressing 4TO_NOS cells.
Trx1 silencing also showed signs of lipid remodeling but diﬀered
from Grx1 in promoting a trend of increasing sphingomyelins and
ceramides (Figs. 6I and 6J). Ceramide is involved in apoptotic processes
and in the formation of membrane raft redox signaling platforms
(MRRSP) that participate in the assembly and activation of NOX com-
plexes [62]. These changes are consistent with the pro-apoptotic eﬀect
of Trx and Grx silencing in these cells as we had already reported [22].
The sensitivity of sphingomyelinases to redox changes is a key to the
cross-talk between sphingolipids and redox signaling through the reg-
ulation of NADPH oxidase, mitochondrial integrity, NOS, and anti-
oxidant enzymes [7]. The trend of sphingomyelins’ pool increase on
Trx1 silencing could have an inﬂuence on mitochondrial lipid compo-
sition and integrity. However, cardiolipin, a typical and prominently
functional mitochondrial phospholipid, was not detected. Hence, in-
volvement of mitochondria cannot be excluded and is worth of further
attention.
4. Conclusions
In the cell there is a delicate balance between eﬀective redox sig-
naling mechanisms and potentially damaging oxidative damage.
Oxidative/nitrosative induced PTMs are critical for the accumulation of
redox modiﬁed proteins, induction of autophagy, and further cellular
apoptosis in unsolved pathophysiological intracellular responses while
Fig. 6. Metabolites concentrations in normal and NOS3 overexpressing HepG2 under Trx1 and Grx1 down-regulation. A metabolomics analysis was per-
formed in normal (WT), 4TO and 4TO_NOS cells treated with siRNA-Trx1, siRNA-Grx1 or control siRNA-nonTarget as described in Materials & Methods. A selection
of metabolites representing the most conspicuous changing trends when cells are treated with siRNA-Trx1 or siRNA-Grx1 is shown. The results presented in this
ﬁgure are part of a larger metabolic study. Extracellular glucose concentration was determined in culture media by a standard method independently of the
metabolomic analysis.
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redox signaling through the transient oxidation/reduction of key Cys
residues in regulatory proteins plays a role in many of the hallmarks of
cancer [31].
The data presented herein show that Trx and/or Grx are involved in
redox modiﬁcations of targeted cysteines of several glycolytic enzymes
aﬀecting their activity, although changes in the activity of one single
enzyme cannot be extrapolated to equivalent changes in overall meta-
bolic ﬂux. These changes are part of a widespread adaptive mechanism
aimed at redistributing metabolic ﬂuxes between Glycolysis and its oﬀ-
shooting pathways to respond to subtle changes in the cellular redox
environment. Trx and Grx share a number of protein Cys redox targets
but down regulation of either redoxin has markedly diﬀerent metabolic
outcomes: silencing of Trx1 stimulates glycolytic ﬂux while silencing of
Grx1 decelerates it.
Besides its canonical antioxidant action, Trx1 also contributes to
oxidative modiﬁcations of protein thiols, likely by activation of NOS3,
reﬂecting the delicate sensitivity of redox equilibrium to changes in any
of the elements involved and the diﬃculty of forecasting metabolic
responses to redox environmental changes.
A correlation can be put forward between the reversible oxidation of
Cys91 of PRDX6 upon Grx1 silencing that is accompanied by a sig-
niﬁcative increase of sn-2-arachidonoyl containing phospholipids and
Cys91 sensitivity to glutathionylation, considering the well-known de-
glutathionylase activity of Grx.
To our knowledge, this is the ﬁrst demonstration of a role for Grx1
and Trx1 in the crosstalk between lipids metabolism and redox sig-
naling. Further and deeper insights into the underlying mechanisms, i.e.
possible involvement of PRDX6 and Nrf2 signaling [40], CD95 ligand or
TNFα induced activation of sphingomyelinases and ceramide induced
MRRSP activation of NOX [18], etc., are expected to be discovered with
ongoing focused experiments.
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Abstract: Peroxiredoxin 6 (Prdx6) is the only member of 1-Cys subfamily of peroxiredoxins in 
human cells. It is the only Prdx acting on phospholipid hydroperoxides possessing two additional 
sites with phospholipase A2 (PLA2) and lysophosphatidylcholine-acyl transferase (LPCAT) 
activities. There are contrasting reports on the roles and mechanisms of multifunctional Prdx6 in 
several pathologies and on its sensitivity to, and influence on, the redox environment. We have 
down-regulated Prdx6 with specific siRNA in hepatoblastoma HepG2 cells to study its role in cell 
proliferation, redox homeostasis, and metabolic programming. Cell proliferation and cell number 
decreased while cell volume increased; import of glucose and nucleotide biosynthesis also 
diminished while polyamines, phospholipids, and most glycolipids increased. A proteomic 
quantitative analysis suggested changes in membrane arrangement and vesicle trafficking as well 
as redox changes in enzymes of carbon and glutathione metabolism, pentose-phosphate pathway, 
citrate cycle, fatty acid metabolism, biosynthesis of aminoacids, and Glycolysis/Gluconeogenesis. 
Specific redox changes in Hexokinase-2 (HK2), Prdx6, intracellular chloride ion channel-1 (CLIC1), 
PEP-carboxykinase-2 (PCK2), and 3-phosphoglycerate dehydrogenase (PHGDH) are compatible 
with the metabolic remodeling toward a predominant gluconeogenic flow from aminoacids with 
diversion at 3-phospohglycerate toward serine and other biosynthetic pathways thereon and with 
cell cycle arrest at G1/S transition. 
Keywords: Peroxiredoxin; thiol redox regulation; redox proteome; redox homeostasis; lipid 
metabolism; cell cycle 
 
1. Introduction 
Peroxiredoxins (Prdx) are ubiquitous, abundant, and highly conserved enzymes whose main 
function is to catalyze the reduction of peroxides, taking part in the antioxidant battle of cells against 
ROS. They all possess a catalytic or “peroxidatic” Cys residue that acts as a hydrogen donor to the 
peroxide substrate and have been classified in six subfamilies, of which three are present in 
mammalian cells [1]. Human Prdx1 to Prdx4 belong to the “typical 2-Cys type” and Prdx5 belongs to 
the “atypical 2-Cys” subfamily. They have a second “resolving” Cys that plays a critical role in the 
catalytic cycle and is then reduced by thioredoxin (Trx). Human Prdx6 belongs to the “1-Cys” 
subfamily, which, unlike the other members of the Prdx family, does not possess a “resolving Cys” 
and may substitute Trx by glutathione in the final step of the catalytic cycle [2–5]. Mouse and human 
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Prdx6 have an additional non-conserved Cys residue (Cys91 in human) with a so far unknown 
function. 
Several members of the Prdx family are moonlighting proteins that have acquired additional 
functions during evolution. For instance, some Prdx of the 2-Cys subfamily can form oligomers with 
chaperone activity when overoxidized [6] or can act as sensors and transmitters of H2O2 signaling 
[7]. Prdx6 is peculiar and stands out from the rest of Prdx for its multiple functions. It is the only 
Prdx acting on phospholipid hydroperoxides and has two additional catalytic sites: one is 
responsible for acidic calcium-independent phospholipase A2 activity (PLA2) [8] and the other 
displays lysophosphatidylcholine acyl transferase (LPCAT) activity [9]. It has been proposed that 
these outstanding properties confer on Prdx6 the capacity to fulfill important functions associated 
with phospholipid turnover and membrane repair [10]. Posttranslational modifications and changes 
in subcellular localization regulate the actions of Prdx6. Phosphorylation of Thr177 by MAPK [11] 
and overoxidation of peroxidatic Cys47 [12,13] stimulate the PLA2 activity. Prdx6 is present in the 
cytoplasm but can translocate to the plasma and mitochondrial membranes and can also associate 
with lysosomal-type organelles [14,15]. Association of Prdx6 with plasma membrane contributes to 
NADPH (reduced nicotinamide adenine dinucleotide phosphate) oxidase (NOX1, NOX2) activity 
[16] and translocation to the mitochondria takes part in the initiation of mitophagy [15]. 
Its multiple functionality makes Prdx6 an important player in cell physiology and pathology 
[17,18] and both peroxidase and PLA2 activities have been associated with tumor progression [19] 
and dopaminergic neuron degeneration [20]. However, contrasting findings have been reported 
concerning its roles in cancer. Down-regulation of Prdx6 with specific siRNA decreased proliferation 
and induced apoptosis in canine haemangiosarcoma cells [21], whereas overexpression of Prdx6 
attenuated apoptosis in ovarian cancer cells [22] and promoted growth of lung tumors in mice 
through activation of JAK2/STAT3 signaling [23]. It has also been reported that Prdx6 either enhance 
tumor multiplicity or reduce tumor number in mice skin cells, depending on the stage of tumor 
development [24]. Both peroxidase and PLA2 activities of Prdx6 were required for tumor 
development in xenografted mice lung in a process dependent on arachidonic acid (AA) release [25]. 
AA production and NOX2 activation was also involved in stimulation of metastasis by Prdx6 PLA2 
activity in several cancer models [25,26], although in another study, NOX2 activation was shown to 
proceed through Prdx6 mediated lysophosphatidic acid (LPA) receptor activation [27]. Prdx6 has 
also been related to pathogenesis of cardiometabolic diseases [17] and inflammatory diseases with 
contrasting roles of peroxidase and PLA2 activities [18]. 
In a recent study, we have found that weakening the cell’s antioxidant potential by 
experimental down-regulation of glutaredoxin 1 (Grx1) in HepG2 cells affects the phospholipid 
metabolism and the redox state of Prdx6 “extra residue” Cys91 [28]. In view of the above-outlined 
background of contrasting reports on the roles and mechanisms of multifunctional Prdx6 in several 
pathologies and its sensitivity to the redox environment, we have undertaken a project based on 
down-regulating Prdx6 with specific siRNA in hepatoblastoma HepG2 cells to study the role of 
Prdx6 in cell proliferation, redox homeostasis and metabolic programming. Silencing with specific 
siRNA provides a good experimental approach to mimic physiological down-regulation events that 
may occur as part of a cell response to various stimuli. We have found that the cells respond to Prdx6 
silencing by adapting carbon and lipid metabolism and by modulating signaling pathways to stop 
cell cycle progression at the G1/S phase transition. 
2. Materials and Methods 
2.1. Materials and Reagents 
All reagents were of analytical grade and were purchased from Sigma (St. Louis, Missouri, 
USA) unless otherwise specified. HepG2 cell line used in this work was obtained from the ATCC 
LGC Standards Company (Teddington, UK). Cell culture dishes and flasks were from TPP 
(Switzerland). The specific small interfering RNA for PRDX6 (siRNAPrdx6) and non-target (NT) 
were from Dharmacon (Lafayette, CO, USA) and ECL was from GE Healthcare (Wauwatosa, 
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Wisconsin, USA). Antibodies against PRDX6 were from Abcam (Cambridge, UK). Antibodies 
against CD95 were from Santa Cruz Biotechnology, (Dallas, TX, USA). Antibodies against Actin 
were from Sigma. 
2.2. Cell Growth Conditions, Proliferation and Cell Viability 
Cells were grown in EMEM Medium (Eagle Minimum Essential Medium), pH 7.4, supplemented 
with 10% fetal bovine serum, 2.2 g/L NaHCO3, 1 mM sodium pyruvate, 100 U/L penicillin, 100 
µg/mL streptomycin, and 0.25 µg/mL amphotericin in 5% CO2 atmosphere at 37 °C. Cell 
proliferation was analyzed using a colorimetric ELISA (Roche Applied Science, Penzberg, 
Germany). 20,000 cells/cm2 were cultured in 96-well multiplates at 37 °C and 5% CO2. 72h after 
siRNAPrx6 addition HepG2 cells were incubated with 10 µM BrdU labeling solution for 6h at 37 °C. 
Then cells were fixed with 200 µl of FixDenat solution for 30 min at room temperature. From this 
point, the incubations were done at room temperature. After this time, fixed cells were incubated 
with 100 µl of anti-BrdU-POD solution with a previous dilution of 1: 100 for 90 min, and washed 
with PBS. Finally, fixed cells were incubated with 100 µl of substrate solution for 30 min. Total 
number of cells and cell viability in a HepG2 cell suspension were quantified using the trypan blue 
dye exclusion method in 90 mm dishes. 
2.3. Silencing of Prdx6 
Human Prdx6 was down-regulated in HepG2 cells using a specific pool of four small 
interfering RNA (Ref. L-019173-00-0005) according to the manufacturer’s recommendations 
(Dharmacon, GE Healthcare, Life Science). 20,000 cells/cm2 were cultured in dishes and treated with 
25 nmol of siRNA mixed with the transfection reagent DharmaFECT-1 preincubated with culture 
medium (antibiotic and serum free) for 20 min at RT, in a 1:2 proportion and the interference 
solution was kept for 72 h to obtain the maximum inhibition of ≈60%. Non-targeting (NT) negative 
controls were run in parallel. Silencing of Prxd6 was always checked by Western blot. 
2.4. Measurement of Cell Death and Area of Cell Nuclei 
Apoptosis in HepG2 cells was analyzed through Annexin V-FITC (Canvax, Córdoba, Spain). 
Annexin-V binds to phosphatidylserine (PS) residues which are on the outer plasma membrane of 
apoptotic cells. Annexin-V is labeled with the fluorophore FITC to visualize apoptotic cells by 
fluorescent microscopy. 20,000 cells/cm2 were cultured on a coverslip introduced in each well of a 
24-well plate at 37 °C and 5% CO2. 2.5 µl of Annexin-V-FITC was added after siRNAPrdx6 following 
the instructions of the manufacturer. Then, cells were fixed in methanol and permeabilized with 
0.2% Triton-X100 solution in PBS. Cells nuclei were stained using DAPI. Fluorescence was measured 
with a fluorescence microscope (Olympus BX43) using standard fluorescein filter set to view 
Annexin-V-FITC fluorescence at 520 nm and view blue DAPI at 460 nm. The area of cell nuclei was 
measured on the DAPI pictures using the open source software “ImageJ” [29]. 
2.5. Measurement of Enzymatic Activities, Glucose and Protein 
HepG2 PLA2 activity was assayed using the Red/Green BODIPY based EnzChek 
Phospholipase A2 Assay (Invitrogen) (pH 7.0, in the absence of calcium) in 96-well plates [30]. Cells 
were sonicated (4 × 5 s) in PLA2 buffer (50 mM Tris-HCl, 1 mM EGTA, pH 7.0) supplemented with 
protease and phosphatase inhibitors, and the supernatant collected by centrifugation at 15,000 ×g for 
15 min was adjusted to ≈ 50 µg protein and preincubated for 10 min at 37 °C in the absence or 
presence of MJ33 (10 µM) [31]. At 60 min, samples were analyzed in a Microplate reader (Varioskan, 
Thermo Scientific) at an excitation of 460 nm and emissions of 515 nm. Background was subtracted 
and the ±MJ33 differential 515 nm emission were recorded. Caspase-3, caspase-8, and caspase-9 
associated activities were determined using the corresponding fluorescence peptide-based 
substrates (100 µM) in the reaction mixture (50 mM HEPES pH7.5, 100 mM NaCl, 10% sucrose, 0.1% 
Chaps, 1 mM EDTA and 5 mM DTT). The substrates used were Ac-DEVD-AFC, Ac-LETD-AFC, and 
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Ac-LEHD- AFC for caspase-3, -8, and -9, respectively. The fluorescence due to the reaction product 
was recorded with a GENIos Microplate Reader (TECAN) set at 400 nm excitation and 505 nm 
emission. Glucose concentration in the culture medium was determined by a standard enzymatic 
colorimetric assay at 505 nm (LabKit, Chemelex, S.A.). Protein concentration in the samples was 
determined by the Bradford method (Bio-Rad) using BSA as the standard. 
2.6. Proteomics 
2.6.1. Sample Preparation and Mass Spectrometry 
The experiments were routinely carried out at 20,000 cells/cm2 and a modification of the 
methodological strategy described previously [28] was used. Reduced cysteines were blocked with 
“light” Iodoacetamide (IAM) while reversibly oxidized Cys were labeled with “heavy” IAM 
(Iodoacetamide-13C2, 2d2) incorporating ∆mass of 4 Da. Cell extracts were obtained with a lysis 
solution (50 mMTris-HCl pH 8.5, 5 mM IAM light, 0.5% CHAPS, 1 mM PMSF); samples were 
centrifuged at 15,000g for 5 min at 4 °C. 100 µg of protein were diluted up to 80 µl with 50 mM 
Tris-HCl pH 8.5 and incubated with 4 µL of 160 mM DTT at 37 °C for 30 min to reduce the reversibly 
oxidized cysteines. Subsequently, cysteines were alkylated adding 6 µL of 240 mM IAM heavy and 
incubated at room temperature for 30 min in darkness. Finally, the excess of IAM and CHAPS was 
removed using Zeba spin desalting columns (Thermo Scientific) equilibrated with 25 mM 
ammonium bicarbonate pH 7.0. The level of silencing was checked at this point by SDS-PAGE. 
Proteolytic digestion and proteomic analyses were performed as described previously [28]. The 
spectrometer used was the Thermo Orbitrap Fusion (Q-OT-qIT, Thermo Scientific) equipped with a 
nano-UHLC Ultimate 3000 (Dionex-Thermo Scientifics). 
2.6.2. Label-Free MS Protein and Redox Quantification 
The “label-free” quantification was performed using the MaxQuant (v1.5.7.0) free software [32] 
configuring “light” IAM and “heavy” IAM and methionine oxidation as variable modifications. No 
imputation of missing values was implemented. Finally, only the conditions with three or more 
values per identification were considered and analyzed using a Student’s T-test. The criteria for 
considering a differentially expressed protein were that it was identified and quantified using at 
least two unique peptides and it showed a fold change of at least 1.5 and a p ≤ 0.05 value. MS2 
spectra were searched with SEQUEST engine against a database of Uniprot_Human_Nov2014 
(www.uniprot.org). The Cys-containing peptides labeled with light and heavy IAM modifications 
independently were quantified using the open software Skyline [33]. The individual 
reduced/oxidized ratio for specific Cys residues was calculated in each sample in order to obtain the 
redox proteome. The intensities of misscleavaged peptides were taken into account for the 
calculations. 
2.7. Metabolomics 
The metabolomic study is part of a larger study and the analyses were performed at Metabolon, 
NC USA (www.metabolon.com). The samples from four different experiments were prepared 
following the company specific guidelines as described before [28]. Briefly, dry cell pellets were 
immediately frozen in liquid nitrogen and stored at −80 ℃ until shipment. Samples were prepared 
using the automated MicroLab STAR® system from Hamilton Company. To remove protein, 
dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to 
recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous 
shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract 
was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS 
methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS 
with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, 
and one sample was reserved for backup. Extraction of raw data, peak identification and 
quantification, and QC were performed using Metabolon’s hardware and software. 
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2.8. SDS-PAGE and Western Blotting 
SDS-PAGE was performed in 12% Criterium XT Precast Gels (Bio-Rad) for detection of specific 
proteins (Prdx6, CD95, Actin). After electrophoresis, proteins were transferred to a nitrocellulose 
membrane in a semi-dry electrophoretic transfer system (Bio-Rad) for 40 min at 400 mA constant. 
Transfer and protein load were checked by staining with Ponceau reagent. The membranes were 
incubated overnight at 4 °C with the corresponding dilutions of primary antibodies: 1:500 CD95, 
1:2000 Prdx6, and 1:4000 Actin. They were then washed with TBS-T and incubated with the 
corresponding secondary antibodies conjugated to peroxidase (anti-rabbit, anti-goat, or anti-mouse) 
used at 1:8000 dilution. The chemiluminescent signal induced by ECL reagent (GE Healthcare) was 
detected in a ChemiDoc image analyzer (Bio-Rad) and quantified by densitometry with 
Quantity-One 1-D analysis software (Bio-Rad) using Actin as reference for loading normalization. 
2.9. Statistics 
Where appropriate, results are expressed as mean ± SD of at least three independent 
experiments and Student t-test used for significance. Large data sets were analyzed using Storey and 
Tibshrani method [34] comparing non-target control vs. siRNA Prdx6 treated. The threshold for 
statistically significant differences was set at p-value adjust ≤ 0.05; q-values are also included as an 
additional reference. 
3. Results and Discussion 
3.1. Prdx6 down-Regulation Reduced Cell Proliferation 
The peroxidatic Cys47 in Prdx6 is predominantly (> 60%) in a reversibly oxidized state in 
HepG2 cells (see data in Supplementary File S2) but its overoxidation would decrease the peroxidase 
activity and stimulate the PLA2 activity [13]. 
It was not possible to measure the Prdx6-specific peroxidase activity in cell lysates, but its 
phospholipase A2 activity (PLA2) was determined using a standard fluorimetric assay in the 
presence of MJ33, a Prdx6 specific PLA2 inhibitor, as described in Materials and Methods. The assay 
gives a high variability and, although the resulting data from five different experiments were not 
statistically significant, a trend was observed with lower activity in siRNA-Prdx6 treated cells 
(Figure 1A) in parallel with decreased levels of Prdx6 protein by ≈ 60%, as determined by Western 
blot and confirmed by mass spectrometry quantitative analysis (See data in Supplementary File 1). 
The number of cells and incorporation of BrdU, indicative of the number of cells in the S phase 
or proliferation, both decreased after 72 h treatment with siRNA-Prdx6 (Figure 1B,C). Cell viability 
did not change in either condition (data not shown), but the size of the cells augmented as evidenced 
by a significant increase in nuclear size (Figure 1D). The nuclear size is an important parameter 
governing entry into the cell cycle. These results suggest cell cycle blockade induced by Prdx6 
down-regulation. 
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Figure 1. Effect of Prdx6 silencing on PLA2 activity, cell viability, nuclear area, apoptosis, and CD95 
level. (A) Prdx6-dependent PLA2 activity was determined, as described in Materials and Methods, in 
cell lysates of HepG2 cells treated with siRNA-Prdx6 or with non-target siRNA (NT) as indicated. 
Activity is expressed as arbitrary fluorescence units normalized for protein content. Data are the 
mean of 5 independent biological replicates. (B) The number of cells determined as indicated in 
M&M. (C) Proliferation in terms of cells entering the S phase was determined by the degree of BrdU 
incorporation to replicating DNA and expressed in absorbance units. (D) The nuclear area of cells 
was determined as indicated in M&M. >500 cells were measured, from 6 different slides, in each 
sample. The area is given in arbitrary units. (E) Apoptosis was determined by the Annexin V 
fluorescence method; the number of positive cells relative to the total number of cells in percentage is 
represented. (F) CD95 levels were determined by western blotting with specific antibodies and band 
density was normalized to the signal for actin. Parameters in (B), (C), (E) and (F) were determined in 
three independent experiments; error bars show SD; statistical significance was assessed by 
Student’s T-test and is shown with a number of asterisks inversely proportional to the p-value (**** < 
0.0001, ** < 0.01, * < 0.05). 
3.2. Prdx6 Silencing Interferes with Apoptotic Signaling from CD95 but does not Induce Apoptosis in HepG2 
Cells 
To check whether the anti-proliferative action of Prdx6 down-regulation could be due to 
activation of cell death mechanisms, we analyzed several apoptotic parameters. Prdx6 silencing did 
not affect apoptosis significantly in HepG2 cells as shown by Annexin V fluorescence (Figure 1 E), 
but did induce a marked decrease in CD95 protein levels (Figure 1F). This effect could not be 
associated to caspase modulation, since the levels and activities of caspases 3, 8 and 9 did not change 
significantly, although caspase 3 displayed unusually high variability (data not shown). It is well 
established that activation of CD95 receptor mediates the induction of apoptosis mostly in the 
context of immune response. CD95 is ubiquitously expressed in all types of cells, including cancer 
cells, but its expression in cancer cells implies that they are themselves resistant to CD95-mediated 
apoptosis [35]. It is now widely accepted that CD95 has multiple non-apoptotic functions and that 
stimulation of CD95 in cancer cells can turn this death receptor into tumor promoting receptor [35] 
through diverse tumorigenic signaling pathways. In lung cancer cells, activation of CD95 induced 
the production of proinflammatory factor PGE2 through the p38 pathway, and promoted cell 
growth that was reduced by administration of the cyclooxygenase-2 inhibitor [36]. Interestingly, 
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accelerated entry into the cell cycle S-phase by CD95 stimulation was demonstrated in pancreatic 
ductal adenocarcinoma cells in vitro in a process not dependent on the DISC (death-inducing 
signaling complex) formation but mediated by recruitment of the adapter protein Sck (SH2 domain 
protein C2) [37]. 
Altogether, these results show that the response of HepG2 cells to Prdx6 silencing is rather 
complex, with a mixture of apparently contradictory outcomes like CD95 down-regulation but no 
changes in caspases and cell swelling. It would be worth determining whether the antiproliferative 
action could be due to the blockade of entry into cell cycle S-phase by down-regulation of CD95 and 
the possible involvement of signaling events dependent on the PLA2 activity of Prdx6. These aspects 
will be discussed below in a wider context including changes at metabolomic, proteomic, and redox 
levels. 
3.3. Metabolic Remodeling after Prdx6 Silencing 
Metabolic remodeling and protein posttranslational modification (PTM) are the first levels of 
cellular response to a stimulus before a stable response is set up at the transcriptional level. We 
carried out a metabolomic analysis (Supplementary File S3) to determine the possible effect of Prdx6 
down regulation in the metabolic profile of HepG2 cells. 
3.3.1. Lipids 
Lipid metabolism plays a critical role in cell survival and proliferation since these varied 
molecules are indispensable for the structural, signaling, and energy needs of every cell. 
Phospholipids are synthesized during entry in the cell cycle but the synthesis pauses for cell 
division, so that the G1 and S phases are characterized by doubling of phospholipid content [38]. 
Increased levels of all kinds of phospholipids, lysophospholipids, plasmalogens and ceramides, 
with the exception of lactosylceramide, was a marked trend in siRNA-Prdx6 treated cells. A parallel 
increase in UDP-glucose and UDP-galactose levels (Figure 2B) is consistent with the enhanced rate 
of glycolipids synthesis. CDP-ethanolamine, P-choline and P-ethanolamine of the Kennedy pathway 
were particularly elevated. Augmented levels of phosphocholine have been observed in a wide 
variety of human cancers, caused in part by the growth factor-activated Ras and 
phosphatidylinositol 3-kinase (PI3K) signaling cascades that stimulate the initial enzyme of the 
choline branch of the pathway [39]. It would be valuable to know if the elevated levels of these 
phospholipid precursors caused by Prdx6 silencing involve this signaling pathway. Increased 
phospholipid content could contribute to the observed increase in the cell volume described above 
(Figure 1D). 
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Figure 2. Summary of significant metabolomic changes. A metabolomic analysis was carried out as 
described in Materials and Methods. The fold change (up-regulation, green; down-regulation, red) of 
each metabolite level on Prdx6 silencing in HepG2 cells is shown in the first column; the second and 
third columns show the p-values and q-values, respectively, for statistical significance; p and 
q-values ≤0.05 are in blue with the color intensity inversely proportional to p- or q-value. The results 
have been clustered into three figures and into pathways therein: (A) Metabolites of lipid 
metabolism; (B) metabolites of other pathways and (C) metabolites of aminoacids and nucleotides 
metabolism. (D) The concentration fold change of extracellular glucose determined by standard 
colorimetric methods in three independent experiments (*** p < 0.001). 
Long chain monoacylglycerols (MAG) were an exception to this trend of increased lipid content 
Some MAG are known as endocannabinoids, like 2-arachidonyl-glycerol and it has been recognized 
that they have important signaling functions [40]. MAG can form through the action of PLA2 on 
phosphatidic acid (PA) while their degradation is carried out by membrane bound MAG hydrolases 
of which two types have been described, the ubiquitously expressed serine hydrolase α/β-hydrolase 
domain 6 (ABHD6) and classical MAG lipase, a housekeeping enzyme. ABHD6 is expressed at high 
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levels in certain tumors and its pharmacological or genetic suppression, which leads to an elevation 
in 1- and 2-MAG content in different tissues, appears to have multiple health benefits, likely 
mediated via MAG signaling [40]. Only three members of this family of lipases were detected in the 
proteomic analysis (ABHD10, ABHD12, and ABHD14B; see data in Supplementary File S1) and none 
of them showed significant quantitative changes on Prdx6 silencing, stressing the possible 
contribution of Prdx6 PLA2 activity down-regulation to unchanged MAG levels. 
Long chain fatty acids decreased in siRNA-Prdx6 treated cells while the levels of carnitine 
followed a reciprocal trend (Figure 2A cont.). The accumulation of carnitine is indicative of reduced 
entry of long chain fatty acids into the mitochondria for ß-oxidation. A natural variant C304➝W 
(VAR_020548; dbSNP: rs80356776) of carnitine O-palmitoyltransferase 1 (CPT1A) with pathological 
consequences produces an unstable, inactive form of the enzyme [41] stressing the importance of 
Cys residues for optimal import of long chain fatty acids into the mitochondria. Redox changes 
observed in CPT1A (See Supplementary File S2) could be relevant to these trends in long chain fatty 
acid metabolism. Our results show that CPT1A-Cys96 was oxidized (0.3 red/ox ratio fold change; p = 
0.005) on siRNA-Prdx6 silencing. Reversible oxidation of CPT1A-Cys96 would slow down fatty acid 
ß-oxidation in favor of increased biosynthesis and incorporation into phospholipids in siRNA-Prdx6 
treated cells. 
There could also be a relationship between the levels of unsaturated long chain fatty acids and 
PLA2 activity of Prdx6. Early characterization of Prdx6 PLA2 activity showed high activity with 
arachidonic acid (AA) containing phospholipids [42,43]. A proapoptotic role of Prdx6 via induction 
of AA release by its PLA2 activity has been postulated in human bronchial epithelial cells [44] but 
another study found that AA production by PLA2 activity of Prdx6 induced cell proliferation 
through activation of Src family kinases in human melanoma cells [26]. These contradictory results 
reveal the complexity of Prdx6 action mechanisms and highlight the importance of lipid signaling in 
cancer. 
3.3.2. Nitrogen Metabolism 
A generalized increase in aminoacids, with few exceptions, was observed that could be a 
consequence of increased biosynthesis and/or protein degradation. A marked similar trend was 
observed for polyamines, a sign of the cells being prepared for proliferation since elevated 
polyamine levels, are necessary for transformation and tumor progression [45]. This increment could 
also contribute to the above-mentioned increase in cell volume (Figure 1D). It would be worth 
checking whether these changes are due to alteration in the PI3/Akt/mTOR pathway. 
There was an overall decrease in metabolites of the purine and pyrimidine metabolism 
subfamilies, with the exception of adenosine, inosine, and hypoxanthine upon Prdx6 silencing. 
These results are indicative of diminished nucleotide biosynthetic activity and activation of adenine 
catabolism, although urate was not detected. 
3.3.3. Other Metabolites 
Several metabolites of the glutathione metabolism subfamily were elevated in siRNA-Prdx6 
treated cells likely as a consequence of glutathione demand in the face of diminished antioxidant 
defenses. A conspicuous increase of the Glutamate and Serine, Threonine, and Glycine pathways 
was also detected at metabolome level reinforcing the idea of metabolic pathways converging on 
glutathione synthesis. 
Regarding carbon metabolism (Figure 2B), treatment of HepG2 cells with siRNA-Prdx6 lowered 
dihydroxyacetone-phosphate (DHAP), pyruvate, ribose, and 2-oxoglutarate (αKG) levels whereas 
extracellular glucose (Figure 2D), phosphoenol-pyruvate (PEP), 3-phosphoglycerate (3-PG), 
sedoheptulose-7-phosphate (Shu7P), malate, aspartate, and serine increased. These changes are 
compatible with reduced import of glucose and diminished flow through the upper glycolytic 
pathway, the non-oxidative part of the Pentose-phosphate pathway (PPP) and the nucleotide 
biosynthetic pathway. In the lower part of the pathway a predominant gluconeogenic flow from 
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aminoacids with diversion at 3-PG toward serine and other biosynthetic pathways thereon would be 
taking place (Scheme 1). 
 
Scheme 1. Overview of metabolic pathways affected by Prdx6 down-regulation. Relative levels of 
metabolites and thiol redox changes in enzymes in siRNA-Prdx6 treated HepG2 cells. Up and down 
arrows indicate increased or decreased levels, respectively. Mapped redox sensitive Cys showing a 
differential redox state (oxidative purple; reductive, orange). See main text for detailed explanation. 
Changes detected in the redox proteome could be relevant to these metabolic set up, since 
glucose-6-phosphate and 6-phosphogluconate dehydrogenases (G6PD and PGD), aldolase 
(ALDOA), hexokinase (HK2), malate dehydrogenase (MDH1), PEP carboxykinase (PCK2), and 
3-phosphoglycerate dehydrogenase (PHGDH) showed redox changes at specific Cys residues that 
could affect their catalytic performance (highlighted in Scheme 1 and commented below). 
3.4. Changes at Proteome Level 
The extent of down-regulation of Prdx6 under our experimental conditions was not incisive 
enough to provoke extensive changes at global proteome level through transcriptional regulation, 
but had a marked effect at posttranslational level as observed by changes in the redox proteome. 
3.4.1. Global Proteome 
As a proof of concept, the quantitative global proteomic analysis (Supplementary File S1) 
detected 0.5-fold Prdx6 down-regulation in silenced cells. The number of differentially expressed 
proteins after siRNA-Prdx6 treatment was rather low. However, a group of differential proteins on 
Prdx6 silencing were significantly enriched in endocytosis (GO:0030100 term and hsa04144 KEGG 
pathway): the ADP-ribosylating factor GTPase-activating protein (ARFGAP1) involved in 
membrane trafficking was up-regulated while vacuolar protein sorting-associated protein 4B 
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(VPS4P) and 4 members of Ras-related proteins (RAB5A, RAB5B, RAB7A and RAB11A) were 
down-regulated (Supplementary File S1). 
These data run parallel to increased phospholipid content and demonstrate that Prdx6 is 
involved in membrane arrangement and vesicle trafficking, but it remains to be determined which 
activity of Prdx6, either the peroxidase, the PLA2, the LPAT, or a combination of these, is responsible 
for this role. 
3.4.2. Redox Proteome 
Down-regulation of Prdx6 should be expected to alter the redox homeostasis by diminution of 
its antioxidant capacity, so we analyzed the Redox Proteome, namely, the set of proteins undergoing 
redox changes at sensitive cysteines on siRNA-Prdx6 treatment in HepG2 cells. A large set of nearly 
one thousand cysteinyl peptides were detected (Supplementary File S2). We selected those 
differential Cys-peptides with statistical significance (p < 0.05) and > 1.5-fold or < 0.6-fold change in 
their Cys reduced/oxidized ratio. The main changes were detected in enzymes of carbon and 
glutathione metabolism, pentose phosphate pathway, citrate cycle, fatty acid metabolism, 
biosynthesis of aminoacids, and Glycolysis/Gluconeogenesis. 
A significant redox target was Hexokinase-2 (HK2) at Cys368, that was half reduced in HepG2 
cells but was reversibly oxidized after siRNA-Prdx6 treatment (Table 1). HK2 is known to play a 
critical role in the connection between metabolic and cell survival pathways and is upregulated in 
hepatocellular carcinoma and other tumors [46,47]. HK2 associates with the outer mitochondrial 
membrane via a binding motif at the N-terminal that interacts with voltage dependent anion channel 
(VDAC). 
Table 1. Reversible thiol redox changes in specific sensitive Cys. 
 siRNA Prdx6 HK2-Cys368 Prdx6-Cys91 PHGDH-Cys18-19 
Ratio red/ox ± sd (n = 4) 
− 
0.58 
± 0.04 
1.78 
± 0.33 
10.43 
± 2.75 
+ 
0.26 
± 0.03 
0.92 
± 0.06 
4.98 
± 1.98 
Fold Change 0.45 0.52 0.48 
p-value 1.6 × 10−5 2.2 × 10−2 2 × 10−4 
The reduced/oxidized ratio of specific cysteines in three proteins, specifically discussed in the main 
text, suffering reversible redox changes upon Prdx6 silencing as determined by the quantitative 
redox proteome protocol described in Materials and Methods. The ratio values (± s.d.; n = 4) are 
shown and the fold change provoked by Prdx6 silencing is also indicated together with the statistical 
significance index (p-value) for HepG2 cells. 
This association provides a metabolic advantage by bringing HK2 closer to the ATP production 
site, and an apoptosis suppressive capacity by competing with proapoptotic factors for the binding 
to VDAC [48]. Cys368 occupies a central position in the VDAC-HK contact area [49] (Figure 3A) and 
it is conceivable that its oxidative modification on siRNA-Prdx6 treatment could have altered its 
interaction with VDAC, affecting its subcellular localization and inducing a decrease in the rate of 
glucose phosphorylation and entry into the cell. 
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Figure 3. Structural mapping of redox sensitive Cys. The 3D structures of three enzymes of 
carbohydrate metabolism, HK2, PCK, and PHGDH, with the indicated PDB ID codes, were analyzed 
to map the Cys residues that showed significant redox changes upon Prdx6 silencing in HepG2 cells. 
(A) One subunit of HK2 is shown below in a ribbon model with Cys368 atoms as yellow Van der 
Waals spheres and sidechains of residues involved in interaction contacts with VDAC1 highlighted 
in orange; the C-terminus is enlarged in molecular surface mode, except for Cys368, with the same 
highlighting criterium as below. (B) PCK in ribbon mode and detected Cys residues with atoms as 
Van der Waals spheres, color CPK; one molecule of substrate PEP (red) is bound at the active site; the 
positions of Cys306, Cys55 and Cys151 are indicated with arrows. (C) PHGDH in ribbon cartoon 
with the coenzyme NAD bound at the active site cleft; sidechains of redox modified Cys residues 
upon Prdx6 silencing are shown in CPK color; acetylation and sumoylation sensitive Lys21 is shown 
in purple next to redox sensitive Cys18-Cys19; catalytic His283 is shown in green with the redox 
sensitive Cys281 in the neighborhood. 
Prdx6 was abundant enough to be clearly detected (24 peptides) even in silenced cells 
(Supplementary Files S1 and S2). The peptide containing the “non-catalytic” Cys91 was prominent 
and showed sensitivity to reversible oxidation, as it was fairly reduced in HepG2cells but was 
significantly more oxidized after siRNA-Prdx6 treatment (Table 1). The peptide containing its 
catalytic peroxidatic Cys47 did not show significant reversible redox changes (See data in 
Supplementary File S2). The “extra” Cys91 is not conserved among members of the 1-Cys subfamily 
of Prx and has been thoroughly neglected or routinely substituted by Ser in the recombinant protein 
and other experimental setups. However, we have found that Cys91 of human Prdx6 was 
specifically sensitive to reversible oxidation in glutaredoxin 1 (Grx1) down-regulated HepG2 cells 
and had shown that it is prone to glutathionylation in recombinant Prdx6 [28]. Experiments are 
under way to elucidate whether this “extra” Cys in human Prdx6 is relevant to its structure and 
function in the context of redox signaling. 
Silencing of Prdx6 in HepG2 cells led to redox changes in Cys191 of the intracellular chloride 
ion channel-1 (CLIC1). This is a soluble globular protein that can undergo an extended 
conformational change to get embedded in intracellular membranes, mainly in the nucleus, and 
form a Cl- ion channel that has been linked to apoptosis, pH, cell volume and cell cycle regulation 
[50,51]. The soluble form of CLIC1 consist of two domains, the N-terminal one with a thioredoxin 
fold similar to glutaredoxin and the C-terminal typical of the GST superfamily; it also contains a 
glutathione binding site [52]. These properties of CLIC1 suggested that it may be under some kind of 
redox control. Cys191, which is located in the GST domain of CLIC1, was more reduced in 
siRNA-Prdx6 treated cells (See data in Supplementary File S2). Coincidentally, Prdx6 interacts with 
GST-π during the peroxidase catalytic cycle [53]. It is tempting to hypothesize on a possible redox 
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relationship between Prdx6 and CLIC1 contributing to the effects of Prdx6 silencing on cell swelling 
and cell cycle arrest described above.  
Redox changes in two enzymes of the Glycolysis/gluconeogenesis pathway are worth of 
mention. Eight cysteines were detected out of a total of 12 in the sequence of mitochondrial 
PEP-carboxykinase (PCK2), which is composed of two large domains, with the active site in 
between, that move relative to each other during the catalytic cycle. Of these Cys, seven are clustered 
in the C-terminal domain (Figure 3B), but only the peptide containing Cys55 and Cys63, conserved 
in eukaryotes, showed significant redox changes. Cys55 could form a disulfide bond with Cys151, 
which would be ≈ 3Å apart. The enzyme is inactivated by glutathionylation of Cys306, which is close 
to the active site, in a way reversed by SH2 [54]. We have detected this cysteine in all the samples in a 
highly reduced state (red/ox >20) insensitive to Prdx6 silencing, allowing for full activity 
(Supplementary File S2). 
3-phosphoglycerate dehydrogenase (PHGDH) plays a critical role in a relevant metabolic 
diversion of Glycolysis that leads to serine, a precursor of proteins, phospholipid head groups and 
glutathione and driving force for the folate and methionine cycles [55]. Its gene is overexpressed in 
several types of cancers, where it can catalyze the reduction of 2-oxo-glutarate to 
2-hydroxyglutarate, a potent oncometabolite [56]. In the current study, we have found several redox 
sensitive Cys in PHDH all of which are in a highly reduced state (red/ox ratios ≈ 5-30). However, 
Cys281 and the peptide containing contiguous Cys18Cys19, three Cys conserved in mammals, were 
significantly less reduced under conditions of Prdx6 silencing in HepG2 cells (Table 1 and 
Supplementary File S2). Cys281, which was identified as a target for S-nitrosation in a 
high-throughput study [57], is in the NAD-binding catalytic domain, close to the essential active site 
residue His293, while Cys18Cys19 are located in the so called allosteric regulatory domain in close 
proximity to Lys21 (Figure 3C), which is a target for acetylation and sumoylation [58]. Reversible 
redox changes in these sensitive Cys of the enzyme could affect its catalytic and regulatory 
properties [59]. 
4. Conclusions 
The complex wide effects of moderate Prdx6 down-regulation should be a reflection of its 
moonlighting properties acting as peroxidase, phospholipase, and LPC-acyltransferase. The 
response of HepG2 cells to Prdx6 silencing spans from metabolic and signaling pathways 
remodeling to alterations in the redox proteome and membrane turnover with effects in cell cycle 
progression and proliferation. The role of Prdx6 in cancer cells has been studied previously with 
conflicting outcomes. Most reports point to a pro-proliferating and antiapoptotic action of Prdx6, but 
some studies have found the opposite effect, depending on the stage of tumor development. 
Moreover, these effects have not always been assigned to a particular activity of Prdx6, either 
peroxidase, PLA2, or LPCAT, neither a common mechanism has been provided. 
In the study reported herein Prdx6 silencing down to ≈ 40% would represent a situation 
mimicking a cellular response to endogenous or exogenous stimuli under normal or oxidative stress 
conditions. 
It appears that the cell responds to Prdx6 down-regulation by initiating a biosynthetic program, 
leading to membrane and vesicle trafficking rearrangement with signs of entering a cell cycle G1 
phase but an inability to proceed on to the S phase. The mechanisms behind these phenomena 
involve reversible thiol oxidative changes in key proteins. HK2-Cys368 and Prdx6 “extra” Cys91 
stand out as relevant thiol switches. The former could affect association with the mitochondrial 
membrane with consequences on the rate of glucose catabolism and mitochondrial permeability; the 
latter is not conserved among the 1-Cys type Peroxiredoxins and has been given little attention so 
far, but could turn out to bear relevant functions in human cells. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1; Supplementary File 1: 
Excel file showing results of global quantitative proteomic analysis in Prdx6 silenced HepG2 cells. The first 
sheet shows protein ID, protein name, gene name and number of unique peptides in the first columns. NT and 
siRNA-Prdx6 indicate treatment with unspecific “non-target” siRNA and with specific siRNA, respectively. 
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Columns M and N with blue colored headings show the calculated fold change induced by siRNA-Prdx6 
treatment together with the statistical significance index (p value). Statistically significant data have been 
selected and disclosed into the second sheet with the fold change colored green and red for down- and 
up-regulated values, respectively. The sheets named “GOTERM_Enrichment” and “KEGG_Enrichment” show 
the results of “Biological Process GO-term” and “KEGG pathway” enrichment analysis of the set of 
differentially expressed proteins on siRNA-Prdx6 treatment; Supplementary File 2: Excel file showing results of 
cysteinyl peptides proteomic quantitative analysis of in Prdx6 silenced HepG2 cells. The peptide sequence, 
accession ID and protein name are shown in the first columns. NT and siRNA-Prdx6 indicate treatment with 
unspecific “non-target” siRNA and with specific siRNA, respectively. The data in columns D to K are the 
reduced/oxidized ratio values for each of 4 replicas for every Cys-peptide; NA, data not available. Columns L 
and M, colored orange show the fold change of the red/ox ratio induced by siRNA-Prdx6 treatment together 
with the statistical p value for significance. The second sheet with the fold change colored green and red for 
down- and up-regulated values, respectively shows the selected significant fold change values (column E) 
induced by Prdx6 silencing ordered by increasing p-values (column F); the position of the Cys residue in the 
sequence of the protein is given in column D and a horizontal double red line marks the statistical threshold for 
significance; Supplementary File 3: Excel file showing results of metabolomic analysis in Prdx6 silenced HepG2 
cells. Columns A and B show the metabolite family and the name of the metabolite, respectively. The data show 
the normalized quantitative values for each metabolite in each of 4 replicas for the treatment with unspecific 
siRNA (NT) and siRNA-Prdx6. NA, missing or outlier value. The fold change induced by Prdx6 silencing is 
shown in column K, together with the statistical p-value for significance, with values <0.05 highlighted in 
yellow. 
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Abstract: Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma
(HCC) in de-differentiation stage (presenting epithelial–mesenchymal transition, EMT). We studied
the role of the thioredoxin system (Trx1/TrxR1) in the sensitivity or resistance of HCC cells to the
treatment with Sorafenib. As a model, we used a set of three established HCC cell lines with different
degrees of de-differentiation as occurs in metastasis. By quantitative proteomics, we found that the
expression levels of Trx1 and TrxR1 followed the same trend as canonical EMT markers in these cell
lines. Treatment with Sorafenib induced thiol redox reductive changes in critical elements of oncogenic
pathways in all three cell lines but induced drastic proteome reprograming only in HCC cell lines of
intermediate stage. Trx1 downregulation counteracted the thiol reductive effect of Sorafenib on Signal
Transducer and Activator of Transcription 3 (STAT3) but not on Mitogen-Activated Protein Kinase
(MAPK) or Protein Kinase B (Akt) and transformed advanced HCC cells into Sorafenib-sensitive cells.
Ten targets of the combined Sorafenib–siRNATrx1 treatment were identified that showed a gradually
changing expression trend in parallel to changes in the expression of canonical EMT markers, likely
as a result of the activation of Hippo signaling. These findings support the idea that a combination of
Sorafenib with thioredoxin inhibitors should be taken into account in the design of therapies against
advanced HCC.
Keywords: hepatocarcinoma; thioredoxin; sorafenib; redox signaling; EMT
1. Introduction
Hepatocarcinoma (HCC) represents 80% of the primary hepatic neoplasms that appear mainly in a
context of chronic liver cirrhosis. It is the sixth most frequent neoplasm, the third cause of cancer death,
and accounts for 7% of registered malignancies [1]. Sorafenib is the standard of care for advanced-stage
HCC, as demonstrated in two large-scale trials [2] and the Asia-Pacific trial [3].
Epithelial–mesenchymal transition (EMT) is an important process that happens in normal
development in which epithelial cells lose many of their properties to become mesenchymal cells
by means of drastic changes in architecture and behavior. A similar transition also occurs during
tumor progression and malignant transformation, leading to increased cell motility and invasiveness.
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Transforming Growth Factor-ß (TGFB) is known as the main, although not exclusive, inductor of
EMT, which takes place through various signaling pathways [4]. A critical molecular event of EMT is
the downregulation of the cell adhesion molecule E-cadherin and its replacement by N-cadherin [5].
Activation of Akt leads to a significant reduction in E-cadherin expression and to nuclear localization of
SNAI1, suggesting a role for the PI3K/Akt signaling pathway in the shift from E-cadherin to N-cadherin
expression and in EMT progression in cancer [6,7]. The serine/threonine kinase Akt is thought to be
responsible for mediating the acquired resistance to Sorafenib in HCC cells [8]. Akt can be activated by
insulin and survival and growth factors through phosphorylation mediated by mTOR2 and PDK1
at specific threonine residues. The process can be reverted by protein phosphatase 2 (PP2A) when
Akt is oxidized, suggesting that Akt is subjected to redox regulation [9]. Moreover, it was shown that
the interaction between Akt and PP2A under conditions of oxidative stress could be impaired by the
reduction of a specific disulfide bond in Akt catalyzed by glutaredoxin (Grx). Activation of Akt after
stimulation with insulin and various growth and survival factors, leading to the phosphorylation at
Thr308 and Ser473 by PDK1 and mTOR2, respectively. Akt in its oxidized form can also be inactivated
by protein phosphatase 2 (PP2A) dephosphorylation, which suggests that Akt is a redox-regulated
protein [9]. It has been shown that Grx prevented Akt from forming a specific disulfide bond between
Cys-297 and Cys-311 and suppressed its association with PP2A under oxidative stress, [9–11].
STAT3 is a pro-survival transcription factor which is constitutively activated in human cancer cell
lines. Constitutive phosphorylation of STAT3 causes important changes in apoptosis, angiogenesis,
invasion, migration, and proliferation, resulting in cell malignant transformation [12]. It has been
observed that STAT3 activation is involved in EMT, invasion, and generation of metastasis in HCC [13].
Tyrosine phosphorylation of STAT3 is dependent on the thiol redox state modulated by H2O2 and Prx2
levels and the thioredoxin system activity [14]. Trx1–STAT3 disulfide exchange intermediates were
detected, suggesting that Trx1 may be a direct mediator of STAT3 disulfide reduction.
Overexpression of Trx1 has been detected in human cervical neoplastic squamous epithelial cells,
lung, colon, and HCC tumors [15–18]. Targeting Trx1 for cancer therapy and as prognostic marker of
HCC has been considered because of the observed relationship between Trx1 expression and tumor
aggressiveness, although the mechanisms underlying this association are still not well known [19].
Overexpression of Trx1 is one of the mechanisms for drug resistance in HCC treatment. A possible
strategy that is gathering strength is to combine Trx1 gene therapy with chemotherapy to increase the
effectiveness of treatments in HCC [20]. Thioredoxin-interacting protein (TXNIP) is a member of the
alpha-arrestin protein family that binds to the active site and counteracts the action of Trx1 functioning
as tumor suppressor [21]. Downregulation of TXNIP exacerbates cancer progression, and its expression
is actually reduced in various human cancer cells [22]. TXNIP deficiency enhances the induction of the
Zinc finger proteins SNAI1 and SNAI2 by TGF-ß and promotes TGF-ß-induced EMT [23].
A comparative genomic characterization of 19 cell lines derived from HCC allowed clustering
them into two groups (I and II) according to their gene expression patterns [24].
In this study, we selected three hepatocarcinoma cell lines, i.e., HepG2 belonging to group I and
SNU423 and SNU475 belonging to group II, to carry out a comparative study of their basal proteome
and of how it responds to Sorafenib treatment and/or thioredoxin downregulation. We also analyzed
redox modifications and phosphorylation of Akt, MAPK, and STAT3. The results obtained support the
use of a combination of Sorafenib with Trx1 inactivation in HCC therapy.
2. Materials and Methods
2.1. Materials
HepG2 (HB-8065™, ATCC/LGC Standards, SLU, Barcelona, Spain), SNU423 (CRL-2238,
ATCC/LGC Standards) and SNU475 (CRL-2236, ATCC/LGC Standards) cell lines were obtained
from American Type Culture Collection (ATCC; LGC Standards, S.L.U., Barcelona, Spain). Anti-Trx1
was obtained in-house from rabbit immunization with Trx1. Antibodies against STAT3 (#4904S),
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MAPK (#9102), Thr202/Tyr204pMAPK (#4370P), Ser473pAkt (#4060S) were obtained from Cell Signaling
Technology. Antibodies against Tyr705pSTAT3 (#sc-7993), TXNIP (#sc-271237), Akt1 (#sc-5298), and
ß-actin (#sc-47778) were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-TrxR1 (#ab124954)
was provided by Abcam, Inc. Secondary antibodies were from Sigma. ECL reagent was from GE
Healthcare (Chicago, Illinois, USA); siRNA for Trx1 was from Dharmacon, Inc. (#L-006340-00; Lafayette,
Colorado, USA).
2.2. Cell Growth Conditions
Cell cultures were negative for mycoplasma contamination. Cells were maintained in Eagle’s
minimum essential medium (EMEM), pH 7.4, supplemented with 10% FBS (#S181G-500, Biowest),
sodium pyruvate (1mM) (#L0642-100, Biowest), and a penicillin–streptomycin–amphotericin solution
(100U/mL–100µg/mL–0.25 µg/mL) (#L0010-100, Biowest) at 37 ◦C in a humidified incubator with 5%
CO2. The cells were seeded at a density of 105 cells/cm2 in 2D culture. When applied, Sorafenib
was added to the cell culture at a concentration of 10 µM, as set up in a previous study [25] and the
cells were incubated for 24 h before cell lysis to measure cell proliferation and protein activities and
expression and to perform proteomic analysis. Cells lysis was carried out using 50 mM HEPES pH 7.5,
5 mM EDTA, 150 mM NaCl, 1% NP-40, a proteases inhibitor cocktail (#P8340, Sigma-Aldrich), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF, and 1mM Na3VO4. The lysates were incubated on
ice and vortexed for 15 s in four intervals of 5 min each. The samples were centrifuged at 13,000 rpm at
4 ◦C. The supernatants were collected for protein quantification and analysis.
2.3. Determination of Proliferation and Caspase-3 Activity Measurement
Cell proliferation was analyzed using a colorimetric ELISA (Roche Applied Science, Penzberg,
Germany). In total, 2 × 104 cells/cm2 were cultured in 96-well plates at 37 ◦C and 5% CO2. At the end of
the experiment, the cells were incubated with a 10 µM BrdU labelling solution for 6h at 37 ◦C following
the protocol recommended by the manufacturer. Caspase-3-associated activity was determined using
the peptide-based substrate Ac-DEVD-AFC (100 µM), as described elsewere [10].
2.4. SDS-PAGE and Western Blotting
The protein expression levels of Trx1, TrxR1, TXNIP, STAT3, pSTAT3, Akt1, pAkt, MAPK, and
pMAPK were determined by SDS-PAGE coupled to Western blotting analysis, following the same
procedure and using the same antibody dilutions as described before [10].
2.5. Silencing of Trx1
Human Trx1 was knocked down in HepG2, SNU423, and SNU475 cells using a pool of four
specific siRNA in 6-well plates (20,000 cells/cm2), according to the manufacturer’s recommendations
(Dharmacon, GE Healthcare Life Sciences) and as described before for HepG2 cells [10]. Non-targeting
negative controls were run. Silencing of Trx1 was always checked by Western blotting and activity
assay to confirm that its levels were reduced by ≈80%.
2.6. Redox Mobility Shift Assay
Detection of thiol redox changes in Akt, MAPK, and STAT3 proteins was performed by differentially
labeling reduced cysteines with 5 mM N-ethylmaleimide (NEM) and reversibly oxidized cysteines by
reduction with 5 mM tris (2-carboxyethyl) phosphine (TCEP), followed by labeling with 10 mM
4-acetamido-4’-maleimidylstilbene-2,2’-disulfonic acid (AMS) (Thermo Scientific Pierce), which
increases the molecular weight of the native protein by 536.44 Da. The protocol was the same
as described before [10].
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2.7. LC–MS/MS, Label-Free MS Protein Quantification, and Systems Analysis
Proteomic analyses were performed at the Proteomics Facility, University of Córdoba (SCAI).
The procedure started with a culture of 2 × 104 cells/cm2, and the protocol was the same as
described previously [26]. Peptides were scanned and fragmented with the Thermo Orbitrap Fusion
(Q-OT-qIT, Thermo Scientific) equipped with a nano-UHLC Ultimate 3000 (Dionex-Thermo Scientifics).
The analysis of MS raw data was performed using the MaxQuant (v1.5.7.0) software [27] and the
label-free quantification configuration described before [26]. Three RAW data files per sample from
three separate experiments were analyzed. Human UniProtKB/Swiss-Prot protein database (February
2018 version) was searched for protein identification as described before [26]. The method used for the
imputation of missing values was the mean imputation. Finally, only the conditions with 3 values per
identification were considered and analyzed through ANOVA and Tukey’s post-hoc tests. A protein
was considered differentially expressed if identified and quantified with at least 2 unique peptides and
had a fold change of at least 1.50 and p value ≤0.05.
The differentially expressed proteins together with the fold change values were analyzed with the
online IPA software package (Qiagen, version 48207413) and the open software DAVID [28]. For IPA,
each protein was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge.
The “core analysis” function was carried out considering direct and indirect relationships experimentally
observed in all mammalian tissues and species, as well as all node types, data sources, and mutations.
The list of significantly enriched canonical pathways, biological functions, and upstream factors is
presented together with the activation or inhibition z-score values in a scale of colors.
2.8. Statistical Analysis
Results are expressed as mean ± SD of data from ≥3 independent experiments. One-way ANOVA
with the least significant difference Tukey’s test as post-hoc multiple comparison analysis with a single
pooled variance was used for comparisons; output p value ranges were handled in GP style: 0.0332 (*),
0.0021 (**), 0.0002 (***), <0.0001 (****). The threshold for statistically significant differences was set at p
adjust ≤0.05 value.
3. Results
3.1. Tracing the Proteomic Signature of EMT in Human Hepatocarcinoma Cell Lines
A “label-free” quantitative proteomics analysis detected 1170 proteins with significant differences
between HepG2, SNU423, and SNU475 cell lines (Supplementary File S1). This is the first comparative
proteomic analysis carried out with these cell lines, and the results obtained for canonical markers
of EMT showed increasing and decreasing gradients, in agreement with the classification of these
human HCC cells as epithelial or mesenchymal [29,30]. These results strongly correlate with previous
microarray and Western blotting analyses of human HCC cell types [29,30] and constitute a definitive
proof of concept for our experimental approach. E-cadherin was not detected, likely because our
proteomic protocol was not optimized for membrane proteins. The members of the Trx system Trx1
and TrxR1 were also present in increasing levels from HepG2 to SNU475 cells (Figure 1), which agrees
with the role described for Trx1 as a pro-metastasis factor [31].
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SNU275 cells showed similar activation and inactivation trends in many processes, although these 
processes were affected to a lesser extent in SNU423 cells, in parallel to their degree of mesenchymal 
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two cell lines by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology 
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A system analysis of these 1170 differential proteins yielded significant enrichments in several
canonical pathways (Figure 2A; the identities of the proteins are shown in Supplementary File S1).
Integrin and actin cytoskeleton signaling, remodeling of epithelial adherent junction, and PI3K/Akt
signaling, which have been described as being involved in EMT, were activated. On the reverse side,
there was an overall inactivation of amino acid metabolism, fatty acid beta-oxidation, neurotransmitter
catabolism, glutathione metabolism, and oxido-reduction processes. SNU423 and SNU275 cells showed
similar activation and inactivation trends in many processes, although these processes were affected to
a lesser extent in SNU423 cells, in parallel to their degree of mesenchymal properties. System analysis
of 100 upregulated and 156 downregulated proteins common to the first two cell lines by Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) biological processes
using DAVID software confirmed and stressed these similarities (Figure S1). A search for upstream
regulators brought to light differences and commonalities (Figure 2B). To name a few, MYCN and MITF
transcription factors appeared to be activated in SNU423 but inactivated in SNU475 cells, whereas
HIF1A and the KDM5A histone H3 demethylase behaved in the opposite way.
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upregulated both by Sorafenib and by siRNATrx1, either independently or jointly, in all three cell 
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Figure 2. Systems Biology analysis of differential proteomic data from three HCC cell lines. Quantitative
data on protein levels in SNU423 and SNU475 cells relative to the levels in HepG2, the more differentiated
cell line, were analyzed. Up- and down-regulated proteins were analyzed using the IPA software
in terms of (A) canonical pathways based on the content of the Ingenuity Knowledge Base, and
(B) Upstream Regulator Analysis to identify the cascade of upstream transcriptional regulators
(see M&M Section 2.7 for more details). The degree of activation is represented in a color scale as
indicated. Red brackets have been added to highlight significant data commented on in the main text.
Altogether, these results identified a number of proteins and regulatory elements related to
de-differentiation of HCC cells that could be an interesting focus for further research.
3.2. The Trx/TrxR/TXNIP System is Highly Sensitive to Sorafenib Treatment in HCC Cell Lines
The basal levels of Trx1 and TrxR1 in control cells were markedly higher in m s nchymal SNU475
cells (Figure 1), but Sorafeni induced a significant decrease in their levels in ll HCC cell lines
(Figure 3A,B). TXNIP beh ved in a reciprocal manner relative to Trx1 and TrxR1. It was upregulated
both by Sorafenib and by siRNATrx1, either independently or jointly, in all th ee cell lines (Figure 3C).
These results indicate t t the downregulation of the Trx system is par of the antitumoral action
mechanism of Sorafenib and su port our hypothesis that co-treat ent with Trx1 inactivation adjuvants
would potentiate Sorafenib-based antitumoral therapy.
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experiments (N = 3) for each cell line were run in the same gel; protein levels between cells cannot be 
compared since each set of 3 replicas for each cell line was developed on a different WB membrane; 
for a comparison of Trx1, TrxR1 between cell lines, refer to quantitative proteomic data in Figure 1; a 
composition of representative blots is shown below each graph. p values 0.0332 (*), 0.0021 (**), 
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Sorafenib alone was very effective in SNU423 cells, inducing significant changes in 465 proteins, 
whereas in HepG2 and SNU475 cells, the number of proteins affected was restricted to only 23 and 
83, respectively (Figure 4A). The effect of siRNATrx1 alone was rather low in all three cell types, as 
should be expected since the effects of this antioxidant protein at the transcriptional regulatory level 
are limited. The cellular environment determined which proteins were affected by Trx1 
downregulation, since there were no common siRNATrx1 targets among the three cell lines, although 
most of the proteins affected did also change when siRNATrx1 treatment was combined with 
Sorafenib (Supplementary File S1). Interestingly, a very strong synergistic effect was observed when 
Sorafenib was applied to Trx1-downregulated SNU475 cells (Figure 4A). This synergistic effect was 
also observed in HepG2 cells, although to a lesser extent, but was absent in SNU423 cells. 
Figure 3. Response of the thioredoxin system to Sorafenib and siRNATrx1 treatments. Changes in
the levels of three components of the thioredoxin system, (A) Trx1, (B) TrxR1 and (C) TXNIP were
determined in HepG2, SNU423 and SNU475 cells by Western blotting with their specific antibodies on
treatment with Sorafenib or siRNATrx1 independently or combined under the conditions described in
M&M. Densitometric data normalized for ß-actin are shown; samples from 3 different experiments
(N = 3) for each cell line were run in the same gel; protein levels between cells cannot be compared since
each set of 3 replicas for each cell line was developed on a different WB membrane; for a comparison
of Trx1, TrxR1 between cell lines, refer to quantitative proteomic data in Figure 1; a composition of
representative blots is shown below each graph. p values 0.0332 (*), 0.0021 (**), 0.0002 (***), <0.0001 (****),
see Materials & Methods for statistical details.
3.3. The Effect of Sorafenib on the Global Proteome Depends on the Cell De-Differentiation Stage
Sorafenib alone was very effective in SNU423 cells, inducing significant changes in 465 proteins,
whereas in HepG2 and SNU475 cells, the number of proteins affected was restricted to only 23 and 83,
respectively (Figure 4A). The effect of siRNATrx1 alone was rather low in all three cell types, as should
be expected since the effects of this antioxidant protein at the transcriptional regulatory level are limited.
The cellular environment determined which proteins were affected by Trx1 downregulation, since
there were no common siRNATrx1 targets among the three cell lines, although most of the proteins
affected did also change when siRNATrx1 treatment was combined with Sorafenib (Supplementary
File S1). Interestingly, a very strong synergistic effect was observed when Sorafenib was applied to
Trx1-downregulated SNU475 cells (Figure 4A). This synergistic effect was also observed in HepG2
cells, although to a lesser extent, but was absent in SNU423 cells.
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and the number of proteins affected by individual Sorafenib and siRNATrx1 treatments. (B) Venn 
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indicated in the legend applies to (A) and (B). (C) Venn diagrams of proteins affected in each cell line 
by treatment. 
Altogether, these proteomic data indicate that Sorafenib is highly active in moderately 
differentiated tumor cells but it has a limited effect in Trx1-rich and poorly differentiated cells, unless 
the antioxidant thioredoxin-related signaling is weakened. Its action is minor in epithelial HepG2 
cells even in combination with Trx1 downregulation. 
A comparison of the Sorafenib and Trx1 silencing targets of each cell line (Figure 4C) highlighted 
the fact that there were no common targets between the se cell lines, suggesting that the effects of 
each treatment are dependent on the de-differentiation stage of HCC cell lines. However, there were 
12 common targets of the combined treatment in the three cell lines (Figure 4C and Figure 5). These 
common proteins are related to lipids biosynthesis, protein nuclear transport, and actin organization. 
The increasing degree of downregulation of most of these common proteins runs parallel to their 
degree of de-differentiation. 
Figure 4. Summary of the quantitative proteomic analysis of HCC cell lines subjected to Sorafenib
and/or siRNATrx1 treatments. (A) The total number of significantly (adjusted p ≤ 0.05) different proteins
(fold change ≥1.5 and ≤0.6) quantified upon each treatment relative to their controls; the numbers above
the brackets and thin lines are the “synergy factor” reached by siRNATrx1 and Sorafenib calculated
by the ratio between the number of proteins affected by the combined treatment and the number of
proteins affected by individual Sorafenib and siRNATrx1 treatments. (B) Venn diagrams of upregulated
and downregulated proteins by each treatment, by cell line; the color code indicated in the legend
applies to (A) and (B). (C) Venn diagrams of proteins affected in each cell line by treatment.
Altogether, these proteomic data indicate that Sorafenib is highly active in moderately differentiated
tumor cells but it has a limited effect in Trx1-rich and poorly differentiated cells, unless the antioxidant
thioredoxin-related signaling is weakened. Its action is minor in epithelial HepG2 cells even in
combination with Trx1 downregulation.
A comparison of the Sorafenib and Trx1 silencing targets of each cell line (Figure 4C) highlighted
the fact that there were no common targets between the se cell lines, suggesting that the effects of each
treatment are dependent on the de-differentiation stage of HCC cell lines. However, there were 12
common targets of the combined treatment in the three cell lines (Figures 4C and 5). These common
proteins are related to lipids biosynthesis, protein nuclear transport, and actin organization. The
increasing degree of downregulation of most of these common proteins runs parallel to their degree
of de-differentiation.
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solvent + Non-target siRNA are indicated in a color scale. Quantitative proteomic analysis as 
described in Materials and Methods (N = 3). Tenfold-change values correspond to proteins that were 
present in the controls but were not detected in the treated samples. 
System analysis of the proteomic data provided some clues about the differential effect of 
Sorafenib in each cell type (Figure 6). The only pathways altered by Sorafenib in SNU475 cells were 
those of IGF-1 and renin–angiotensin signaling, which appeared inactivated with the concomitant 
differential inactivation of several upstream regulators, i.e., NFE2L2, PDGF-B, a potent mitogen for 
cells of mesenchymal origin, XBP1, involved in the unfolded protein response (UPR), and Ige (Figure 
6). None of these pathways and upstream regulators were affected in SNU423 cells. 
Figure 5. Common target proteins of the Sorafenib + siRNATrx1 treatment. Twelve proteins that
changed significantly in HepG2, SNU423, and SNU475 cells are shown. A brief description of their
function was extracted from UniProt; fold changes relative to their respective controls treated with
solvent + Non-target siRNA are indicated in a color scale. Quantitative proteomic analysis as described
in Materials and Methods (N = 3). Tenfold-change values correspond to proteins that were present in
the controls but were not detected in the treated samples.
System analysis of the proteomic data provided some clues about the differential effect of Sorafenib
in each cell type (Figure 6). The only pathways altered by Sorafenib in SNU475 cells were those of
IGF-1 and renin–angiotensin signaling, which appeared inactivated with the concomitant differential
inactivation of several upstream regulators, i.e., NFE2L2, PDGF-B, a potent mitogen for cells of
mesenchymal origin, XBP1, involved in the unfolded protein response (UPR), and Ige (Figure 6). None
of these pathways and upstream regulators were affected in SNU423 cells.
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affected by Sorafenib treatment alone were analyzed using the IPA software in terms of canonical 
pathways, upstream regulators, and biofunctions as indicated, in the three cell lines studied. Brackets 
and arrow highlight elements that are commented on in the main text. 
Pathways affected by Sorafenib solely in SNU423 cells were those related to integrin and EIF2 
signaling, oxidative phosphorylation, and phosphoinositol metabolism, which were inactivated, and 
to sumoylation and sirtuin, which were activated (Figure 6). In parallel with these changes, a set of 
upstream regulators were uniquely either inactivated—IL4, SREBF2, NRF1, FOXO1, EGFR, MTOR, 
MYCN—or activated—KDM5A histone H3 demethylase, KLF3, and PDGF, to name the most 
relevant. 
Despite the striking differential outcomes of Sorafenib treatment between SNU423 and SNU475 
cells in terms of pathways and number of proteins affected, several upstream regulators responded 
equally to Sorafenib in both cell types. Briefly, MAP4K4 and the protein PML, which is regulated by 
sumoylation, were activated, whereas MYC, E2F1, the growth enhancer and cysteine-rich receptor 
tyrosine-protein kinase ERBB2, which interacts with STAT3, the steroid regulatory element-binding 
factor 1 SREBF1, and the insulin receptor tyrosine kinase INSR were inactivated. TGFB1, the main 
inducer of EMT [4], was the only regulator affected in all the cells and was inactivated even in HepG2. 
3.4. The Alteration of the Global Proteome by Sorafenib in Human HCC Cell Lines at Different De-
Differentiation Stages is Conditioned by Trx1 Downregulation 
The number of new proteins affected by Sorafenib under conditions of Trx1 downregulation was 
81, 133, and 679 in HepG2, SNU423, and SNU475 cells, respectively (Figure 4B). GO terms enrichment 
analysis of these newly affected sets of proteins with DAVID software revealed some common 
biological processes affected in the three cell lines: cholesterol and isoprenoid metabolism, cell–cell 
adhesion, and proteostasis. 
Figure 6. Enrichment analysis of proteins affected by Sorafenib treatment in each cell line. Proteins
affected by Sorafenib treatment alone were analyzed using the IPA software in terms of canonical
pathways, upstream regulators, and biofunctions as indicated, in the three cell lines studied. Brackets
and arrow highlight elements that are commented on in the main text.
Pathways affected by Sorafenib solely in SNU423 cells were those related to integrin and EIF2
signaling, oxidative phosphorylation, and phosphoinositol metabolism, which were inactivated, and
to sumoylation and sirtuin, which were activated (Figure 6). In parallel with these changes, a set of
upstream regulators were uniquely either inactivated—IL4, SREBF2, NRF1, FOXO1, EGFR, MTOR,
MYCN—or activated—KDM5A histone H3 demethylase, KLF3, and PDGF, to name the most relevant.
Despite the striking differential outcomes of Sorafenib treatment between SNU423 and SNU475
cells in terms of pathways and number of proteins affected, several upstream regulators responded
equally to Sorafenib in both cell types. Briefly, MAP4K4 and the protein PML, which is regulated by
sumoylation, were activated, whereas MYC, E2F1, the growth enhancer and cysteine-rich receptor
tyrosine-protein kinase ERBB2, which interacts with STAT3, the steroid regulatory element-binding
factor 1 SREBF1, and the insulin receptor tyrosine kinase INSR were inactivated. TGFB1, the main
inducer of EMT [4], was the only regulator affected in all the cells and was inactivated even in HepG2.
3.4. The Alteration of the Global Proteome by Sorafenib i Human HCC Cell Lines a Diff rent
De-Differentiation Stages is Conditioned by Trx1 Downregulation
The number of new proteins affected by Sorafenib under conditions of Trx1 downregulation was
81, 133, and 679 in HepG2, SNU423, and SNU475 cells, respectively (Figure 4B). GO terms enrichment
analysis of thes newly affected sets of proteins with DAVID software revealed some common biologic l
processes affected in the three cell lines: cholestero and isoprenoid metabolism, cell–cell adhesio ,
d proteostasi .
An ysis of the set of proteins affected in SNU475 c lls under the combined treatment reveal d
the target pathways (Figure 7). The general trend was inactivation of most pathways (actin, integrin,
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14-3-3-mediated signaling, PI3K/Akt, sirtuin, mTOR, ILK, EIF2 signaling pathways, glycolysis,
gluconeogenesis, and pentose phosphate pathway), except for two pathways that were activated:
HIPPO and RhoGDI signaling (Figure 7). Despite the profound effect of the Sorafenib+siRNATrx1
treatment on the proteome and pathways of SNU475 cells, only a small number of transcriptional
regulators was markedly affected, with TGFB1 inactivation standing out. These changes were paralleled
at the level of diseases and biofunctions by the inactivation of cytoskeleton organization, tumoral cell
movement, migration, invasion, viability, and survival, and by the activation of cell death (Figure 7)
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Activation of the HIPPO signaling pathway by the combined treatment of Sorafenib and 
siRNATrx1 would restrict cell proliferation and promote differentiation to cell death [32]. 
3.5. Effect of Sorafenib and Trx1-Silencing on Proliferation and Apoptosis in Three HCC Cell Lines 
Proliferation under basal conditions was higher in HepG2 cells. Sorafenib and siRNATrx1, either 
individually or combined, had a significant, non-additive, negative effect on cell proliferation, as 
determined by BrdU incorporation (Figure 8A). The effect of Sorafenib was lower in SNU423 cells, 
despite the thorough change induced on the proteome (Figure 4). 
Figure 7. Enrichment analysis of proteins affected by combined treatment of Sorafenib and siRNATrx1
in SNU475 cells. In total, 761 proteins differentially quantified in SNU475 cells upon the combined
treatment of Sorafenib and siRNATrx1 were analyzed using the IPA software by canonical pathways,
transcriptional factors, and biofunctions. The enrichment results are indicated in colored scale in the
right column (“Treated”) in each panel; the left column, headed “Basal”, shows the proteomic signature
of SNU475 cells obtained by reference to HepG2 cells in the absence of treatment.
Activation of the HIPPO signaling pathway by the combined treatment of Sorafenib and siRNATrx1
would restrict cell proliferation and promote differentiation to cell death [32].
3.5. Effect of Sorafenib and Trx1-Silencing on Proliferation and Apoptosis in Three HCC Cell Lines
Proliferation under basal conditions was higher in HepG2 cells. Sorafenib and siRNATrx1, either
individually or combined, had a significant, non-additive, negative effect on cell proliferation, as
determined by BrdU incorporation (Figure 8A). The effect of Sorafenib was lower in SNU423 cells,
despite the thorough change induced on the proteome (Figure 4).
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Figure 8. Proliferation and apoptosis of HCC cell lines subjected to Sorafenib and/or siRNATrx1 
treatments. (A) Proliferation as determined by BrdU incorporation into DNA and (B) caspase-3 
activity determined by fluorescence using a specific peptide substrate. Three different experiments 
(N = 3) for each cell line. p values 0.0332 (*), 0.0021 (**), 0.0002(***), <0.0001 (****), see Materials & 
Methods for statistical details. 
Regarding apoptosis (Figure 8B), Trx1 downregulation induced a significant increase in caspase-
3 activity in all three cell types, which was inversely proportional to the basal levels of Trx1: 
prominent in HepG2 cells, as described previously [10], but subtle in SNU423 and SNU475. The effect 
of Sorafenib alone was slightly significant in SNU423 cells but was markedly enhanced by Trx1 
silencing. Again, the enhancing effect was especially prominent in HepG2 cells (Figure 8B). 
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death in SNU423 and SNU475 cells (Figure 6). Regulated cell death can proceed by mechanisms 
different from apoptosis and it has been described that Sorafenib induces cell death by ferroptosis in 
hepatocarcinoma cell lines [33]. 
3.6. Sorafenib Reductive Effect on the Thiol Redox State of Akt, MAPK, and STAT3 Is General but the 
Counteracting Action of Trx1 Knock-Down is Specific for STAT3 
Systems biology analysis of our proteomic data indicated activation of PI3K/Akt signaling in 
SNU423 and SNU475 cells (Figure 2), but, surprisingly, no significant changes were observed in the 
ratio between phosphorylated and dephosphorylated Akt, MAPK, and STAT3 in all three cell lines 
(Figure 9A,D,F). However, Sorafenib treatment provoked a prominent thiol reductive change in Akt, 
Ser473Akt, MAPK, and STAT3 in all three cell types that was higher for Akt and Ser473Akt in SNU475 
cells (Figure 9B,C,E,G). This may be indicative of predominance of redox changes over 
phosphorylation changes regarding the action of Sorefenib on these signaling pathways. This 
reductive thiol redox change was insensitive to siRNATrx1, except for STAT3 for which it was totally 
blunted by Trx1 downregulation (Figure 9G). The involvement of Trx1 in thiol redox changes of 
STAT3 agrees with the report of the formation of Trx1–STAT3 disulfide exchange intermediates [14], 
suggesting that Trx1 may be a direct mediator of STAT3 disulfide reduction. 
Proliferati and apoptosis of HCC ce l lines subj t to Sorafe i / si
at ents. (A) Proliferation as determined by BrdU incorporati n into DNA and (B) caspase-3 activity
de ermined by fluorescence using a specific pe tide substrate. Three different xperiments (N = 3) for
each cell lin . p values 0.0332 (*), 0.0021 (**), 0. 002 (** ), < . 01 ( **), see Materials & ethods for
statistical details.
Regarding apoptosis (Figure 8B), Trx1 downregulation induced a significant increase in caspase-3
activity in all three cell types, which was inversely proportional to the basal levels of Trx1: prominent
in HepG2 cells, as described previously [10], but subtle in SNU423 and SNU475. The effect of Sorafenib
alone was slightly significant in SNU423 cells but was markedly enhanced by Trx1 silencing. Again,
the enhancing effect was especially prominent in HepG2 cells (Figure 8B).
It see s that the ore epithelial HepG2 cells have a progra ed cell death response to Sorafenib
under Trx1 do n-regulation ai ed at tissue survival, but this response echanis see s to be
i paired in the ore esenchy al cells. The proteo ic data showed a decrease in proteins involved
in cell proliferation, survival, invasiveness and igration but an increase in proteins involved in cell
death in S U423 and S U475 cells (Figure 6). Regulated cell death can proceed by echanis s
different fro apoptosis and it has been described that Sorafenib induces cell death by ferroptosis in
hepatocarcino a cell lines [33].
3.6. Sorafenib Reductive Effect on the Thiol Redox State of Akt, MAPK, and STAT3 Is General but the
Counteracting Action of Trx1 Knock-Down is Specific for STAT3
Systems biology analysis of our proteomic data indicated activation of PI3K/Akt signaling in
SNU423 and SNU475 cells (Figure 2), but, surprisingly, no significant changes were observed in the
ratio between phosphorylated and dephosphorylated Akt, MAPK, and STAT3 in all three cell lines
(Figure 9A,D,F). However, Sorafenib treatment provoked a prominent thiol reductive change in Akt,
Ser473Akt, MAPK, and STAT3 in all three cell types that was higher for Akt and Ser473Akt in SNU475
cells (Figure 9B,C,E,G). This may be indicative of predominance of redox changes over phosphorylation
changes regarding the action of Sorefenib on these signaling pathways. This reductive thiol redox
change was insensitive to siRNATrx1, except for STAT3 for which it was totally blunted by Trx1
downregulation (Figure 9G). The involvement of Trx1 in thiol redox changes of STAT3 agrees with the
report of the formation of Trx1–STAT3 disulfide exchange intermediates [14], suggesting that Trx1 may
be a direct mediator of STAT3 disulfide reduction.
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Materials and Methods; samples from three different experiments (N = 3) for each cell line were run 
in the same gel; protein levels cannot be compared between cells. p values 0.0332 (*), 0.0021 (**), 
0.0002(***), see Materials & Methods for statistical details. (A) Ratio of Ser473pAkt/Akt; (B) and (C) thiol 
redox changes of Ser473pAkt and Akt; (D) and (E) phosphorylation and redox changes, respectively, of 
MAPK; the same is shown for STAT3 in (F) and (G). 
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Nowadays, however, two-thirds of patients are diagnosed in more advanced stages of the disease 
[35], urgently requiring new effective and safe drugs. The transition from well-differentiated 
carcinoma to poorly differentiated invasive carcinoma is a predominant event in the aggressive 
tumor progression of human HCC. Actually, EMT has been linked to tumor cell invasion and 
metastasis [36]. 
We made the first comparative characterization of EMT at the level of expressed proteins in three 
hepatocarcinoma cell lines, HepG2, SNU423, and SNU475, that present markers indicative of a 
gradual transition from epithelial to mesenchymal characteristics. A global proteome analysis of 
these cell lines revealed a thorough change in metabolic processes, consistent with the fact that 
mesenchymal cells have different metabolic needs compared to epithelial cells, in part because of 
their motility and invasiveness. Metabolic reprogramming upon EMT in different types of cancer 
cells is complex and controversial [37], but mitochondrial dysfunction has been widely linked to 
aggressiveness of cancer and activation of EMT. The finding of a significant decrease in succinate 
dehydrogenase (SDH) and isocitrate dehydrogenase (IDH) in the Tricarboxylic Acid Cycle (TCA) 
Figure 9. Phosphorylation and thiol redox state of key signaling elements in HCC cell lines treated with
Sorafenib and/or siRNATrx1. The phosphorylated/unphosphorylated ratios of the indicated proteins
were calculated from the densitometric quantitation data of each form normalized for ß-actin. The
ratio Red/Ox reflects the thiol redox state and was calculated from the densitometric data of the bands
obtained by the “thiol redox electrophoretic mobility shift assay” as described in Materials and Methods;
samples from three different experiments (N = 3) for each cell line were run in the same gel; protein
levels cannot be compared between cells. p values 0.0332 (*), 0.0021 (**), 0.0002 (***), see Materials &
Methods for statistical details. (A) Ratio of Ser473pAkt/Akt; (B,C) thiol redox changes of Ser473pAkt and
Akt; (D,E) phosphorylation and redox changes, respectively, of MAPK; the same is shown for STAT3
in (F,G).
4. Discussion
4.1. Proteomic Changes during EMT
The current curative treatments of HCC are indicated during the early stages of the disease [34].
Nowadays, however, two-thirds of patients are diagnosed in more advanced stages of the disease [35],
urgently requiring new effective and safe drugs. The transition from well-differentiated carcinoma to
poorly differentiated invasive carcinoma is a predominant event in the aggressive tumor progression
of human HCC. Actually, EMT has been linked to tumor cell invasion and metastasis [36].
We made the first co parative characterization of EMT at the level of expressed proteins in
three hepatocarcinoma cell lines, HepG2, SNU423, and SNU475, that present markers indicative
of a gradual transition from epithelial to mesenchymal characteristics. A global proteome analysis
of these cell lines revealed a thorough change in metabolic processes, consistent with the fact that
mesenchymal cells have different metabolic needs compared to epithelial cells, in part because of
their motility and invasiveness. Metabolic reprogramming upon EMT in different types of cancer
cells is co plex and controversial [37], but mitochondrial dysfunction has been widely linked to
aggressiveness of cancer and activation of EMT. The finding of a significant decrease in succinate
dehydrogenase (SDH) and isocitrate dehydrogenase (IDH) in the Tricarboxylic Acid Cycle (TCA) cycle
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in the most de-differentiated SNU475 cells (Supplementary File S1), together with a specific activation
of a few upstream regulators, including SNAI1 (Figure 2B), agrees with the report that silencing or
mutation of both enzymes promoted cell migration and invasion in different types of cancer cells
mediated by TGF-ß/SNAI1 [38,39].
Altogether, this first characterization of EMT at a proteome level should help to focus research on
events that occur when cancer cells acquire their metastatic and invasive potential and would help in
the design of therapies for advanced HCC.
4.2. Effect of Trx1 Downregulation on Sorafenib Antitumoral Treatment
Our data show that Sorafenib downregulates specific EMT-related pathways like integrin
signaling. However, we found that its proteomic reprogramming capacity is prominent in moderately
differentiated SNU423 cells but limited in poorly differentiated SNU475 cells, which represent the most
advanced stage of the disease.
Interestingly enough, weakening cell antioxidant defenses by Trx1 downregulation exerted a
marked synergistic effect on proteomic rearrangement in Sorafenib-treated SNU475 cells (Figure 4).
Sorafenib itself had a down-regulatory effect on the Trx/TrxR1 system and an up-regulatory effect
on TXNIP in all three cell types (Figure 3) but only triggered an extensive proteomic reprograming
in SNU423, where the basal levels of Trx1/TrxR1 are lower and those of TXNIP might be higher
(Figures 1 and 3). However, additional Trx1 downregulation exerted an adjuvant effect that dramatically
expanded the action of Sorafenib in SNU475 cells where the basal Trx1/TrxR1 levels are higher and
those of TXNIP might be lower. The effect was minor in HepG2 cells.
Although the general significance of these in vitro data in the context of cancer treatment is
limited, they strongly support the importance of an anticancer therapy based on a combined treatment
of Sorafenib with inhibitors of the Trx system or other prooxidant agents for advanced HCC and
encourage the undertaking of further research on this ground.
Few common target proteins were identified in the three cell lines (Figure 4C), likely as a
consequence of differences in their cell de-differentiation staging, though several commonalities were
obvious at the level of upstream regulators that were affected. A careful characterization of these few
common targets may lead to the discovery of true markers for diagnostic and therapeutic purposes.
At this point, it is worth mentioning that Protein Phosphatase 1 Regulatory Subunit 14B (PPP1R14B)
disappeared from the three cell lines after the Sorafenib + siRNATrx1 combined treatment. PPP1R14B
interacts with ROCK2 (“IntAct” EBI-7009696), which is a key regulator of the actin cytoskeleton and cell
polarity and is one of the most highly overexpressed phosphatase-related proteins in triple-negative
breast cancer (TNBC), which has the worst prognosis among all breast cancers [40].
The only pathway clearly activated by co-treatment was HIPPO signaling, which promotes
cell differentiation and contact inhibition of cell proliferation and plays a central role in regulating
organ growth and regeneration [32]. It is a critical regulator of liver growth and a potent suppressor
of liver tumor formation [41]. Activation of HIPPO signaling by Sorafenib treatment under Trx1
downregulation in poorly differentiated SNU475 HCC cells might impact on the alleviation of EMT and
cancer malignancy. To dig deeper into the mechanism, it would be worth checking for possible thiol
redox changes in members of the HIPPO signaling pathway that have been reported to be sensitive to
the redox environment [42,43].
4.3. Involvement of the Trx1-Dependent Thiol Redox State of Key Signaling Pathways
Sorafenib and Trx1 downregulation had a significant negative effect on the proliferation in HCC
cell lines independently of their degree of de-differentiation, although their effects were not additive
(Figure 8A). Regarding cell death, Trx1 knock-down induced apoptosis in all three cell lines, but the
effect was prominent only in differentiated HepG2 cells. The effect of Sorafenib alone was negligible
in either cell type, but Sorafenib combined with Trx1 downregulation had a marked pro-apoptotic
effect, particularly in HepG2 cells (Figure 8B) and also appreciable in SNU475 cells (Figures 7 and 8B,
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biofunctions). It seems that the ability of HCC cells to trigger a pro-apoptotic response to Trx1
downregulation and to Sorafenib treatment declines as their basal Trx1 levels and their degree of
de-differentiation increase.
The phosphorylation states of Akt, MAPK, and STAT3 were not altered by Sorafenib and/or
siRNATrx1 treatments. However, Sorafenib induced a thiol reductive burst that was independent
of Trx1 in the case of Akt and MAPK but was totally abolished by Trx1 downregulation in the case
of STAT3. These results provide further insight into the importance of redox homeostasis in the
mechanism of Sorafenib action and suggest that Sorafenib might protect Akt from PPA2 inactivation
by inducing a thiol reductive change, particularly in SNU475 cells. The lack of sensitivity of the thiol
redox state of Akt to Trx1 downregulation indicates that this redox change could be mediated by the
glutathione system, as had also been previously pointed out in HepG2 cells [10].
Thiol reductive changes in MAPK were also independent of Trx1 silencing but were coincident
with the activation of MAP4K4 detected in SNU423 and SNU475 cells treated with Sorafenib alone
(Figure 6). The strong enhancing effect of Trx1 silencing on the action of Sorafenib at the proteome
level in the poorly differentiated SNU475 cells did not seem to be mediated by phosphorylation or
redox changes of Akt and MAPK in the studied cell lines.
Reactive Oxygen Species (ROS) induce tyrosine phosphorylation by inactivation of tyrosine
phosphatases and upregulate the DNA binding activity of STAT3 [44]; however, ROS could also induce
oxidation of conserved cysteines, impeding STAT3 transcriptional activity [45]. The mechanism of this
redox regulation in HepG2 cells involves glutathionylation of STAT3 at Cys328 or Cys542, which are
within the DNA-binding domain and the linker domain, respectively, and would affect STAT3 activity
under oxidative stress, even when it is phosphorylated at Tyr705 [46,47]. The formation of Trx1–STAT3
disulfide exchange intermediates has been reported, suggesting that Trx1 may be a direct mediator of
STAT3 disulfide reduction [14]. The activity of STAT3 must have been affected by the observed redox
changes, despite the lack of differences in the degree of phosphorylation, and could have played a role
in the response of SNU475 cells to the combined Sorafenib+siRNATrx1 treatment.
Combined treatments of Sorafenib with other agents have been reported. For instance, its
combination with metformin downregulated the expression of Trx1 and improved the efficacy of
Sorafenib in the treatment of HCC, decreasing tumor invasiveness and cell motility [31], while its
combination with tetrandrine was described to induce apoptosis through ROS/Akt signaling in human
HCC [48].
5. Conclusions
The proteomes of the three HCC cell lines studied reveal differences in proteins involved in
motility and invasiveness, coherent with their EMT markers outfit. The present study shows that
Sorafenib treatment induces the highest proteomic reprogramming in SNU423 cells whose Trx1/TrxR1
levels are lower and TXNIP levels are higher. However, its effect was limited in poorly-differentiated
HCC SNU475 cells, which are expected to be present at high proportion in the advanced stage of the
disease and whose basal Trx1/TrxR1 levels are high. However, application of Sorafenib combined with
Trx1 knock-down, dramatically enhances proteomic rearrangement, including inactivation of TGFß
and activation of HIPPO signaling, accompanied by thiol oxidative changes in STAT3. Combination of
Sorafenib with thioredoxin inhibitors should be taken into account in the design of anticancer therapies
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/8/10/501/s1,
Figure S1: System analysis of differential proteins common to SNU423 and SNU475 cells. (A) Proteins upregulated
or downregulated in both cell lines relative to HepG2 cells; (B) common proteins from each set were analyzed
for enrichment by KEGG pathways and GO biological processes using DAVID software; number of proteins on
the right side of the bars refers to the number of proteins clustered in each term; adjusted p value is shown on
the horizontal axis in a logarithmic scale for statistical significance; Supplementary File S1. Excel file showing
the results of quantitative proteomic analysis of HepG2, SNU423, and SNU475 cells. The 1st, 2nd, and 3rd sheets,
(“HepG2 treatments”, “SNU4232 treatments”, and “SNU475 treatments”) show protein ID, number of unique
peptides, and protein name in columns A–C. Columns D–O show the normalized abundance for each of three
replicates of untreated (“control”), Sorafenib-treated (“Sorab”), siRNATrx1-treated (“Trx1”), and Sorafenib +
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siRNATrx1 combined treatment (“ST”); columns P–U show the abundance fold change (“FC”) relative to the
control and their respective statistical significance (p-values, a value of “1” means not significant FC). In the 4th
sheet, (“Cell lines”), columns A–D show protein ID, protein name, gene name, and number of unique peptides;
columns E–M show the normalized abundance for each of three replicates of untreated HepG2 cells (“HepG2”),
SNU423 cells (“S3”), and SNU475 cells (“S5”); columns N–Q show the protein abundance fold change of SNU423
and SNU475 cells (“FCS3_HepG2” and “FCS5_HepG2”) relative to HepG2 together with the statistical significance
index (p value). A value of “1” means not significant FC.
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a b s t r a c t
Nitric oxide (NO) plays relevant roles in signal transduction in physiopathology and its effects are de-
pendent on several environmental factors. NO has both pro-apoptotic and anti-apoptotic functions but
the molecular mechanisms responsible for these opposite effects are not fully understood. The action of
NO occurs mainly through redox changes in target proteins, particularly by S-nitrosylation of reactive
cysteine residues. Thioredoxin (Trx) and glutaredoxin (Grx) systems are the main cellular controllers of
the thiolic redox state of proteins exerting controversial effects on apoptosis with consequences for the
resistance to or the development of cancer.
The aim of this study was to ascertain whether Trx and/or Grx systems mediate the antiproliferative
effect of NO on hepatoblastoma cells by modulating the redox-state of key proteins.
Proliferation decreased and apoptosis increased in HepG2 cells overexpressing Nitric Oxide Synthase-
3 (NOS-3) as a result of multilevel cellular responses to the oxidative environment generated by NO.
Enzyme levels and cysteine redox state at several metabolic checkpoints were consistent with promi-
nence of the pentose phosphate pathway to direct the metabolic ﬂux toward NADPH for antioxidant
defense and lowering of nucleotide biosynthesis and hence proliferation. Proteins involved in cell sur-
vival pathways, proteins of the redoxin systems and phosphorylation of MAPK were all signiﬁcantly
increased accompanied by a shift of the thiolic redox state of Akt1, Trx1 and Grx1 to more oxidized.
Silencing of Trx1 and Grx1 neutralized the increases in CD95, Akt1 and pAkt levels induced by NO and
produced a marked increase in caspase-3 and -8 activities in both control and NOS-3 overexpressing cells
concomitant with a decrease in the number of cells.
These results demonstrate that the antiproliferative effect of NO is actually hampered by Trx1 and
Grx1 and support the strategy of weakening the thiolic antioxidant defenses when designing new an-
titumoral therapies.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Nitric oxide (NO) is a very small, lipophilic, readily diffusible,
chemically unstable molecule with a very short half-life (seconds)
that plays a relevant role in signal transduction in physiopathology
such as vasodilation, respiration, cell migration, immune response
and apoptosis [1]. NO is known to be synthesized in a large
number of different tissues by the NO synthases (NOS) using L-
arginine as substrate. Three different isoforms of NOS have been
identiﬁed, products of different genes, with different localization,
regulation, catalytic properties and inhibitor sensitivity [2]. Their
expression and activity are cellular and tissue speciﬁc with dif-
ferential regulation at transcriptional, translational and post-
translational levels [3,4]. These isoforms in mammals are: neuro-
nal NOS (nNOS or NOS-1), inducible NOS (iNOS or NOS-2) and
endothelial NOS (eNOS or NOS-3) [5–8]. The NOS-1 and NOS-3
isoforms are constitutively expressed and can be activated as a
result of calmodulin (CaM) binding following a rise in intracellular
calcium, and also by phosphorylation/dephosphorylation mod-
iﬁcations. The expression of NOS-2 isoform is induced by in-
ﬂammatory stimuli and is maximally activated by Ca2þ/CaM even
at basal levels of intracellular Ca2þ [1,2,9]. The intracellular loca-
lization is relevant for the activity of NOS and accumulating evi-
dence indicates that NOSs are subject to speciﬁc targeting to
subcellular compartments (plasma membrane, Golgi, cytosol, nu-
cleus and mitochondria) and that this trafﬁcking is crucial for NO
production and speciﬁc posttranslational modiﬁcations of target
proteins [10–12].
NO can have opposite biological effects, depending on their
local concentration, the target cell type involved and the levels of
reactive oxygen species (ROS). The role of NO as a bioregulator of
apoptosis is well established, having both antiapoptotic and
proapoptotic functions [13]. The molecular mechanisms re-
sponsible for its opposite effect are not fully understood but there
is strong evidence indicating the involvement of redox changes in
key proteins [14].
The cellular redox state plays a critical role in regulating many
signaling pathways including activation, differentiation, prolifera-
tion, and apoptosis [15–17]. ROS and reactive nitrogen species
(RNS), cause irreversible damage when their amounts exceed the
cellular antioxidant defense capacity, and are harmful to biomo-
lecules, including genomic and mitochondrial DNA, membrane
lipids and proteins. But they can also lead to reversible oxidations
that play regulatory roles of protein function. Within proteins, the
thiol group (–SH) of cysteine (Cys) can be oxidized in several ways:
two thiols can form a disulﬁde bond as in some proteins (PSSP), or
mixed disulﬁde in glutathionylated proteins (PSSG). Additionally,
cysteine can be reversibly oxidized by ROS or RNS to sulfenic acid
(–SOH) and nitrosothiol (–SNO). The nitrosylation of reactive cy-
steine residues in proteins takes part in NO signaling processes
and can affect a multitude of intracellular events, beneﬁcial or
harmful, depending upon biological context [18–22].
The redox states of Cys residues are controlled by two major
cellular systems, the Trx/thioredoxin reductase system and the
glutathione (GSH)/Grx system [15,23,24]. The Trx system consists
of redox active Trx, thioredoxin reductase (TrxR) and NADPH,
which are critical for maintaining DNA synthesis and the cellular
redox balance. Human Trx1 and TrxR1 are located in cell cytosol/
nucleus. The Grx system consists of Grx, GSH and NADPH-de-
pendent glutathione reductase. Human Grx1 is located in the cy-
tosol [25] and is involved in redox-regulation through the reduc-
tion of protein disulﬁdes and mixed disulﬁdes, e.g. deglutathio-
nylation of proteins [24,26].
A relationship exists between redoxins levels and apoptosis
with consequences for the resistance or the development of can-
cer. As an antioxidant system Trx/TrxR catalyzes the
denitrosylation of SNO-caspase-3 [27] and some experimental
data suggested that it also participates in the denitrosylation of
SNO-caspase-9 and the reductive reactivation of caspase-8 [28].
But as a pro-oxidant Trx has been described trans-nitrosylating
and inactivating caspase-3 thus showing an anti-apoptotic action
[29].
It has been shown that Trx1 and TrxR1 are often overexpressed
in tumor cells and that high Trx could be linked to drug resistance
during cancer treatment [30]. Other studies suggest that high Trx
and TrxR may induce apoptosis and reduce the mitotic index of
certain tumors linked to p53 dependent cell death [31]. Reduced
Trx is a negative regulator of ASK1 (apoptotic-inducing kinase),
which relates the Trx system to evasion of apoptosis [32]. Another
apoptosis-regulatory enzyme whose nitrosylation status is re-
versibly regulated by Trx1 is glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) [33]. Because reduced Trx1 plays a critical role
in cellular proliferation and viability, excessive oxidation of Trx
will lead to cell death [30,34].
On the other hand, Grx1 plays an important role in protecting
cells from apoptosis by regulating the redox state of Akt1, also
called protein kinase B (PKB), that has consequences for cell sur-
vival and also affect the multiple roles played by Akt1, as in the
Akt-mTOR signaling cascade [35]. Mitochondrial Grx2 also exerts a
protective effect on mitochondrial mediated apoptosis, preventing
cardiolipin oxidation and cytochrome c release [36].
The intracellular mechanism regulating cell death and cell
proliferation are intimately connected and different studies have
shown that NO production has an important role in the regulation
of the carcinogenic process. For instance, S-nitrosylation of some
proteins, such as GAPDH and CD95, stimulates apoptosis whereas
S-nitrosylation of other proteins, such as caspases and Bcl-2, in-
hibits apoptosis [33]. NO exerts an antineoplastic effect in tumoral
cells by increasing cell death [37] and a speciﬁc pattern of S-ni-
trosylation has been observed during induction of apoptosis in
hepatocytes [38].
The role of antioxidants in cancer has been controversial for
decades. On one hand, ROS could mediate the activation of mul-
tiple signaling cascades that promote cell proliferation and on the
other hand, the consequent increase in oxidative stress could
cause senescence or apoptosis and became a tumor suppressor.
Recent evidence indicates that antioxidants such as GSH and Trx
can actually contribute to tumorigenesis by preventing ROS accu-
mulation in cancer cells. The cellular response will depend on the
levels of ROS and antioxidant status in the cell [31,39,40].
The main objective of this study was to ascertain whether Trx
and/or Grx systems mediate the antiproliferative effect of NO on
hepatoblastoma cells by modulating the redox-state of key pro-
teins. We demonstrate that Trx1 and Grx1 behave differentially
depending on the intracellular oxidative/nitrosative stress in
HepG2 cells. They are required for proliferation but they also
contribute to the antiproliferative effect of NO, associated with
Akt1 redox changes.
2. Material and methods
2.1. Materials
All reagents were of analytical grade and were purchased from
Sigma, unless otherwise speciﬁed.
HepG2 cell line used in this work was obtained from ATCC LGC
Standards Company (Teddington, UK). Cell culture dish and ﬂasks
were from TPP (Switzerland). Anti-Trx1 and anti-Grx1 were ob-
tained from rabbit in our laboratory. Antibodies against STAT3,
MAPK, Thr202/Tyr204p-MAPK (p-MAPK) and Ser473p-Akt (p-Akt)
were from Cell Signaling Technology. Antibodies against ACO1 and
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UROD were from Aviva Systems Biology (San Diego, CA, USA).
Antibodies against ACO2, TKT, TXNIP, Akt1, MATII, Bcl2, PKM2,
caspase-3, CD95, NOS-3 and β-actin were from Santa Cruz Bio-
technology, Inc. (Dallas, TX, USA). Anti-TrxR1 was from Abcam, Inc.
Secondary antibodies were from Sigma. ECL was from GE
Healthcare (Wauwatosa, Wisconsin, USA). Caspase substrates Ac-
DEVD-AFC, Ac-LETD-AFC and Ac-LEHD-AFC were from Alexis
Biochemicals (Enzo Life Sciences, Farmingdale, NY, USA). DNAse I
was from Ambion Life Technologies, Inc. (Foster City, California).
siRNA for Grx1 and Trx1, and DharmaFECT 1 were from GE
Healthcare Dharmacon, Inc. (Wauwatosa, Wisconsin, USA).
2.2. Cell growth conditions
HepG2 cells were transfected with the pcDNA/4TO (5100 bp;
Invitrogen, Molecular Probes, Inc.) expression vector containing
NOS-3 cDNA sequence (3462 bp; NCBI, ImaGenes, full length cDNA
clone sequence BC063294) under the control of the cytomegalo-
virus promoter (4TO-NOS). Cell lineages 4TO and 4TO-NOS were
selected with zeocin (15 mg/L; Invitrogen) as described by Gon-
zález et al. [37]. Cells were maintained in EMEM Medium (Mini-
mum Essential Medium Eagle), pH 7.4, supplemented with 10%
fetal bovine serum, 2.2 g/L HCO3Na, 1 mM sodium pyruvate, 100 U/
L penicillin, 100 μg/mL streptomycin, 0.25 μg/mL amphotericin,
and the corresponding selective zeocin antibiotic in 5% CO2 at-
mosphere at 37 °C. The experiments were routinely carried out at
100,000 cells/cm2. Cell extracts were obtained using lysis solution
containing 50 mM HEPES (pH 7.5), 2 mM EDTA, 100 mM NaCl, 0.6%
Nonidet NP-40, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF),
5 μg/mL aprotinin, 10 μg/mL leupeptin. Afterward, samples were
homogenized and centrifuged at 15,000 g for 5 min at 4 °C and the
supernatant was stored at 80 °C until use.
2.3. Assay of enzymatic activities
Grx activity was determined spectrophotometrically by mea-
suring the reduction of 0.5 mM 2-hydroxyethyl disulﬁde (HED) by
0.5 mM GSH in the presence of NADPH and 0.5 units of yeast
glutathione reductase, at 25 °C. The disappearance of NADPH was
monitored at 340 nm [41]. Trx activity was determined spectro-
photometrically by measuring its ability to reduce insulin dis-
ulﬁdes in the presence of NADPH and rat thioredoxin reductase
[42]. An assay mixture was prepared by mixing 200 μL 1 M HEPES
pH 7.6, 40 μL 0.2 M EDTA, 40 μL 40 mM NADPH and 500 μL insulin
(10 mg/mL). 40 μL of this mixture was added to test tubes con-
taining 20 μL mammalian TrxR (1 μg) and the sample of protein
and the assay volume was completed up to 120 μL with water. The
tubes were incubated at 37 °C for 20 min and the reaction was
stopped by the addition of 500 μL of a solution containing
0.4 mg/mL DTNB in 6 M guanidine–HCl, 50 mM Tris–HCl, pH 7.5.
The absorbance at 412 nm was determined.
2.4. SDS-PAGE and Western blotting
The protein expression of Trx1, TrxR1, TXNIP, Grx1, Bcl-2,
STAT3, Akt1, p-Akt, MAPK, p-MAPK, MATII, UROD, ACO, PKM2, TKL,
caspase-3, CD95, NOS-3 and TKT were determined by SDS-PAGE
coupled to Western blotting analysis. SDS-PAGE was performed
with homogeneous 6% (NOS-3) 8% (STAT3, MAPK, ACO1, and TKT),
10% (Trx1, TXNIP, Akt, MATII, UROD, and ACO2), 12% (CD95) and
14% (Trx1, Grx1, Bcl-2, PKM2, and caspase-3) acrylamide gels. After
electrophoresis, proteins were transferred to nitrocellulose mem-
brane with a semi-dry electrophoretic transfer system (Bio-Rad).
The membranes were incubated overnight at 4 °C with the cor-
responding primary antibodies against Thr202/Tyr204p-MAPK,
1:2000 dilution; or against ACO1 and UROD, 1:500 dilution; or
against Trx1, Grx1, STAT3, MAPK, ACO2, TKT, TXNIP, TrxR1, Akt1,
Ser473p-Akt, MATII, Bcl-2, PKM2, caspase-3, CD95 and NOS-3,
1:1000 dilution. Then washed and incubated with the corre-
sponding secondary antibodies conjugated to peroxidase (anti-
rabbit, anti-goat or anti-mouse) used at 1:8000 dilution and the
chemiluminescent signal was induced by ECL reagent. β-actin
detected with the corresponding antibody at 1:5000 dilution, was
used as cell protein-loading control.
2.5. Measurement of cell death
Caspase-8, caspase-9 and caspase-3-associated activities were
determined using the corresponding peptide-based substrates
(100 μM) in the reaction mixture (50 mM HEPES, pH 7.5, 100 mM
NaCl, 10% sucrose, 0.1% Chaps, 1 mM EDTA and 5 mM DTT). The
substrates used were Ac-DEVD-AFC, Ac-LETD-AFC and Ac-LEHD-
AFC for caspase-3, -8, and -9, respectively. The ﬂuorescence due to
the reaction product was recorded with a GENIos Microplate
Reader (TECAN) set at 400 nm excitation and 505 nm emission
[37].
The level of protein caspase-3-active fragment (p17) and cell
death receptor, CD95, were also determined by SDS-PAGE coupled
to Western blotting analysis as described in the previous section.
Apoptosis in HepG2 cells was also analyzed through DNA
fragmentation detected by terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick end labeling (TUNEL) (Biotool). HepG2
cells 72 h after siRNA interference were ﬁxed in 4% paraf-
ormaldehyde solution in PBS (pH 7.4) and later these cells were
permeabilized with 0.2% Triton X-100 solution in PBS. Processing
the cells was performed according to the recommendations of the
manufacturer (Biotool) using DAPI (Molecular Probes) to stain the
cell nuclei. Fluorescence provided by the cells was analyzed with
ﬂuorescence microscope (Olympus BX43) using standard ﬂuor-
escein ﬁlter set to view the Apo-green ﬂuorescence at 520þ20 nm
and view blue DAPI at 460 nm.
2.6. Cell viability and total number of cells
Total number of cells and cell viability in a HepG2 cell sus-
pension were determined using the trypan blue dye exclusion
method. The cells attached to the plate were washed with PBS and
trypsinized for 7 min at 37 °C followed by incubation with com-
plemented culture medium to halt the effect of trypsin. The cell
suspension was centrifuged at 238g for 5 min at room temperature
and the pellet was resuspended in 0.5 mL complemented culture
medium. Cell viability and total number of cells were measured by
mixing equal volumes of cell suspension and trypan blue. A viable
cell will have a clear cytoplasmwhereas a non-viable cell will have
a blue cytoplasm. Cell viability was obtained by referring the
number of living cells to the total number of cells in the initial cell
suspension.
2.7. Cell proliferation
This parameter was analyzed using a cell proliferation colori-
metric ELISA (Roche Applied Science) based on the measurement
of BrdU incorporation during DNA synthesis in proliferating cells.
Cells were cultured (20,000 cells/cm2) in ﬂat-bottomed 96-well
multiplates at 37 °C and 5% CO2. 72 h after siRNA Trx1 and Grx1
downregulation HepG2 cells were incubated with 10 μM BrdU
labeling solution for 6 h at 37 °C. Later on were followed the steps
according to the recommendations of the manufacturer (Roche)
and detected the absorbance of the samples at 370 nm (reference
wavelength 492 nm).
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2.8. Determination of nitrotyrosine
The levels of nitrotyrosine were determined by Western blot-
ting after 12% non-reducing SDS-PAGE as described before. The
primary antibody was anti-3-nitrotyrosine (1:1000) from Sigma.
2.9. Silencing of Grx1 and Trx1
Human Grx1 and Trx1 were knocked-down in wild type, 4TO
and 4TO-NOS cells using speciﬁc siRNA in 6-well plate
(20,000 cells/cm2) according to the manufacturer's recommenda-
tions (Dharmacon, GE Healthcare Life Sciences). Grx and Trx siRNA
(25 nmol) were mixed with the transfection reagent DharmaFECT
1, previously pre-incubated with culture medium (antibiotic/an-
timycotic and serum free), and incubated for 20 min at room
temperature. These interference solutions were added to cells in
2% of culture medium without antibiotic/antimycotic solution and
kept for 72 h [43].
2.10. Redox mobility shift assay
Cells were treated with lysis buffer consisting of 50 mM HEPES
pH 7.5, 2 mM EDTA, 100 mM NaCl, 1% Nonidet NP-40, 8 M urea,
1 mM PMSF and containing 5 mM N-ethylmaleimide (NEM) to
block all free cysteine thiols. The lysates were centrifuged at
15,000 g for 5 min at 4 °C and the supernatant was desalted with
Zeba spin desalting columns (Thermo Scientiﬁc Pierce) to elim-
inate the remaining NEM reagent, and then treated with 5 mM Tris
(2-carboxyethyl)phosphine (TCEP) at room temperature for
30 min to reduce all cysteine disulﬁdes. Recovered cysteine thiols
were reacted at room temperature for 4 h with 6.25 mM Methyl-
PEG24-Maleimide (MM(PEG)24, Thermo Scientiﬁc Pierce), which
adds a 1239.44 Da label to any free thiol present, and desalted
again on Zeba spin desalting columns. Labeled proteins in the
samples processed this way would show an increase of 1.2 kDa in
their apparent Mw per each reversibly oxidized cysteine, com-
pared to the same protein with their cysteines originally in the free
thiol form, which had been initially blocked with the non-PEG
maleimide reagent present in the lysis buffer. Protein concentra-
tion was determined and the samples were processed for SDS-
PAGE and Western blotting as described above.
2.11. Statistical analysis
Results are expressed as mean7SEM of three independent
experiments. Data were compared using ANOVA with the least
signiﬁcant difference test a post hoc multiple comparison analysis.
The threshold for statistically signiﬁcant differences was set at
pr0.05. The values labeled with “a” were signiﬁcantly different
versus the corresponding internal control in the same cell lineage.
The values labeled with “b” were signiﬁcantly different versus the
corresponding control cell lineage.
3. Results
3.1. Characterization of NOS-3 overexpressing HepG2 cells
NOS-3 overexpression was performed as described before and
was conﬁrmed by measurement of mRNA and protein levels by
Western blotting (supplementary Fig. S1A and B) CD95 protein
levels and caspase-3, -8 and -9 activities were also determined and
conﬁrmed that their levels increased signiﬁcantly in NOS-3 over-
expressing HepG2 cells (supplementary Fig. S1C–F). The con-
centrations of NO and ROS were E40% higher and the levels of
nitrite and nitrate in the culture medium also increased sig-
niﬁcantly in NOS-3 overexpressing cells compared to the cells
carrying the empty plasmid, as described before [37]. These results
Fig. 1. Effect of high levels of NO on different metabolic pathways. Western blot analysis of the expression of different metabolism proteins and their relative quantitation in
the HepG2 wild type cells (WT) and control cells (4TO), as well as in NOS-3 overexpressing cells (4TO-NOS). The levels of two key cytosolic proteins involved in iron
metabolism, ACO1 (A), and one carbon metabolism, MATII (B), were signiﬁcantly lower in NOS-3 overexpressing cells compared to control cells. However, mitochondrial
ACO2 from energy metabolism and cytosolic UROD (heme biosynthesis), PKM2 (glycolysis) and TKT (pentose phosphate pathway) were up-regulated in NOS-3 over-
expressing cells (C–F). Data are presented as mean7SEM (n¼3 independent experiments). The values labeled with “a” were signiﬁcantly different (pr0.05) versus the
corresponding control cell lineage. The images are representative of three different experiments.
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indicate that NOS3 overexpressing cells are subject to oxidative
stress and that the apoptotic pathways are activated.
3.2. Effect of high levels of NO produced by overexpression of NOS-3
on different metabolic pathways
Metabolic impairment is a characteristic feature of tumor cells
due to the demand of biomass for cellular division, so we analyzed
several checkpoints of biosynthetic, energetic and iron metabolic
pathways. ACO1, a marker of cytosolic iron homeostasis and MATII
involved in one carbon metabolism were diminished in NOS-3
overexpressing cells (Fig. 1A and B). By contrast, mitochondrial
ACO2 from energy metabolism and cytosolic UROD (heme bio-
synthesis), PKM2 (glycolysis) and TKT (pentose phosphate path-
way) increased signiﬁcantly under NOS-3 overexpression condi-
tions (Fig. 1C–F). These results conﬁrm that NOS3 overexpression
induces a marked metabolic rearrangement in HepG2 cells.
3.3. Effect of high levels of NO produced by overexpression of NOS-3
on different signaling pathways
Growing evidence shows that some transcription factors and
proteins involved in signaling pathways could be modulated by
both oxidation/reduction and phosphorylation [44]. We choose
several well-established representative proteins involved in cell
survival pathways to study their response to the oxidative condi-
tions prevailing in NOS-3 overexpressing cells. MAPK, p-MAPK,
Bcl-2, STAT3, Akt1 and p-Akt, were all signiﬁcantly increased in
NOS-3 overexpressing cells compared to the control cells (Fig. 2A–
F). The ratio of p-MAPK/MAPK increased markedly as a con-
sequence of empty vector introduction but was further increased
in NOS3 overexpressing cells (Fig. 2G). However, the ratio p-Akt/
Akt1 did not change signiﬁcantly despite the increase in both
forms (Fig. 2H). These results demonstrate that the cell signaling
pathways are thoroughly affected by overexpression of NOS3.
3.4. Effect of overexpression of NOS-3 on the redoxin levels
Proteins related to the thioredoxin and glutaredoxin systems
are prominent players in thiol redox homeostasis in cells and were
studied. Protein levels and activity of Trx1, Grx1 and levels of
TrxR1 and TXNIP, increased signiﬁcantly in NOS-3 overexpressing
HepG2 cells (Fig. 3A–F). The simultaneous increase of both Trx1
and its opposing protein TXNIP is a conﬂicting situation likely a
reﬂection of the cellular response to redox changes under the
prevailing nitrosative conditions where Trx1 and TXNIP may not
Fig. 2. Effect of NOS-3 overexpression on different signaling pathways. Western blot analysis of the expression of different signaling proteins and their relative quantitation
in the HepG2 wild type cells (WT) and control cells (4TO), as well as in NOS-3 overexpressing cells (4TO-NOS). The levels of MAPK (A), p-MAPK (B), Bcl-2 (C), STAT3 (D), Akt1
(E) and p-Akt (F) were all signiﬁcantly increased in NOS-3 overexpressing cells compared to cells transfected with the empty vector. The proportion of p-MAPK/MAPK ratio
increased markedly (G) whereas the p-Akt relative to total Akt1 did not change (H). Data are presented as mean7SEM (n¼3 independent experiments). The values labeled
with “a” were signiﬁcantly different versus the corresponding control cell lineage. The images are representative of three different experiments.
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Fig. 3. High levels of nitric oxide induced activity and expression of redox proteins. Trx activity (A) and Trx1 protein expression (B), Grx activity (C) and Grx1 protein
expression (D), TrxR (E) and TXNIP (F) protein expression increased in NOS-3 overexpressing cells compared to cells transfected with the empty vector. Data are presented as
mean7SEM (n¼3 independent experiments) and the groups labeled with “a” were signiﬁcantly statistical (pr0.05) versus the corresponding control group. Representative
Western blotting images are shown.
Fig. 4. Effect of overexpression of NOS-3 on thiolic redox state of different proteins. Electrophoretic redox mobility shift to detect the oxidized and reduced forms (arrows)
are showed. The high levels of NO known to prevail in these cells caused a redox shift to more oxidized in ACO1 (A), UROD (B), Akt1 (C) and in both studied redoxins, Trx
(D) and Grx (E).
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be interacting (see below).
3.5. Effect of overexpression of NOS-3 on thiolic redox state of several
proteins
Thiol redox changes may be part of regulatory mechanisms of
proteins, so we analyzed the thiolic redox state of several proteins
to check whether this type of mechanism could be potentially
operative in NOS3 overexpressing cells. We have detected a redox
shift of ACO1 and UROD towards more oxidized states (Fig. 4A and
B), which could result in iron metabolism perturbation. Signaling
pathways could also be affected by redox changes since Akt1
shifted to more oxidized state under nitrosative pressure (Fig. 4C).
Changes in the redox state of MAPK, STAT3 and Bcl-2 could not be
detected under our experimental conditions and with our redox
electrophoretic mobility shift assay. However, the thiolic redox
state of Trx1 and Grx1 shifted to more oxidized in the NOS-3
overexpressing cells (Fig. 4D and E) a likely consequence of the
nitrosative and oxidative stress [37].
3.6. Speciﬁc silencing of Trx1 and Grx1
As shown above, Trx1 and Grx1 levels increased upon NOS3
overexpression in HepG2 cells. To go deep into the role of these
proteins in the adaptation to high NO levels, we studied the effect
of down-regulation of both proteins. Treatment of WT, 4TO and
NOS-3 overexpressing HepG2 cells with vectors harboring siRNA
speciﬁcally directed to Trx1 and Grx1 mRNA produced a E75%
decrease in Trx1 and Grx1 protein levels in the three cell lineages
(Fig. 5A and C). These changes in protein levels were accompanied
by equivalent functional fall off, as indicated by their canonical
enzymatic activities (Fig. 5B and D).
3.7. Effect of Trx1 and Grx1 silencing on the levels of tyrosine ni-
tration in normal and NOS-3 overexpressing HepG2 cells
Tyrosine nitration is mediated by reactive nitrogen species such
as peroxynitrite (ONOO) anion and nitrogen dioxide, formed as
secondary products of NO metabolism in the presence of oxidants
including superoxide radicals (O2  ) and hydrogen peroxide
(H2O2) [45]. For this reason, the level of Tyr nitration is indicative
of the degree of nitrosative and oxidative stress and we measured
it to check the effect of Trx1 and Grx1. Overexpression of NOS-3 in
HepG2 cells induced protein Tyr nitration (Fig. 6, black bars). Si-
lencing of Trx1 and Grx1 also increased protein tyrosine nitration
in wild type and 4TO cells, but, interestingly, had the opposite
effect on NOS-3 overexpressing cells (Fig. 6). These results uncover
an apparent conﬂict, e.g., a decrease in antioxidant defenses, Trx1
Fig. 5. Down regulation of Trx1 and Grx1 in HepG2 cells by treatment with speciﬁc siRNAs. Protein levels and activity of Trx1 (A, B) and Grx1 (C, D) were determined in
HepG2 cells with and without NOS-3 overexpression and treated or not with siRNATrx and siRNAGrx. Representative images of Western blot membranes used to quantify
protein levels are shown in A and C. The protein levels and activities of both redoxins were signiﬁcantly higher in NOS-3 overexpressing cells (4TO-NOS, black bars).
Treatment with the speciﬁc siRNA produced a E75% decrease in protein levels and activities of both redoxins in control and NOS-3 overexpressing cells, conﬁrming the
efﬁcacy of the treatments. Data are presented as mean7SEM (n¼3 independent experiments). The values labeled with “a” were signiﬁcantly different versus the corre-
sponding internal control in the same cell lineage. The values labeled with “b” were signiﬁcantly different versus the corresponding control cell lineage. The images are
representative of three different experiments.
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and Grx1, results in alleviation of oxidative stress.
3.8. Cellular proliferation and apoptosis in NOS-3 overexpressing
cells: effect of Trx1 and Grx1
Nitrosative stress in HepG2 cells as a consequence of NOS3
overexpression results in reduction of cell number and prolifera-
tion (Fig. 7A and C) in agreement with a previous report [37]. In
the current study we show that silencing Trx1 or Grx1 further
decreased the number of cells and proliferation in all cell lineages
and siRNATrx further reduced cell viability (Fig. 7A–C). siRNAGrx
or siRNATrx treatments also provoked a striking increase in cas-
pase-3 and caspase-8 activities in all cells (Fig. 7D and E), but
lowered the levels of CD95 in NOS-3 overexpressing cells (Fig. 7F).
Increase in caspases activities was actually accompanied by signs
of increased apoptosis like DNA fragmentation as determined by
TUNEL assay (Fig. 8). These results are worthy of consideration as
they point to a moonlighting role of the redoxins depending on
the prevailing cellular redox conditions as will be discussed in the
next section (Fig. 9).
3.9. Effect of Trx1 and Grx1 silencing on the levels and redox state of
Akt1 in normal and NOS-3 overexpressing HepG2 cells
Akt1 is known to be affected by thiol redox changes and is a
major agent in the control of apoptosis, so it was pertinent to
study its response to redoxins dow-regualtion. Trx1 or Grx1 spe-
ciﬁc siRNA counteracted the effect of the NOS-3 overexpression,
regarding both, total levels (Fig. 8A–C) and redox state (Fig. 8D) of
Akt. Grx1 and Trx1 down-regulation shifted Akt towards a more
reduced state but at the same time, there was a parallel marked
decrease in total Akt protein.
4. Discussion
NOS3 overexpression in HepG2 cells induces oxidative stress
and slight but signiﬁcant activation of apoptosis. In these condi-
tions the cells undergo a pronounced metabolic remodeling as
deduced from the changes observed in the levels of checkpoint
enzymes from key metabolic pathways.
In mammals, there are two genes encoding pyruvate kinase
that produce two isoforms. Whereas PKM1 is a constitutively ac-
tive enzyme, PKM2 is expressed in all cancers and cancer cell lines
studied to date. PKM2 is highly regulated at both the activity and
expression levels allowing this isoform to act as ﬂoodgate keeper
to change the metabolic ﬂux from lactate production to NADPH
and anabolic pathways. This metabolic change is particularly re-
levant under conditions of oxidative stress [46], thus explaining
the induction of PKM2 in NOS3 overexpressing cells and in co-
herent with the observed concomitant induction of TKT.
UROD has been considered a target for head and neck cancer
treatment [47]. It plays a key role in the biosynthesis of heme
group and its down-regulation has been shown to increase oxi-
dative stress and affect the cellular iron homeostasis. It's up-reg-
ulation in NOS3 overexpressing cells (Fig. 1D) could be counter-
balanced by inactivation through thiol oxidation [48] as shown in
Fig. 4B. These results, together with the observed down-regulation
of ACO1, indicate that cytosolic iron metabolism is perturbed.
MATs (methionine adenosyltransferases) are regulated by oxi-
dative stress and are associated to different pathologies such as
hepatocellular carcinoma and diabetes [49]. The decrease in MATII
levels we have observed in NOS-3 overexpressing cells mean that
AdoMet levels were reduced in those cells, with negative con-
sequences for nucleotide biosynthesis and hence for proliferation,
which would agree with the results on cell proliferation shown in
Fig. 6. Detection of nitrotyrosine levels in NOS-3 overexpressing HepG2 cells with Grx and Trx down regulation. The detection of this postranslational modiﬁcation was
performed by Western blot with the analysis focused on a representative 55 kDa band (arrow). The image is representative of three different experiments and densitometric
data of n¼3 independent experiments are presented in the histogram below as mean7SEM. The numbers 1, 2 and 3 indicate the cell treatments control, siRNAGrx and
siRNATrx respectively. NOS-3 overexpression induced Tyr nitration of proteins in HepG2 cells (black bars). This effect was offset by treatment with siRNAGrx and siRNATrx as
shown in the 4TO-NOS group. However, in WT and 4TO HepG2 cells siRNAGrx and siRNATrx treatment had the opposite effect, inducing Tyr nitration of proteins. Statistical
signiﬁcance was assessed by (pr0.05). The values labeled with “a” were signiﬁcantly different versus the corresponding internal control in the same cell lineage. The values
labeled with “b” were signiﬁcantly different versus the corresponding control cell lineage.
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Fig.7. This situation would make sense under the oxidative con-
ditions prevailing in those cells, since the metabolic ﬂux would be
compensated by diversion towards pentose phosphate pathway
for NADPH production and antioxidant defense.
The serine/threonine kinase Akt is a critical component of an
intracellular signaling pathway that exerts effects on cell survival
and apoptosis. Akt is activated by insulin and various growth and
survival factors. The unphosphorylated form of Akt is inactive and
it is activated by phosphorylation at Thr308 by PDK1 and at Ser473
by mTOR2. It can also be inactivated by protein phosphatase 2A
(PP2A) dephosphorylation when Akt is in its oxidized form [50]. It
has been shown that Grx prevented Akt from forming a speciﬁc
disulﬁde bond and suppressed its association with PP2A under
oxidative stress, resulting in phosphorylation of Akt and inhibition
of apoptosis. In Fig. 2E–H, we show that nitrosative stress caused
the increase of both Akt forms (Akt1 and p-Akt), accompanied by a
shift towards a more oxidized state (Fig. 4C). This would mean that
Akt is prone to inactivation by dephosphotylation under NOS-3
overexpression conditions, which indicates that apoptosis is being
favored.
The redox state and total protein levels of Akt are both under
the inﬂuence of Trx1 and Grx1 as will be detailed in another
section below.
The mitogen-activated protein kinase (MAPK) cascades are
multifunctional signaling pathways involved in cell growth, dif-
ferentiation, apoptosis and cellular response to stress. Two differ-
ent MAP kinase cascades that converge to c-Jun N-terminal ki-
nases (JNK) and p38 MAP Kinases are mainly activated by citotoxic
stresses, oxidative/nitrosative stress and proinﬂammatory cyto-
kines such as tumor necrosis factor (TNF)-α [32].
Our results show that MAPK is more phosphorylated in NOS3
overexpressing cells and hence less active. At ﬁrst sight, this result
would conﬂict with the fact that Trx1 and Grx1 had shifted to
more oxidized state in these cells (Fig. 4D and E) because oxidation
of both redoxins would suppress their inhibiting interaction with
apoptosis signal-regulating kinase 1 (ASK1) [50]. ASK1 would then
be free to initiate the MAPK cascade leading to activation of JNK or
p38 [51]. The explanation of this apparently contradictory result
could be that downstream p38MAPK, which is prone to tyrosine
nitration as opposed to phosphorylation, could not be activated
under the nitrosative pressure with elevated levels of nitrotyrosine
(see Fig. 6).
Human Bcl-2 is an anti-apoptotic, membrane-associated on-
coprotein that can be directly affected by oxidative stress induced
by NO [44] and could play an important role in NO-induced
apoptosis. In Fig. 2C, we show a signiﬁcant increase in Bcl-2 in
HepG2 cells under nitrosative stress. STAT3, the key cell growth
regulator signal transducer and activator of transcription, is sub-
ject to redox regulation by glutathionylation and ROS trigger tyr-
osine phosphorylation and nuclear translocation of STAT3. Glu-
tathionylated STAT3 was a poor Janus protein tyrosine kinase
2 substrate, and it exhibited low DNA-binding activity [52]. Fur-
thermore, the effect of inactivation of STAT3 has resulted in in-
hibition of growth and metastasis of human hepatocellular carci-
noma cells, and increase in their chemo-sensitivity.
The observed increases in Bcl-2 and STAT3 in NOS3 over-
expressing cells may be part of a counteracting cellular response to
induction of cell death, although the activation state of Bcl-2 and
the glutathionylation state of STAT3 should have to be determined
to support this reasoning. So far, we could not detect redox
changes in both proteins by the electrophoretic redox mobility
shift assay, but ongoing redox proteomic studies could throw light
to this question.
Trx1 was detected in a more oxidized state in NOS3
Fig. 7. Effect of down-regulation Grx and Trx on cell proliferation and cell death induced by NOS-3. Number of total cells (A), cell viability (B) and incorporation of BrdU (C) in
WT, 4TO and 4TO-NOS cells. Treatment with siRNAGrx and siRNATrx signiﬁcantly diminished the number of cells (gray and white bars) and siRNATrx further reduced cell
viability in all cell lineages (white bars). Caspase-3 (D) and caspase-8 (E) activities, known markers of apoptosis, were also markedly increased in all cell types by treatment
with either siRNAGrx or siRNATrx, whereas the same treatments offset the increase in CD95 receptor levels induced by NOS-3 overexpression (F). The numbers 1, 2 and
3 refer to control, siRNAGrx and siRNATrx treatments, respectively. Data are presented as mean7SEM (n¼3 independent experiments). The values labeled with “a” were
signiﬁcantly different versus the corresponding internal control in the same cell lineage. The values labeled with “b” were signiﬁcantly different versus the corresponding
control cell lineage. The images are representative of three different experiments.
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overexpressing cells than in normal HepG2 cells (Fig. 4D). Trx1 is
mostly found in the cytoplasm; however, it moves to the nucleus
as a response to nitrosative/oxidative stress and this Trx1 nuclear
migration has been described as part of a survival signaling
pathway, associated with intracellular compartmentalization and
activation of ERK1/2 MAP Kinases. TXNIP prevents Trx1 nuclear
migration and its expression was down-regulated in different
human carcinomas [53], however, it binds to reduced Trx1 but not
to oxidized Trx1. Hence, in the oxidative environment of NOS-3
overexpressing cells, inhibition of Trx1 by TXNIP might not be fully
operative despite the increase in TXNIP levels.
The increase in protein Tyr nitration occurring in WT cells upon
Trx1 and Grx1 down-regulation was an indication of oxidative
stress [54], the expected consequence of a drop in thiol anti-
oxidant defenses. However, in NOS-3 overexpressing cells, whose
redoxins levels are markedly higher (Fig. 3), silencing of Trx1 and
Grx1 provokes a decrease in nitro-Tyr levels (Fig. 6). It has been
noted that nitration processes are promoted over other oxidative
modiﬁcations in speciﬁc protein targets [55] and it has also been
suggested that nitration is a reversible process [56]. Whether the
observed parallel drop in protein nitration and Trx1 and Grx1 le-
vels in NOS-3 overexpressing cells is an indication of speciﬁcity of
the nitration process, its reversibility or the degradation of nitrated
proteins, is an interesting matter for further research and adds up
Fig. 8. Effect of down-regulation of Grx and Trx on apoptosis. DNA fragmentation in cells detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick
end labeling (TUNEL). We have selected representing merged images of FITC and DAPI ﬂuorescence of these treatments in the cell lineages studied (A). Apoptotic nuclei vs.
total nuclei in percentage detected in different ﬂuorescence images of control, siRNAGrx and siRNATrx treated cells in 3 independent experiments (B). The values labeled
with “a” were signiﬁcantly different (pr0.05) versus the corresponding internal control in the same cell lineage. The values labeled with “b” were signiﬁcantly different
versus the corresponding control cell lineage.
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to the debate [57].
The observed neutralization of CD95 induction in NOS-3 over-
expressing cells by Trx1 or Grx1 down regulation (Fig. 7F) suggest
that the high levels of both thiol-disulﬁde oxidoreductases pre-
vailing in these cells (Fig. 3) are required to induce the expression
of CD95. Activation of the extrinsic apoptotic pathway, indicated
by the increase in caspase-8 activity (Fig. 7E), despite the drop in
dead receptor CD95 levels, points to the operation of other pro-
apoptotic mechanism involving thiol redox changes.
Many reports have documented the inﬂuence of redox changes
on the apoptotic signaling pathways in a variety of cell types
through glutathionylation and S-nitrosylation of cysteines in var-
ious proteins along the signaling cascade, from receptors to cas-
pases, with the involvement of Grx and Trx in most cases [58].
Trx1 acting as denitrosylating enzyme counteracted inactivation of
caspase-3 and -8 by S-nitrosylation in HepG2 cells [28]. But on the
other hand, Trx1 can be S-nitrosylated itself [59] and this oxidized
Trx1 can impede apoptosis by S-transnitrosylation of caspase-3
[29,60]. Thus, depending on the redox state of the cell, Trx1 can
catalyze either trans-S-nitrosylation or S-denitrosylation reactions
[29,61]. Total levels of Trx1 increase in NOS-3 overexpressing cells
but a measurable proportion of the protein is in the oxidized state
(Fig. 4D) and could be acting on caspase-3 to inhibit it. This in-
hibitory effect would be alleviated in siRNATrx treated cells in
which the total amount of Trx1 drops down to E25%.
Most of the effects of siRNATrx treatment were also attained by
treatment with siRNAGrx, reﬂecting a degree of similarity of both
redoxins in the control of redox homeostasis, although differences
also exist. Both proteins have been related to apoptosis regulation
through redox modulation of stress activated and ASK1 [32] al-
though the role of Grx1 has been documented to more extent [50].
This increase of thiolic form of Akt when the levels of thiol
antioxidant redoxins decrease would favor activation by phos-
phorylation and apoptosis inhibition, whereas the parallel
Fig. 9. Effect of down-regulation of Grx and Trx on Akt phosphorylation and redox state. Western blot analysis of the expression of Akt1 (A) and p-Akt (B) proteins and their
relative quantitation in the HepG2 wild type cells (WT) and control cells (4TO), as well as in NOS-3 overexpressing cells (4TO-NOS). The numbers 1, 2 and 3 refer to control,
siRNAGrx and siRNATrx treatments, respectively. The enhancing effect of NOS-3 overexpression on Akt1 (A) and p-Akt (B) protein levels was offset by siRNA Grx (gray bars, 2)
and even more by siRNA Trx (white bars, 3). None of these siRNA treatments had effect on the p-Akt/Akt1 ratio (C). However, silencing Grx1 and more prominently Trx1,
shifted the redox state of Akt1 to the reduced form (arrows) in NOS-3 overexpressing cells (D). Data are presented as mean7SEM (n¼3 independent experiments). The
values labeled with “a” were signiﬁcantly different (pr0.05) versus the corresponding internal control in the same cell lineage. The values labeled with “b” were signiﬁcantly
different versus the corresponding control cell lineage. The images are representative of three different experiments.
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decrease in total Akt protein would attenuate the antiapoptotic
potential of Akt. This increase of thiolic form of Akt when the le-
vels of thiol antioxidant redoxins decrease may sound contra-
dictory, but could be caused by the proteasome differentially de-
grading the oxidized form, thus unbalancing the redox equilibrium
towards the reduced form. Inactivation and proteasomal de-
gradation of Akt upon Grx1 down-regulation had been observed
before [35]. The effect of down-regulation of Grx1 and Trx1 on Akt
redox state followed the same trend but the changes were more
pronounced when Trx1 was silenced, which could be correlated
with fading of its denitrosylase activity.
5. Conclusions
Overexpression of NOS-3 has antiproliferative effect on HepG2
cells. Activation of apoptosis, as demonstrated by increases in
caspases activity, is the ﬁnal outcome resulting from the balance of
multilevel and conﬂicting cellular responses to the oxidative stress
generated by the elevated level of NO. Among these, metabolic
remodeling potentiates the pentose phosphate pathway to in-
crease the metabolic ﬂux towards NADPH production for anti-
oxidant defense at the expenses of lowering nucleotide bio-
synthesis and therefore proliferation. Proteins of the antioxidant
redoxin systems and proteins involved in cell survival pathways
and phosphorylation of MAPK increase signiﬁcantly. At the same
time, the thiolic redox state of Akt1, Trx1 and Grx1 shifts to more
oxidized.
The important ﬁnding of our study is that Trx1 and Grx1,
principal actors of the antioxidant response induced by increased
NO levels, are actually a hindrance to the antiproliferative action of
NO. Down regulation of either redoxin by speciﬁc siRNAs activates
caspases dramatically and reduces cell proliferation. These results
support the contention that weakening the thiolic antioxidant
defenses enhances the antiproliferative effects on tumoral cells.
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Quantification of the activity and expression levels of Trx1, Grx1 and Prdx6 in 
HepG2 cells subject or not to high levels of NO as well as low levels of Prdx6 
 According to the objective 4, quantification of the activity and expression levels 
of Trx1, Grx1 and Prdx6 in HepG2 cells that express high levels of NO or normal as well 
as low levels of Prdx6 was done but these results are not included in the thesis articles.  
 
Methodology 
 Human Prdx6 was down-regulated in control cells (4TO) and cells that 
overexpressed NOS3 (4TO_NOS) using specific siRNA according to the manufacturer's 
recommendations (Dharmacon, GE Healthcare Life Sciences). The cells were incubated 
with the interference solution for 72h in 2% culture medium in the absence of 
antibiotic/antimycotic solution.  
 The protein expression of Trx1, Grx1 or Prdx6 were determined by Western 
blotting analysis using specific primary antibodies against Trx1 and Grx1, 1:500 dilution; 
or Prdx6, 1:2000 dilution(dilution...). The secondary antibodies were conjugated to 
peroxidase and the chemiluminescent signal was induced by ECL reagent (Thermo-
Fisher). β-actin protein was used as cell protein-loading control.  
 Trx activity was determined spectrophotometrically at 412 nm, as described by 
Holmgren in 1979, through its ability to reduce insulin disulfides in the presence of 
NADPH and rat thioredoxin reductase. Grx activity was also determined 
spectrophotometrically, as described by Luthman and Holmgren in 1982, by measuring 
the reduction of 2-hydroxyethyl disulfide (HED) in the presence of NADPH and yeast 
glutathione reductase. The consumption of NADPH was monitored at 340 nm. By the 
other hand, it was not possible to measure the Prdx6-specific peroxidase activity in cell 
lysates, but its phospholipase A2 activity (PLA2) was assayed using the Red/Green 
BODIPY based EnzChek Phospholipase A2 Assay (Invitrogen) in the presence or 
absence of MJ33. The samples were measured at excitation 460 nm and emission 515 
nm.  
Results and Discussion  
 As proof of concept, it has always been checked by Western Blot the Prdx6 
silencing and in all cases, the Prdx6 levels went down ~ 60%. The level of Prdx6 does 
not change in cells that overexpressed NOS3 with respect to control cells. The PLA2 
assay gives a high variability and, although the resulting data from four different 
experiments were not statistically significant, a trend was observed with higher activity in 
NOS3 overexpressing cells. Prdx6 is S-nitrositated in NOS3 overexpressing HepG2 cells 
as shown in Article 1.  
 Regarding Trx1 and Grx1, the results obtained showed that Prdx6 silencing did 
not significantly affect the activity and expression of Trx1 and Grx1 in both normal cells 
and those that overexpressed NOS3. However, proteins levels and activity of Trx1 and 
Grx1 show a tendency to increase in NOS3 overexpressing HepG2 cells as it is 
published (González R., et al. 2015) (Other scientific contributions). 
Conclusion 
 There is a cross-relationship between the signaling function of NO and the activity 
of Prdx6 that may be due to its regulation by S-nitrositation. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generation of a stable HepG2 cell line Knockout for Prdx6 (HepG2prdx6-/-) by 
CRISPR/Cas9 
 According to the objective 7, the HepG2 Knockout cell line for Prdx6 through 
CRISPR/Cas9 technology was obtained.  
 
Methodology 
 The CRISPR-Cas9 technique was used into the human hepatocarcinoma cell line 
HepG2, transfected using lipofectamine (LipofectamineTM CRISPRMAX Cas9 
Transfection Reagent, Thermo Fisher) with a specific gRNA directed to the peroxiredoxin 
6 gene and with the Cas9 nuclease (TrueCutTM Cas9 Protein v2, Thermo Fisher), 
responsible for the double chain cut in DNA. This gRNA was designed using the website 
of “Thermo Fisher TrueGuide Synthetic gRNA” so that the double-stranded cut was 
directed towards the third coding region of human prdx6 gene. To optimize the 
transfection method, different proportions of Cas9 nuclease and gRNA were used 
following the instructions of the manufacturer and then the efficiency of the CRISPR-
Cas9 technique was calculated using a kit (GeneArtTM Genomic Cleavage Detection Kit, 
Thermo Fisher).  
The cells, preserved after transfection, were used to carry out a limit dilution in 
96-well plates. Due to the difficulty of HepG2 cells to grow isolated, the medium was 
supplemented with the 50% of filtered medium used to grow the HepG2 cells 
(approximately at 50% confluence) to provide the growth and survival factors necessary 
for a greater number of isolated cells to grow in the different wells of the 96-well plate. 
The selected clones were transfected to 24-well plates for later analysis by Western 
blotting (WB) with specific antibodies against Prdx6 (Abcam). Moreover, the sequence 
analysis of peroxiredoxin 6 gene of the positive clone was carried out through Sanger 
sequencing methods using primers which encoding the peroxiredoxin 6 gene area that 
would be susceptible for cutting by Cas9. 
 
Results and Discussion  
The best efficiency of transformation was obtained with 1:2 proportions of Cas9 
nuclease and gRNA, getting an efficiency of 0.153, which meant a probability of yield a 
knockout clone of 3.3%. A number of 157 clones grew and them, they were transfected 
to 24-well plates for later analysis by WB. All of them were analyzed and only clone 39 
did not express Prdx6. This knockout for Prdx6 was characterized and sequence 
analysis allowed to know that both alleles were mutated by deletion: one allele had a 
deletion of one nucleotide and the other had elimination of 11 nucleotides. 
 
Conclusion 
A stable HepG2 cell line knockout for human Prdx6 has been successfully 
obtained by CRISPR/Cas9 technology. The mutation has been characterized and has 
been shown to be a biallelic and heterozygotic deletion. 
 
 
